Index for Years 1968, 1969, and 1970

(Volumes 52, 53, and 54)

Note: The volume year is in *italic* type. Page numbers of symposium and article titles are in **boldface** type.

SYMPOSIUM TITLES

1968

January	PAIN AND ITS CLINICAL MANAGEMENT
March	ENDOCRINE DISORDERS
May	RHEUMATOID ARTHRITIS
July	NEUROLOGIC DISORDERS
September	RECENT ADVANCES IN CARDIOVASCULAR DISEASE
November	GASTROINTESTINAL AND LIVER DISEASE

1969

January	ADVANCES IN LABORATORY DIAGNOSIS
March	MEDICAL EMERGENCIES
May	REHABILITATION
July	GENETICS IN CLINICAL MEDICINE
September	I. PROBLEMS IN REPRODUCTION AND SEXUAL ADJUSTMENT
	II. COMMON EYE DISORDERS AND INJURIES
November	BASES OF THERAPY

1970

January	MODERN CHALLENGES IN MEDICINE
March	DIFFICULT MEDICAL PROBLEMS
May	NEW DEVELOPMENTS IN MEDICINE
July	SOPHISTICATED DIAGNOSTIC PROCEDURES
September	EFFICACY OF ANTIMICROBIAL AND ANTIFUNGAL AGENTS
November	CURRENT CONCEPTS IN CLINICAL NUTRITION

ABDOMEN, pain in, acute intermittent porphyria and, *1968:* Nov., 1277
diffuse angiokeratoma of Fabry and, *1968:* Nov., 1277
patterns of, *1968:* Jan., 104–108
Abetalipoproteinemia, jejunal biopsy in, *1970:* July, 856
Abnormalities and deformities, congenital, genetic counseling in, *1969:* July, 993, 994, 997
of spinal column, management, *1969:* May, **487–509**
with childhood cancer, *1969:* July, 931
craniofacial, deafness and, *1969:* July, 769
low back pain and, *1968:* Jan., 58
Abortion, cytogenetics and, *1969:* July, **773–794**
genetic disorders and, *1969:* Sept., 1039
habitual, chromosome abnormalities and, *1969:* July, 785
induced, chromosome abnormalities and, *1969:* July, 784
mechanisms of, *1969:* July, 775–778
recurrent, *1969:* Sept., 1043
septic, coagulation defects following, *1969:* Sept., 1089
threatened, management of, *1969:* July, 790
Abruptio placentae, *1969:* Sept., 1088
Abscess, liver. See *Liver, abscess.*
lung. See *Lungs, abscess.*
staphylococcal, intravenous hyperalimentation for, *1970:* May, 585
subphrenic, and prolonged fever, *1970:* March, 385
Absorption, bile salts and, *1969:* Sept., 1178
disorders of. See *Malabsorption.*
mechanisms of, localization, *1968:* Nov., 1344
normal, *1968:* Nov., 1340–1345
Acanthocytosis, jejunal biopsy in, *1970:* July, 856
Accommodation, of eyes, amplitude of, *1969:* Sept., 1140
Accommodative squint, correction of, *1969:* Sept., 1137
Acenocoumarol (Sintrom), to prevent thromboembolism, *1969:* March, 348
Acetaminophen, site of action, *1968:* Jan., 8
Acetazolamide (Diamox), for refractory heart failure, *1968:* Sept., 1173
Acetohexamide (Dymelor), hypoglycemia from, *1969:* March, 465
Acetophenetidin, methemoglobinemia from, *1969:* July, 848
Acetylsalicylic acid, for juvenile rheumatoid arthritis, *1968:* May, 584
site of action, *1968:* Jan., 8
Achalasia, esophageal. See under *Esophagus.*
staphylococcal abscess and, intravenous hyperalimentation for, *1970:* May, 585
Achromobacter infections, choice of therapy for, *1970:* Sept., 1162
Acid-base balance, evaluation of, *1970:* Nov., 1543
Acid-base determinations, on arterialized capillary blood, *1969:* Jan., **137–145**
Acid-peptic disease, belladonna for, physiology and pharmacology, *1969:* Nov., **1379–1388**
hyperparathyroidism and, *1970:* Jan., 132
diet in, *1970:* Nov., 1357–1359
Acidemia, methylmalonic, dietary control, *1970:* Nov., 1444
fibroblast cultures in, *1970:* May, 705
Acidosis, metabolic, *1969:* March, 407–409; *1970:* Nov., 1548–1550
in diabetes mellitus, *1969:* Nov., 1367
renal tubular, dietary control, *1970:* Nov., 1442
Acids, balance, *1970:* Nov., 1547
production and excretion, *1970:* Nov., **1543–1554**
Aciduria, beta-aminoisobutyric, as example of polymorphism, *1969:* July, 892
orotic, hereditary, dietary control, *1970:* Nov., 1443
xanthurenic, management, *1970:* Nov., 1445
Acne vulgaris, tetracyclines for, *1970:* Sept., 1181
Acromegaly, body compositional studies in, *1970:* Nov., 1475
diabetes in, *1970:* Nov., 1477
laboratory tests in, *1968:* March, 371
radioimmunoassay of gonadal hormones in, *1970:* July, 1056
Acromioclavicular joint, in rheumatoid arthritis, *1968:* May, 497
Acropachy, thyroid, *1968:* March, **393–398**
Acropathy, mutilating, *1968:* July, 899
ACTH. See *Corticotropin.*
Actinobacillus mallei infections, choice of therapy for, *1970:* Sept., 1163
Activity. See also *Exercise.*
caloric requirements and, *1970:* Nov., 1578
limitation of, in chronic heart failure, *1970:* March, 324
Adaptation, persistent, physical, *1969:* July, 985–987
vs. genetic selection, *1969:* July, 983
Addiction, to drugs. See *Drugs, addiction.*
Addison's disease, *1968:* March, **327–338**
diabetes mellitus and, *1968:* March, 336
erythropoiesis in, *1968:* March, 238
hyperthyroidism and, *1968:* March, 335
hypothyroidism and, *1968:* March, 334
metabolic and nutritional aspects, *1970:* Nov., 1475, 1486–1488
Adenohypophysis, hormones of, regulation of secretion, *1968:* March, 357
Adenomas, chromophobe, endocrine glands and, *1968:* July, 830–834
symptoms and signs of, early, *1968:* July, **827–834**
endocrine, multiple, peptic ulcer and, *1968:* Nov., 1278
islet cell, tolbutamide and leucine tolerance tests in, *1968:* March, 287
Adenomatosis, multiple endocrine, *1968:* March, 303
Adenylcyclase, adrenergic receptors and, *1968:* Sept., 1014

ADH. See *Hormone, antidiuretic*
Adie's pupil, *1968:* July, 880
Adipose tissue, cell size and number, *1970:* Nov., 1536–1537
metabolism, cell size and, *1970:* Nov., 1538
physiologic studies of, *1970:* May, 749
Adrenal glands, atrophy, idiopathic, *1968:* March, 330
chromophobe adenoma and, *1968:* July, 831
cortex, carcinoma of, chemotherapy for, *1969:* Nov., 1275
neoplasms, congenital abnormalities and, *1969:* July, 932
steroids. See *Corticosteroids.*
disorders, amenorrhea and, *1968:* March, 344
tests in, *1969:* Jan., 89–93
function, erythropoiesis and, *1968:* March, 237
in amenorrhea, *1968:* March, 351
leukopoiesis and, *1968:* March, 240
fungus infections, *1968:* March, 328
hyperplasia, clinical and pathological characteristics, *1968:* March, 317
treatment for, *1968:* Sept., 1228
hypofunction, hypoglycemia and, *1970:* March, 533
infections, *1968:* March, 327–330
insufficiency, *1969:* March, **459–463**
nutritional disturbances in, *1970:* Nov., 1486–1488
orthostatic hypotension and, *1968:* July, 812
malignant disease metastatic to, *1969:* March, 461
tuberculosis, *1968:* March, 327
tumors, amenorrhea and, *1968:* March, 344
clinical and pathological characteristics, *1968:* March, 317
diagnosis, *1968:* Sept., 1217
metastatic, *1968:* March, 330
pathophysiology, *1968:* March, 320
treatment, *1968:* March, 324
Adrenalectomy, corticosteroid dependency after, *1969:* March, 460
Adrenalin. See *Epinephrine.*
Adrenergic receptors, blockers of, *1968:* Sept., 1011
angina pectoris and, *1968:* Sept., **1031–1039**
cardiac arrhythmias and, *1968:* Sept., **1017–1029**
hyperdynamic cardiovascular states and, *1968:* Sept., **1041–1048**
in pheochromocytoma, *1969:* Nov., **1349–1358**
in shock, *1968:* Sept., **1049–1060**
mechanism of action, *1968:* Sept., 1017–1019, 1052
sympathetic nervous system and, *1968:* Sept., **1049–1060**
concepts of, *1968:* Sept., **1009–1016**
in blood vessels, *1968:* Sept., 1012, 1079
subgroups, *1968:* Sept., 1013
Adrenocortical insufficiency, chronic. See *Addison's disease.*
Adrenocorticoids. See *Corticosteroids.*
Adrenocorticotropic hormone. See *Corticotropin.*
Adrenocorticotropin. See *Corticotropin.*
Adrenogenital syndrome, amenorrhea and, *1968:* March, 344
Aerosol therapy, for status asthmaticus, *1970:* March, 500
Afferent loop syndrome, after gastrointestinal surgery, *1969:* Nov., 1391
AFP. See *Alpha-fetoprotein.*
Agammaglobulinemia, "acquired," genetics and detection, *1969:* July, 915–917
alymphocytic (Swiss type), *1969:* July, 910; *1970:* March, 288
sex-linked, infantile, *1969:* July, 907
recessive (Bruton type), *1970:* March, 285
with thymoma, *1970:* March, 297
Age, body fat and, *1970:* Nov., 1369
Aged persons, delirium in, *1969:* March, 276
nutrition in, *1970:* Nov., **1589–1597**
Agglutination, *1969:* Sept., 1063
Agrypnotic drugs, anorexia from, *1968:* July, 785–786
use of, general considerations, *1968:* July, 781
pitfalls in, *1968:* July, 784–785
Airway, restoration, in cardiopulmonary resuscitation, *1969:* March, 387
Alcaligenes infections, choice of therapy for, *1970:* Sept., 1162
Alcohol, as neurolytic agent, *1968:* Jan., 163
excessive intake, polyneuropathy and, *1968:* Jan., 112
heart disease and, *1968:* Sept., **1183–1191**
liver disease and, *1970:* March, 468–469
implications of current research in, *1968:* Nov., 1404
metabolism, *1970:* Nov., 1568
as model for other drugs, *1969:* Nov., **1413–1423**
withdrawal, delirium and, *1969:* March, 276
Alcoholic muscle disease, *1970:* May, **723–730**
Alcoholism, cirrhosis and, *1968:* Nov., **1445–1455**
hypoglycemia and, *1970:* March, 535
liver disease and, nutritional management, *1970:* Nov., 1464
malnutrition and, *1970:* Nov., **1567–1575**
pancreatitis and, *1970:* March, 480
Aldactone. See *Spironolactone.*
Alderlin. See *Pronetalol.*
Aldolase deficiency, *1969:* July, 821
Aldomet. See *Methyldopa.*
Aldosterone, antagonists, for ascites in Laennec's cirrhosis, *1969:* Nov., 1362
for refractory heart failure, *1968:* Sept., 1174
secretion, angiotensin and, *1968:* March, 267
Aldosteronism, primary, diagnosis, *1968:* Sept., 1223
treatment, *1968:* Sept., 1228
Alexia, *1969:* Sept., 1125

ALG. See *Antilymphocyte globulin.*
Algesic agents, chemical, *1968:* Jan., 4–6
Alimentation, intravenous. See *Intravenous alimentation.*
Alkaline phosphatase, plasma, hyperparathyroidism and, *1968:* March, 454
serum, test for, *1968:* Nov., 1410, 1428, 1429; *1969:* Jan., 115–118
Alkalis, production and excretion, *1970:* Nov., **1543–1554**
sources, *1970:* Nov., 1546
Alkaloids, plant, bases of action of, *1969:* Nov., 1268
Alkalosis, from peptic ulcer therapy, *1969:* March, 429
metabolic, *1970:* Nov., 1550–1553
potassium therapy for, *1968:* Sept., 1105
with hypokalemia, *1969:* March, 409–410
Alkylating agents, bases of action, *1969:* Nov., 1265–1267
for rheumatoid arthritis, *1968:* May, 696, **747–757**
Allergy. See also specific allergens.
injection therapy for, immunologic basis of, *1969:* Nov., **1257–1264**
prolonged fever and, *1970:* March, 391
to antibiotics, *1970:* Jan., **59–73.** See also *Antibiotics, allergy to;* and specific antibiotics.
Allopurinol (Zyloprim), for gout, *1970:* March, 440
for hyperuricemia, basis of action, *1969:* Nov., 1341
for nephrolithiasis in gout, *1970:* March, 435
Alpha-adrenergic receptors. See *Adrenergic receptors.*
Alpha cells of pancreas. See *Pancreas, islet cells.*
Alpha-fetoprotein, in malignant diseases, *1970:* May, **797–803**
ALS. See *Antilymphocyte serum.*
Alveolar-capillary block, vs. intractable heart disease, *1970:* March, 314
Alveolar-capillary block syndrome, hypoxia due to, *1970:* May, 619
Alveolar proteinosis, bronchopulmonary lavage for, *1970:* May, 762
Amantidine (Symmetrel), for Parkinsonism, *1970:* May, 784
Amaurosis fugax, cerebrovascular disease and, *1970:* March, 353
Amblyopia, tests for, *1969:* Sept., 1133
Ambu bag, in cardiopulmonary resuscitation, *1969:* March, 390
Amenorrhea, adrenal disorders and, *1968:* March, 344
hypopituitarism and, *1968:* March, 342
hypothalamus and, *1968:* March, 340
nutritional factors in, *1968:* March, 341
oral contraception and, *1969:* Sept., 1032–1035; *1970:* Jan., 167
ovarian disorders and, *1968:* March, 345
ovarian failure and, *1968:* March, 346
secondary, *1968:* March, **339–355**
diagnosis, *1968:* March, 347–354
Amenorrhea (*Continued*)
secondary, estrogen-progesterone test in, *1968:* March, 349
factors in, *1968:* March, 339
progesterone test for, *1968:* March, 349
treatment, *1968:* March, 354–355
thyroid disorders and, *1968:* March, 343
uterine failure and, *1968:* March, 347
Amethopterin. See *Methotrexate.*
Amicar. See *Epsilon-aminocaproic acid.*
Aminex, sympathomimetic, adrenergic receptors and, *1968:* Sept., 1010
Amino acids, metabolism, disorders, dietary control of, *1970:* Nov., 1433–1438
in liver disease, *1970:* Nov., 1456
sulfur-containing, disorders, nutritional management, *1970:* Nov., 1437–1438
Aminoglycosides, allergic reactions to, incidence of, *1970:* Jan., 63
Aminophylline, for asthma, *1969:* March, 242, 243
for status asthmaticus, *1970:* March, 498
in acute pulmonary edema, *1969:* March, 329
Aminopterin, for immunosuppression, *1969:* Nov., 1227
Aminopyrine, site of action, *1968:* Jan., 8
Ammonia, blood, test for, *1968:* Nov., 1412
intoxication, bleeding esophageal varices and, *1968:* Nov., 1459
toxicity, hepatic coma and, *1968:* Nov., 1477
Amnesia, global, transient, cerebrovascular disease and, *1970:* March, 354
Amniocentesis, *1969:* Sept., 1073–1077
chromosome analysis and, *1969:* July, 789
cell culture, *1969:* July, 806
Amniotic fluid, embolus, *1969:* Sept., 1089
in examination of fetus, *1969:* Sept., 1053
Amphotericin B, for bacterial endocarditis, *1968:* Sept., 1098
Ampicillin, *1970:* Sept., **1145–1159**
clinical indications, *1970:* Sept., 1148–1154
for bacterial endocarditis, *1968:* Sept., 1098
for emergency treatment of infection, *1969:* March, 441
in patients with renal disease, *1970:* Sept., 1146, 1154
pediatric use, *1970:* Sept., 1154
serum protein-binding, *1970:* Sept., 1117
spectrum of activity, *1970:* Sept., 1129, 1148
toxic reactions, *1970:* Sept., 1154
Amputation, for malignant disease, rehabilitation after, *1969:* May, 611–614
management of patients in practice, *1969:* May, **659–664**
of leg, conditioning for prosthesis, *1969:* May, 661–662
immediate prosthetic fitting, *1969:* May, **665–676**
rehabilitation after, *1969:* May, 674–676
Amylase, serum, tests for, *1969:* Jan., 118–119
urinary, tests for, *1969:* Jan., 118

Amyloid, Congo red test for, *1968:* May, 650
nature of, *1968:* May, 644–646
Amyloidosis, jejunal biopsy in, *1970:* July, 855, 857
nerve biopsy in diagnosis, *1968:* July, 891
neuropathy and, *1968:* July, 906
orthostatic hypotension and, *1968:* July, 812
with rheumatoid arthritis, *1968:* May, 619, **643–653**
clinical aspects, *1968:* May, 647–649
diagnosis, *1968:* May, 649–651
treatment, *1968:* May, 651–652
Amyotrophic lateral sclerosis, speech disturbances in, *1968:* July, 838–842
Amyotrophy, neuralgic, *1968:* July, 776–777
Analgesics, cervical block, in office, *1968:* Jan., 181
effects on laboratory values, *1969:* Jan., 218
field block, in office, *1968:* Jan., 179
for neck and shoulder pain, *1969:* May, 517
in labor, indications for, *1968:* Jan., 138
techniques of administering, *1968:* Jan., 138–145
infiltration, in office, *1968:* Jan., 179
inhalational, for postoperative pain, *1968:* Jan., 88
in labor, *1968:* Jan., 141
intercostal block, in office, *1968:* Jan., 180
local, in office, *1968:* Jan., 174–177
narcotic, *1968:* Jan., 33–45
dependence on, *1968:* Jan., 33–36
duration of action, *1968:* Jan., 42
for postoperative pain, *1968:* Jan., 85
in children, *1968:* Jan., 132
in labor, *1968:* Jan., 140
oral administration, *1968:* Jan., 41
potency and efficacy, *1968:* Jan., 39
regulations of use, *1968:* Jan., 36
selection, *1968:* Jan., 39–44
non-narcotic, for postoperative pain, *1968:* Jan., 87
mechanisms of action, *1968:* Jan., **3–14**
new, *1968:* Jan., 38
site of action, *1968:* Jan., 8–13
regional, in labor, *1968:* Jan., 142
in office, *1968:* Jan., 179
systemic, in labor, *1968:* Jan., 138
topical, in office, *1968:* Jan., 178
Anaphylactoid reaction, to antibiotics, *1970:* Jan., 61, 62
to penicillins, *1970:* Sept., 1094
to vancomycin, *1970:* Sept., 1281
Anaphylaxis, *1969:* March, **249–257**
asthma and, *1969:* March, 240
substances causing, *1969:* March, 252, 253
Anastomosis, portacaval, emergency, for bleeding esophageal varices, *1968:* Nov., 1467
prophylactic, for esophageal varices, *1968:* Nov., 1470
Androgens, adrenal, tests of, *1969:* Jan., 92
erythropoiesis and, *1968:* March, 232
leukopoiesis and, *1968:* March, 239
Anemias, Biermer's. See *Anemia, pernicious.*
Cooley's (thalassemia major), hemoglobin synthesis in, *1969:* July, 880
copper-deficiency, *1970:* Nov., 1512
differentiation of, *1969:* Jan., **47–60**
due to chloramphenicol, *1970:* Sept., 1190
erythropoietin and, *1970:* Jan., 175–177
Heinz body, *1969:* Jan., 54
hemolytic, acquired, *1969:* Jan., 57
autoimmune, immunosuppression for, *1969:* Nov., 1233
congenital, enzyme deficiencies and, *1969:* July, 820, 821, 822
due to penicillins, *1970:* Sept., 1094
prosthetic heart valves and, *1968:* Sept., 1138
hypochromic, causes, *1969:* Jan., 48
hypothyroidism and, *1968:* March, 235
in rheumatoid arthritis, *1968:* May, **527–532,** 543
complicated, *1968:* May, 529–530
management, *1968:* May, 530–531
simple chronic, *1968:* May, 527–529
in uremia, *1970:* March, 419
iron-deficiency, *1970:* July, **903–915;** Nov., **1406–1412.** See also *Iron, deficiency.*
macrocytic, *1969:* Jan., 50
megaloblastic, *1969:* Jan., 50
vs. normocytic, *1969:* Jan., 50
marrow failure, *1969:* Jan., 57, 58
mechanisms in, *1969:* Jan., 47
megaloblastic, causes, *1969:* Jan., 52
normochromic, causes, *1969:* Jan., 50–51
vs. hypochromic, *1969:* Jan., 47
normocytic, with acute hemorrhage, *1969:* Jan., 52
nutritional, recent advances in, *1970:* May, **631–645**
pernicious, genetic factors in, *1968:* Nov., 1277
immunity and, *1970:* May, 640
in infancy, dietary management, *1970:* Nov., 1445
intrinsic factor antibodies and, *1968:* Nov., 1288
juvenile, *1970:* May, 641
lactate dehydrogenase activity in, *1969:* Jan., 122
parietal cell antibody and, *1968:* Nov., 1286
red cell, 2,3-diphosphoglycerate and, *1970:* May, 736
refractory, *1969:* Jan., 57, 58
Anesthesia, epidural, for pain, *1968:* Jan., **209–215**
Anesthetics, for neck and shoulder pain, *1969:* May, 517
local, for postoperative pain, *1968:* Jan., 87
Aneurysm, aortic, ascending, with cystic medionecrosis, *1968:* Sept., **1145–1156**
basilar artery, cerebellopontine angle syndrome and, *1968:* July, 792
intracranial, hemorrhagic stroke and, *1968:* Sept., 1200
treatment, *1968:* Sept., 1209

Aneurysm (*Continued*)
ventricular, causes of and surgery for, *1968:* Sept., 1122–1124
ANFl-Liver test, for antinuclear factors, *1968:* May, 561
ANFl-WBC test, for antinuclear factors, *1968:* May, 561
Angiitis, hypersensitivity, vs. juvenile rheumatoid arthritis of acute onset, *1968:* May, 575
Angina, before myocardial infarction, *1968:* Sept., 1062
pectoris, adrenergic receptor blockers for, *1968:* Sept., **1031–1039**
carotid sinus nerve stimulation for, *1968:* Sept., 1036
coronary arteriography in selection of treatment, *1970:* July, 989–991
intractable, *1970:* March, **333–348**
propranolol for, *1968:* Sept., 1031
Angiography, fluorescein, of ocular fundus, *1968:* July, **853–869**
in pulmonary embolism, *1969:* March, 376
Angiokeratoma, diffuse, of Fabry, abdominal pain and, *1968:* Nov., 1277
Angioneurotic edema, anaphylaxis and, *1969:* March, 252
Angiotensin, activation, *1968:* March, 264
effects, *1968:* March, 267
inactivation, *1968:* March, 266
proposed physiological actions, *1968:* March, 269
salt excretion and, *1968:* March, 276
Angle-closure glaucoma. See under *Glaucoma.*
Anhidrosis, with congenital insensitivity to pain, *1968:* July, 899
Animal models, adjuvant arthritis in, *1968:* May, 669–671
infectious arthritis in, *1968:* May, 667–669
of rheumatoid arthritis, *1968:* May, **667–672, 677–686**
immunological processes and, *1968:* May, 669–671
Anisocoria, contraction, alternating, *1968:* July, 878
third nerve paresis and, *1968:* July, 880
Anisometropia, *1969:* Sept., 1141
Ankle, deformities, in spina bifida and myelomeningocele, *1969:* May, 504
examination, in hemiplegic patient, *1969:* May, 555
in rheumatoid arthritis, surgery, *1968:* May, 729
Ankylosing spondylitis. See *Spondylitis, ankylosing.*
Ankylosis, bony, in rheumatoid arthritis, *1968:* May, 663
of joints, in rheumatoid arthritis, *1968:* May, 614
Anorexia, agrypnotic drugs and, *1968:* July, 785–786
nervosa, amenorrhea and, *1968:* March, 341
Anosognosia, in hemiplegia, *1969:* May, 579
Anoxia. See *Hypoxia.*
Ansolysen. See *Pentolinium.*
Antibiotics. See also specific drugs.
allergy to, *1970:* Jan., **59–73**
alternate drugs and, *1970:* Jan., 69
corticosteroids and antihistamines for, *1970:* Jan., 71
desensitization and, *1970:* Jan., 70
incidence of, *1970:* Jan., 62–64
mechanism of, *1970:* Jan., 64–66
prevention of reactions, *1970:* Jan., 66–68
treatment of reactions, *1970:* Jan., 68–69
alternate, history of allergic reaction and, *1970:* Jan., 69
choice, for emergency treatment of infection, *1969:* March, 438–441
contaminants of, reactions and, *1970:* Jan., 64
effects on laboratory values, *1969:* Jan., 219
empiric therapy with, *1970:* Sept., 1167
for bacterial endocarditis, *1968:* Sept., 1097, 1098
for diarrheal disease in children, *1970:* March, 450
for immunosuppression, *1969:* Nov., 1227
for status asthmaticus, *1970:* March, 500
for tropical sprue, *1968:* Nov., 1379
for urinary tract infection, *1970:* March, 402
superinfections, *1970:* Sept., 1170
Antibody(ies), anticolon, ulcerative colitis and, *1968:* Nov., 1291
homocytotropic, *1969:* March, 249
immune response and, *1969:* Nov., 1225–1227
intrinsic factor, gastrointestinal disease and, *1968:* Nov., 1287
liver disease and, *1968:* Nov., 1289
parietal cell, gastrointestinal disease and, *1968:* Nov., 1286
penicillin allergy and, *1970:* July, 999
production of, nutrition and, *1970:* Nov., 1497
synthesis of, *1969:* Nov., 1226
Anticholinergic drugs, for dumping syndrome, *1969:* Nov., 1409
Anticholinesterase drugs, overdoses of, *1969:* March, 285, 287
Anticoagulants, for refractory heart failure, *1968:* Sept., 1165
for transient ischemic attacks, *1970:* March, 356
oral, and coagulation factor deficiencies, *1970:* July, 898
prophylactic, *1969:* March, 348
pulmonary embolism and, *1970:* March, 366
tests for, *1969:* Jan., 73
Anticonvulsants, *1968:* July, 963
for trigeminal neuralgia, *1968:* July, 798
side effects, *1968:* July, 969
Antidiuretic hormone. See *Hormones, antidiuretic.*
Antienzyme therapy, for pancreatitis, *1969:* March, 434
Antifungal drugs, effects on laboratory values, *1969:* Jan., 220
efficacy of, *1970:* Sept., **1329–1345**

Antigen-antibody reactions, *1969:* March, **249–257**
rheumatoid arthritis inflammation and, *1968:* May, 630–631
Antigens, Australia, viral hepatitis and, *1970:* May, **805–817**
Rh-Hr, *1969:* Sept., 1067
transplantation, *1970:* Jan., 45–53
detection of, *1970:* Jan., 46–52
immunologic tolerance and, *1970:* Jan., 54–55
inheritance of, *1970:* Jan., 52–53
Antihistamines, for allergy to antibiotics, *1970:* Jan., 71
Antihypertensive drugs, vision and, *1969:* Sept., 1116
Anti-inflammatory drugs, for neck and shoulder pain, *1969:* May, 517
for rheumatoid arthritis, *1968:* May, 691–696
Antilymphocyte globulin (ALG), after kidney transplants, *1970:* Jan., 87
Antilymphocyte serum, after kidney transplants, *1970:* Jan., 87
Antimalarial therapy, for rheumatoid arthritis, *1968:* May, 692, **759–764**
juvenile, *1968:* May, 586
Antimetabolites, antibody synthesis and, *1969:* Nov., 1227
bases of action, *1969:* Nov., 1267–1268
chromosome breakage and, *1969:* Nov., 1252
Antimicrobial drugs, choice of therapy for various organisms, *1970:* Sept., 1162
efficacy of, symposium on, *1970:* Sept., **1075–1350**
Antinuclear factors in rheumatoid arthritis, tests for, *1968:* May, 547, **559–565**
Antiprotozoal drugs, effects on laboratory values, *1969:* Jan., 220
Antipurines, bases of action of, *1969:* Nov., 1267
Antipyrimidines, bases of action of, *1969:* Nov., 1267
Antipyrine, metabolism of, inherited variations in, *1969:* July, 849
Anuria, causes, *1969:* March, 398
Anus, and rectum, anomalies of, inheritance, *1968:* Nov., 1274
area of, topical analgesia, *1968:* Jan., 179
Anxiety, cardiovascular response to, adrenergic receptor blockers and, *1968:* Sept., 1043
Aorta, ascending, cystic medionecrosis and aneurysmal dilatation, *1968:* Sept., **1145–1156**
coarctation of, cardiac catheterization in, *1970:* July, 978
diagnosis, *1968:* Sept., 1216
insufficiency of, cardiac catheterization in, *1970:* July, 977
Aortic valve, disease of, coronary arteriography in, *1970:* July, 988
lactate dehydrogenase activity in, *1969:* Jan., 125
stenosis of, cardiac catheterization in, *1970:* July, 974
AP. See *Alkaline phosphatase.*
Aphakia, contact lenses for, *1969:* Sept., 1139
Aphasia, after cerebrovascular disease, *1969:* May, 567
characteristics, *1969:* May, 563
tests for, *1969:* May, 571
Apoplexy, adrenal, *1969:* March, 460
Apoproteins, in plasma lipid transport, *1970:* Nov., 1384
Appendicitis, pain pattern in, *1968:* Jan., 104
Apraxia, verbal, *1969:* May, 565
Apresoline. See *Hydralazine.*
Aralen. See *Chloroquine.*
Aramine. See *Metaraminol.*
Arfonad. See *Trimethaphan camphorsulfonate.*
Arginine vasopressin, secretion, *1968:* March, 381. See also *Hormone, antidiuretic.*
Argyll Robertson pupil, *1968:* July, 879
Aristocort. See *Triamcinolone.*
Arm, disabilities, use of telephone and, *1969:* May, **697–702**
examination, in hemiplegic patient, *1969:* May, 544–551
local analgesia of, in office, *1968:* Jan., 180
lymphedema, after radical mastectomy, *1969:* May, 615
nerve blocks in, *1968:* Jan., 124
pain in, neurologic disorders and, *1968:* July, **773–779**
thrombophlebitis, complicating hemiplegia, *1969:* May, 549
Arrhythmia, cardiac. See also *Tachycardia.*
after myocardial infarction, prevention, *1969:* March, 319
atrial (supraventricular), *1969:* March, 320–322
conversion by pacing, *1969:* Nov., 1292–1293
beta-adrenergic receptor blocking drugs for, *1968:* Sept., **1017–1029**
cellular genesis of, *1969:* Nov., 1299–1301
chronic, complicating heart failure, *1970:* March, 318, 323
office treatment for, *1969:* March, 333
pacemakers in prevention and treatment of, *1969:* Nov., **1287–1295**
potassium therapy in, *1968:* Sept., 1105
propranolol for, *1968:* Sept., 1020–1026
prosthetic heart valves and, *1968:* Sept., 1138
therapy for, basis and evaluation of, *1969:* Nov., **1297–1308**
ventricular, after myocardial infarction, *1968:* Sept., 1068
prevention by pacing, *1969:* Nov., 1287–1292
treatment, *1969:* March, 323–324
with myocardial infarction, treatment, *1969:* March, **315–326**
Arsenic poisoning, neuropathy and, *1968:* July, 905
Arterial occlusion, retinal, fluorescein angiography in, *1968:* July, 866

Arteriography, coronary, indications for, *1970:* July, **979–995**
in diagnosis of intracranial disorders, *1969:* March, 294
of pancreas, *1970:* March, 485
pulmonary, in pulmonary embolism, *1970:* March, 365
selective, in pulmonary embolism, *1969:* March, 370
Arteriosclerosis, cerebral, pathogenesis of, *1970:* March, 352
Arteritis, rheumatoid arthritis and, *1968:* May, 618
Artery(ies), basilar, aneurysm of, cerebellopontine angle syndrome and, *1968:* July, 792
cerebral, hemorrhagic stroke and, *1968:* Sept., 1200, 1204
malformations, hemorrhagic stroke and, *1968:* Sept., 1202
epigastric, rupture, *1969:* March, **361–363**
femoral, occlusion, vs. thrombophlebitis, *1969:* May, 554
occlusion of, sudden, *1969:* March, **335–340**
renal, stenosis, diagnosis, *1968:* Sept., 1217
treatment, *1968:* Sept., 1229
Arthritis, adjuvant, in animals, *1968:* May, 669–671
gouty. See also *Gout.*
acute, *1969:* Nov., 1334
chronic (tophaceous gout), *1969:* Nov., 1336
infectious. See *Arthritis, septic.*
of hypogammaglobulinemia, *1968:* May, 578
psoriatic vs. rheumatic, *1968:* May, 506–507
rheumatoid, acromioclavicular joint in, *1968:* May, 497
alkylating agents for, *1968:* May, 696, **747–757**
amyloidosis with, *1968:* May, 619, **643–653**
anemia in, *1968:* May, **527–532,** 543
animal models for, *1968:* May, **667–672, 677–686**
anti-inflammatory drugs for, *1968:* May, 691–696
antimalarial therapy for, *1968:* May, 692, **759–764**
antinuclear factor tests in, *1968:* May, 547, **559–565**
arteritis and, *1968:* May, 618
articular cartilage in, *1968:* May, 660
azathioprine for, *1968:* May, 751
bacteria and, *1968:* May, 674
bed rest for, *1968:* May, 689, 700
bedsoniae and, *1968:* May, 676
betamethasone for, *1968:* May, 743
blood abnormalities in, *1968:* May, 543–544
bone changes in, *1968:* May, 661, 663
cartilage destruction and, *1968:* May, 611
chloroquine for, *1968:* May, 761
chrysotherapy for, *1968:* May, **733–738**
Arthritis (*Continued*)
rheumatoid, connective tissue cell changes and, *1968:* May, 598–600
corticosteroids for, *1968:* May, 693, **739–746**
cortisone for, *1968:* May, 743
course of, intermittent, *1968:* May, 551–552
remissions in, *1968:* May, 552–554
cyclophosphamide for, *1968:* May, 696, 750, 751
cytotoxic drugs for, *1968:* May, 696, **747–757**
dexamethasone for, *1968:* May, 743
diagnosis of, criteria for, *1968:* May, 480
differential, *1968:* May, **503–515**
ankylosing spondylitis in, *1968:* May, **517–526**
laboratory studies in, *1968:* May, **539–548**
elbow in, *1968:* May, 496
epidemiology, *1968:* May, **479–491**
familial factors in, *1968:* May, 489–490
genetic factors in, *1968:* May, 489–490
methods of examination in, *1968:* May, 479
rheumatoid factor and, *1968:* May, 487–488
erythrocyte sedimentation rate in, *1968:* May, 543
etiology of, infectious, *1968:* May, **673–676**
foot in, *1968:* May, 498
gold therapy for, *1968:* May, 691, **733–738**
granuloma in, *1968:* May, 616
hand in, *1968:* May, 495
hip in, *1968:* May, 501
hydrocortisone for, *1968:* May, 743
hydroxychloroquine for, *1968:* May, 761
hypercortisonism and, *1968:* May, 740–742
immunological factors in, *1968:* May, 594–598
immunosuppression for, *1969:* Nov., 1235
indomethacin for, *1968:* May, 694
infectious agents and, *1968:* May, 598
inflammation in, *1968:* May, 611, **623–634**
antigen-antibody reactions, *1968:* May, 630–631
cellular responses, *1968:* May, 629–630
chemical mediators, *1968:* May, 624–626
complement system and, *1968:* May, 628–629
immune factors, *1968:* May, 630–631
kallikrein-kininogen-kinin system and, *1968:* May, 624
lysosomes and, *1968:* May, 626–628, 637
neutrophils and, *1968:* May, 629
polymorphonuclear leukocytes and, *1968:* May, 629
vascular reactions, *1968:* May, 629
vasoactive amines and, *1968:* May, 625

Arthritis (*Continued*)
rheumatoid, joint ankylosis and, *1968:* May, 614
joint aspiration in, *1968:* May, 539
joint effusion in, *1968:* May, 609
joint space narrowing in, *1968:* May, 660
juvenile, antimalarial therapy for, *1968:* May, 586
aspirin for, *1968:* May, 584
corticosteroids for, *1968:* May, 585
course, *1968:* May, 581–583
early natural history, *1968:* May, **567–591**
gold therapy for, *1968:* May, 586
management, *1968:* May, 583–587
modes of onset, *1968:* May, 568
prognosis in, *1968:* May, 587
knee in, *1968:* May, 499
laboratory tests in, *1968:* May, **539–548**
leukocytosis in, *1968:* May, 543
low back pain and, *1968:* Jan., 64
lung lesions in, *1968:* May, 619
lymph node hyperplasia in, *1968:* May, 619
lymphoid nodules of joints in, *1968:* May, 610
lysosomal enzymes and, *1968:* May, 600–601
lysosomes and, *1968:* May, 637–638
malalignment of joints in, *1968:* May, 660
management of, conservative, *1968:* May, **699–702**
orthopedic, *1968:* May, 696–697
metabolic changes in, *1968:* May, 601
metatarsophalangeal joints in, *1968:* May, 498
methotrexate for, *1968:* May, 750, 754
methylprednisone for, *1968:* May, 743
mycoplasmas and, *1968:* May, 675
myositis in, *1968:* May, 619
nitrogen mustard for, *1968:* May, 696, 750
orthopedic surgery for, *1968:* May, **717–731**
osteoarthrosis in, secondary, *1968:* May, 663
osteoporosis in, *1968:* May, 656
pannus formation in, *1968:* May, 611
pathogenesis, *1968:* May, **593–605**
lysosomes and, *1968:* May, **635–641**
pathology, *1968:* May, **607–621**
phenylbutazone for, *1968:* May, 694
physical signs in, *1968:* May, **493–502**
physical therapy for, *1968:* May, 701, **707–716**
prednisone and prednisolone for, *1968:* May, 693, 743
prevalence, *1968:* May, 482–487
prognosis, favorable factors in, *1968:* May, 555
pulmonary lesions in, *1968:* May, 619
radiologic manifestations, *1968:* May, **655–665**
rehabilitation in, *1968:* May, 713–714
rheumatoid factor in, tests for, *1968:* May, 545

Arthritis (*Continued*)
rheumatoid, salicylate therapy for, *1968:* May, 699, **703–706**
serologic tests in, *1968:* May, 544–547
seropositive, nodular, optimum therapeutic program in, *1968:* May, **687–698**
vs. seronegative, *1968:* May, **533–538**
serum abnormalities in, *1968:* May, 543–544, **559–565**
serum protein changes in, *1969:* Jan., 150
shoulder in, *1968:* May, 497
soft tissue changes in, *1968:* May, 656
spine in, *1968:* May, 501
splints and appliances for, *1968:* May, 712–713
sternoclavicular joint in, *1968:* May, 497
subluxation of joints in, *1968:* May, 660
symposium on, *1968:* May, **477–764**
synovial fluid examination in, *1968:* May, 539–543
synovitis in, acute, *1968:* May, 608
systemic nature, *1968:* May, 493
triamcinolone for, *1968:* May, 743
types of course and prognosis in, *1968:* May, **549–557**
variants, *1968:* May, **503–515**
vs. progressive systemic sclerosis, *1968:* May, 560, 562
vs. systemic lupus erythematosus, *1968:* May, 560, 562
viruses and, *1968:* May, 675
with leukopenia, *1968:* May, 529
with psoriasis, *1968:* May, 506–507
with splenomegaly, *1968:* May, 529
with ulcerative colitis, *1968:* May, 507–509
with urethritis and conjunctivitis, *1968:* May, 504–505
septic, in animals, *1968:* May, 667–669, **677–686**
oxacillin and cloxacillin for, *1970:* Sept., 1134
penicillins for, *1970:* Sept., 1090
vs. juvenile rheumatoid arthritis of monarticular onset, *1968:* May, 580
traumatic, vs. juvenile rheumatoid arthritis of monarticular onset, *1968:* May, 580
tuberculous, vs. juvenile rheumatoid arthritis of monarticular onset, *1968:* May, 580

Ascites, in Laennec's cirrhosis, basis of therapy for, *1969:* Nov., **1359–1365**
in liver disease, dietary control, *1970:* Nov., 1466

Ascorbic acid deficiency, osteoporosis and, *1970:* Jan., 145
tests for, *1969:* Jan., 74

Asphyxia, intrapartum, recognition of, *1969:* Sept., 1055

Aspiration pneumonia, penicillins for, *1970:* Sept., 1088

Aspirin. See *Acetylsalicylic acid; Salicylates.*

Assortative mating, genetic consequences, *1969:* July, 978
Asthma, acute, vs. intractable heart failure, *1970:* March, 312
bronchial, bronchopulmonary lavage for, *1970:* May, 765
treatment, *1969:* March, **239–248**
immunologic familial, *1969:* March, 239
immunologic sporadic, *1969:* March, 240
nonimmunologic sporadic, *1969:* March, 240
status asthmaticus, *1970:* March, **493–509**
Astigmatism, *1969:* Sept., 1135
Astrocytoma, cerebellopontine angle syndrome and, *1968:* July, 792, 793
Asystole, ventricular, *1969:* March, 324
Ataractics, in labor, *1968:* Jan., 141
Ataxia, Friedreich's, *1968:* July, 900
Ataxia-telangiectasia, *1969:* July, 909; *1970:* March, 293
Atelectasis, right-to-left shunt secondary to, *1970:* May, 626
Atheroembolism, skin necrosis and, *1969:* March, 263
Atherogenesis, cerebral, *1970:* March, 352
Atherosclerosis, dietary management, *1970:* Nov., 1449–1452
hyperlipidemia in, dietary and drug therapy, *1970:* May, **657–669**
lipid alterations in, *1970:* Nov., 1450
Athetosis, speech disturbances in, *1968:* July, 838–841
Atopy, *1969:* March, 239
injection therapy for, immunologic basis of, *1969:* Nov., **1257–1264**
Atrial fibrillation. See *Fibrillation, atrial.*
Atrial septum, defects, cardiac catheterization in, *1970:* July, 975–976
Atromid S. See *Clofibrate.*
Atropine, for cholinergic crisis, *1969:* March, 287
for heart block, *1969:* March, 325
for sinus bradycardia, *1969:* March, 322
for slow ventricular rate, *1968:* Sept., 1070
Auricular nerve, greater, biopsy, *1968:* July, 886
Auscultation, of heart, *1969:* Jan., 104–109
Australia antigen, viral hepatitis and, *1970:* May, **805–817**
Autoanalyzer, in serum screening, *1969:* Jan., **175–188**
Autoimmunity, exophthalmic goiter and, *1970:* Jan., 120–123
gastrointestinal disease and, *1968:* Nov., **1285–1295**
immunosuppression and, *1969:* Nov., 1229–1231
skin disease and, *1970:* Jan., **95–105**
thyroid disease and, *1970:* Jan., 120
Automated Medical History, *1970:* July, 828
Automated personality assessment, *1970:* July, **835–849**
Automatisms, features, *1968:* July, 961
Autonomic blockade, neurolytic agents for, *1968:* Jan., 163
Autonomic drugs, effects on laboratory values, *1969:* Jan., 218
Autosomal dominant inheritance, *1969:* July, 749
Autosomal recessive inheritance, *1969:* July, 746, 749
of metabolic disorders, detection by direct measurements, *1969:* July, 857
Avitaminosis. See under *Vitamin.*
Azathioprine (Imuran), after kidney transplants, *1970:* Jan., 84
for immunosuppression, *1969:* Nov., 1227
for rheumatoid arthritis, *1968:* May, 751
Azotemia, dietary control, *1970:* Nov., 1453
during tetracycline therapy, *1970:* Sept., 1182

BACILLURIA, chronic, tetracyclines for, *1970:* Sept., 1180
Bacitracin, *1970:* Sept., 1291–1292
Back, lower, anatomic considerations, *1969:* May, 525–528
pain in, *1968:* Jan., **55–71**
evaluation and medical management, *1969:* May, **525–540**
Bacteremia, emergency treatment, *1969:* March, 446
gentamicin for, *1970:* Sept., 1312
oxacillin and cloxacillin for, *1970:* Sept., 1133
Bacteria, diarrhea and, *1970:* March, 445–446
gram-negative, antibacterials for, *1970:* Sept., 1167
rheumatoid arthritis and, *1968:* May, 674
Bacterial endocarditis. See under *Endocarditis.*
Bacteriological tests, in community hospital laboratory, *1969:* Jan., 13
in office laboratory, *1969:* Jan., 8
Bacteriuria, in children, long-term sulfonamide therapy for, *1970:* Sept., 1080
Bacteroides infections, ampicillin for, *1970:* Sept., 1153
tetracyclines for, *1970:* Sept., 1179
Balanoposthitis, candidal, nystatin for, *1970:* Sept., 1336
Balloon tamponade, for bleeding esophageal varices, *1968:* Nov., 1466
Barbiturates, for pain, *1968:* Jan., 49
for seizures, *1968:* July, 963
in labor, *1968:* Jan., 139
metabolism, *1970:* Nov., 1569
Basal metabolic rate, thyroid function and, *1968:* March, 463
Bases of therapy, symposium on, *1969:* Nov., **1223–1423**
Bed rest. See under *Rest.*
Bedsoniae, rheumatoid arthritis and, *1968:* May, 676
Behavior, driving, psychological factors in physically handicapped, *1969:* May, 692–695
modification, in hemiplegic patients, *1969:* May, 580–583
therapy, for obesity, *1970:* May, 752
Behavioral genetics, future of, *1969:* July, 1005
Belladonna, for acid-peptic disease, physiology and pharmacology of, *1969:* Nov., **1379–1388**
for dumping syndrome, *1969:* Nov., 1409

Benadryl. See *Diphenhydramine hydrochloride.*
Benedict's test, drug effects on, *1969:* Jan., 212
Benemid. See *Probenecid.*
Benzathine penicillin, hypersensitivity reactions, *1970:* Sept., 1094
Benzothiadiazine therapy, potassium and, *1968:* Sept., 1105
Benzylpenicillin. See *Penicillin G.*
Benzylpenicilloyl-polylysine, in skin test of penicillin allergy, *1970:* July, 1001, 1004; *1970:* Sept., 1097
Beta-adrenergic receptors. See *Adrenergic receptors.*
Beta-aminoisobutyric aciduria, as example of polymorphism, *1969:* July, 892
Beta cells of pancreas, tumors, *1968:* March, 300
Betalipoproteins, deficiency, congenital, *1968:* Nov., 1277
  plasma transport, *1970:* Nov., 1385
Betamethasone, for rheumatoid arthritis, *1968:* May, 743
Biermer's anemia. See *Anemia, pernicious.*
Bifocals, for children, *1969:* Sept., 1137
Bile pigment excretion, test for, *1968:* Nov., 1412
Bile salts, absorption and, *1969:* Sept., 1178
  implications of current research on, *1968:* Nov., 1271
Biliary tract, disease of, pain pattern in, *1968:* Jan., 106
  pancreatitis and, *1970:* March, 480
Bilirubin, metabolism, *1968:* Nov., 1417
  congenital defects in, *1968:* Nov., 1276
  serum, test for, *1968:* Nov., 1409, 1428
    drug effects on, *1969:* Jan., 212
Biochemical genetics, future of, *1969:* July, 1001
Biopsy, bone marrow, in iron deficiency states, *1970:* Nov., 1405
  endometrial, in amenorrhea, *1968:* March, 350
  jejunal, *1970:* July, **851–862**
  of lung, transbronchoscopic, *1970:* July, **951–959**
    transthoracic (needle), *1970:* July, **961–971**
  of nerves, *1968:* July, **885–893**
Bladder, carcinoma of, radiation therapy for, *1968:* Jan., 205
  function, after myocardial infarction, *1968:* Sept., 1066
  incontinence, in children with spina bifida, *1969:* May, 491
    in hemiplegic patient, *1969:* May, 557–558
  neurogenic, with spina bifida and myelomeningocele, management, *1969:* May, 496–501
Blastomycosis, of adrenal glands, *1968:* March, 329
Bleeding. See *Hemorrhage.*
Bleeding time tests, *1970:* July, 890
Blood, abnormalities, in rheumatoid arthritis, *1968:* May, 543–544
  capillary, for gas and pH measurements, *1969:* Jan., 142
Blood (*Continued*)
  cells. See also under names of cells.
    differentiation of, erythropoietin and, *1970:* Jan., 174
  coagulation. See *Coagulation.*
  drug effects on, *1969:* Jan., 217
  dyscrasias, due to chloramphenicol, *1970:* Sept., 1189, 1190
  examination, iron-deficiency anemia and, *1970:* July, 904
  flow, delayed venous return, as factor in thromboembolism, *1969:* March, 342
    renal, kidney failure and, *1969:* March, 399
  gases, in pulmonary embolism, *1970:* March, 365
    in status asthmaticus, *1970:* March, 495–497
    measurement, clinical interpretation of, *1970:* May, **617–629**
      in capillary blood, *1969:* Jan., **137–145**
  groups, as examples of polymorphism, *1969:* July, 890
    normal agglutinins and, *1969:* Sept., 1064
    properties of, *1969:* Sept., 1063
  lipids. See *Lipids.*
  osmolarity of, intraocular pressure and, *1969:* Sept., 1116
  pH, measurement in capillary blood, *1969:* Jan., **137–145**
  plasma, factors, deficiencies, evaluation of, *1969:* Nov., 1318
    role in hemostasis, *1969:* Nov., 1310
  platelets. See *Platelets.*
  pressure, central venous, in myocardial infarction, *1970:* Jan., 238–239
    jugular veins and, *1969:* Jan., 100
    significance, *1968:* Sept., 1083
    venomotor tone and, *1968:* Sept., **1077–1090**
  high. See *Hypertension.*
  low. See *Hypotension.*
  orthostatic, *1968:* July, 809
  sampling and storage, for measurements of acid-base status, *1969:* Jan., 143
  storage, oxygen affinity and, *1970:* May, 739
  tests, in office laboratory, *1969:* Jan., 6
  transfusion. See *Transfusion.*
  vessels, diseases, skin necrosis and, *1969:* March, 264
    fragility, hemorrhage and, *1969:* Nov., 1316
    of leg, in hemiplegic patient, *1969:* May, 553
    permeability, in rheumatoid arthritis, *1968:* May, 629
    role in hemostasis, *1969:* Nov., 1310
  volume, reduced, from pancreatitis, *1969:* March, 432
BMR. See *Basal metabolic rate.*
Body composition, as measure of energy stores, *1970:* Nov., 1367
  measurement, *1970:* Nov., 1371
Body fluids. See under *Fluids.*
Body image, disturbances, in obesity, *1970:* May, 751

Bone, changes, in hyperparathyroidism *1970:* Jan., 134–135
density, determination of, in metabolic bone disease, *1970:* July, 1067–1069
disorders, in rheumatoid arthritis, *1968:* May, 661, 663
malignant, amputation for, rehabilitation after, *1969:* May, 611–614
metabolic, tests for, *1970:* July, **1061–1070**
marrow, biopsy, in iron deficiency states, *1970:* Nov., 1405
depression, complicating immunosuppression, *1969:* Nov., 1231
due to chloramphenicol, *1970:* Sept., 1190
examination, for iron, *1970:* July, 910
function, in rheumatoid arthritis, *1968:* May, 528
metabolism, fluoride and, *1970:* Nov., 1559
osteoporosis and, *1970:* Jan., **141–152**
periosteal formation, hyperthyroidism and, *1968:* March, **393–398**
tumors, low back pain and, *1968:* Jan., 68
radiation therapy for, *1968:* Jan., 204
Borrelia infections, tetracyclines for, *1970:* Sept., 1179
Bowel. See also *Intestines.*
congenital atresia of, intravenous hyperalimentation for, *1970:* May, 587
function, after myocardial infarction, *1968:* Sept., 1066
incontinence, in children with spina bifida, *1969:* May, 491
in hemiplegic patient, *1969:* May, 557–558
resection, mesenteric vein thrombosis with, intravenous hyperalimentation for, *1970:* May, 585
short, medium chain triglycerides in, *1970:* Nov., 1375
BPPL. See *Benzyl penicilloylpolylysine.*
Braces. See *Orthoses.*
Brachial neuritis, paralytic, *1968:* July, 776–777
Brachial pain, neurologic disorders and, *1968:* July, **773–779**
Brachial plexus, compression, *1968:* July, 777
lesions, *1968:* July, 776
Bradycardia, sinus, *1969:* March, 322
Bradykinin, activation, *1968:* March, 266
as mediator of anaphylaxis, *1969:* March, 251
inactivation, *1968:* March, 267
peptides, pain stimulation by, *1968:* Jan., 5, 6–8
salt excretion and, *1968:* March, 278
Brain. See also *Cerebellum* and *Cerebrum.*
arteriovenous malformations, hemorrhagic stroke and, *1968:* Sept., 1202
treatment for, *1968:* Sept., 1208
cortex of, pain originating in, *1968:* Jan., 117
damage to, creatine phosphokinase levels in, *1969:* Jan., 122
dyslexia and, *1969:* Sept., 1124
Brain (*Continued*)
damage to, in adults, speech disorders and, diagnosis, *1969:* May, **561–573**
function, nutrition and, *1970:* Nov., 1421–1428
growth, fetal, critical periods in, *1970:* Nov., 1419
measurement, *1970:* Nov., 1420
physicochemical, *1970:* Nov., 1414–1421
lesions, electroencephalographic patterns in, *1968:* July, 937–939
physicochemical changes, *1970:* Nov., 1419–1421
radioisotope scanning of, dual channel, *1969:* Jan., 199
stem, astrocytoma, cerebellopontine angle syndrome and, *1968:* July, 792
trauma, rehabilitation after, *1969:* May, **677–684**
trauma or disease, speech disorders and, *1969:* May, 569
tumor, vs. cerebrovascular insufficiency, *1969:* March, 297
weight, malnutrition and, *1970:* Nov., 1419
Branched-chain ketonuria. See *Maple syrup urine disease.*
Breast, carcinoma of, chemotherapy for, *1969:* Nov., 1273
surgery for, rehabilitation after, *1969:* May, 614–615
thermography in, *1970:* May, 606–611
Breast-feeding, importance in undernourished populations, *1970:* Nov., 1427
Breathing. See also *Respiration; Ventilation.*
assisted, in respiratory failure, *1969:* March, 246
deep, and coughing, to promote venous return, *1969:* March, 345
intermittent positive pressure, for bronchospasm in anaphylaxis, *1969:* March, 256
for myasthenic crisis, *1969:* March, 288
in cardiopulmonary resuscitation, *1969:* March, 390
restoration, in cardiopulmonary resuscitation, *1969:* March, 390
Bretylium tosylate, for cardiac arrhythmia, basis of action of, *1969:* Nov., 1306
Bricker procedure, for urinary tract damage with myelomeningocele, *1969:* May, 499, 500
Broad-beta lipoproteinemia, diagnosis and diet therapy, *1970:* Nov., 1396
5-Bromodeoxyuridine, chromosome breakage and, *1969:* Nov., 1252
Bromsulphalein excretion test, *1968:* Nov., 1411
drug effects on, *1969:* Jan., 212
Bronchial asthma. See *Asthma, bronchial.*
Bronchiectasis, tetracyclines for, *1970:* Sept., 1180
Bronchitis, acute, ampicillin for, *1970:* Sept., 1149
chronic, tetracyclines for, *1970:* Sept., 1180

Bronchodilators, for asthma, *1969:* March, 242, 243
Bronchogenic carcinoma. See *Lungs, carcinoma of.*
Bronchopulmonary lavage, *1970:* May, **755–771**
Bronchoscopy, lung biopsy via, *1970:* July, **951–959**
Bronchospasm, acute, with bronchial asthma, *1969:* March, 242
anaphylaxis and, *1969:* March, 252
Brucellosis, choice of therapy for, *1970:* Sept., 1163, 1164
tetracyclines for, *1970:* Sept., 1179
Bruton type agammaglobulinemia, *1969:* July, 907; *1970:* March, 285
Bulbar palsy, speech disturbances in, *1968:* July, 838–841
Bullous pemphigoid, autoimmunity and, *1970:* Jan., 100–104
Bundle branch block, *1969:* March, 325
Burns, infection and, emergency treatment, *1969:* March, 445
sepsis, gentamicin for, *1970:* Sept., 1314
Bursa, subacromial, palpation, in neck and shoulder pain, *1969:* May, 515
Bursitis, in rheumatoid arthritis, *1968:* May, 493
pain of, radiation therapy for, *1968:* Jan., 203
Butazolidin. See *Phenylbutazone.*
Byler's disease, *1968:* Nov., 1275

CACHEXIA, cardiac, complicating heart failure, *1970:* March, 319
Cadmium, nutritional significance of, *1970:* Nov., 1527
Cajal-Retzius cells, *1970:* Nov., 1419
Calcium, absorption, normal, *1968:* Nov., 1343
studies, *1968:* Nov., 1351
balance, in thyrotoxicosis, *1970:* Nov., 1482
body, measurement with whole-body counter, *1969:* Jan., 209
concentration, cardiovascular system and, *1968:* Sept., 1245
deficiency, after gastrointestinal surgery, *1969:* Nov., 1401
metabolism, disorders of, in uremia, *1970:* March, 421–425
osteoporosis and, *1969:* Jan., 145–146
radioactive, in tests for metabolic bone disease, *1970:* July, 1061–1063
serum, hyperparathyroidism and, *1968:* March, 452; *1970:* Jan., 132
screening, hyperparathyroidism and, *1970:* March, 516–517
tests for, drug effects on, *1969:* Jan., 212
tolerance test, hyperparathyroidism and, *1968:* March, 457
urinary, hyperparathyroidism and, *1968:* March, 452; *1970:* Jan., 135
Calcium ion, angiotensin and, *1968:* March, 268
Caloric deficiency, after gastrointestinal surgery, *1969:* Nov., 1389–1395
Caloric requirements, activity and, *1970:* Nov., 1578
Caloric stores, variability of, *1970:* Nov., 1368
Cancer. See *Carcinoma.*
Cancer family syndrome, *1969:* July, 929
Candidiasis, nystatin for, *1970:* Sept., 1329–1337
Capillaria philippinensis infestation, jejunal biopsy and, *1970:* July, 860
Capillary fragility test, *1970:* July, 890
Carbamazepine (Tegretol), for seizures, *1968:* July, 972
for trigeminal neuralgia, *1968:* Jan., 112; July, 799
Carbohydrates, absorption, normal, *1968:* Nov., 1341
studies, *1968:* Nov., 1351
disorders, nutritional management, *1970:* Nov., 1438–1441
metabolism, disturbances, in celiac disease, *1970:* May, 651
in liver disease, *1970:* Nov., 1457
oral contraception and, *1970:* Jan., 166
pheochromocytoma and, *1970:* Nov., 1489
pregnancy and, *1968:* March, 253–257
thiazide diuretics and, *1969:* Nov., 1327
requirements, for diabetics, *1970:* Nov., 1579
Carbon dioxide, for acute cerebrovascular disease, *1970:* March, 357
Carbonic anhydrase inhibitors, for refractory heart failure, *1968:* Sept., 1173
intraocular pressure and, *1969:* Sept., 1117
Carbuncle, renal, and prolonged fever, *1970:* March, 386
Carcinoid, bradykinin and, *1968:* March, 268
chemotherapy for, *1969:* Nov., 1275
syndrome, pancreatic islet cell tumors and, *1968:* March, 305
Carcinoma, chemotherapy of, basis of, *1969:* Nov., 1272–1275
complicating celiac disease, *1970:* May, 655
cytogenetics and, *1969:* July, 933–936
genetic factors in, *1969:* July, **923–939**
hepatocellular, alpha-fetoprotein in, *1970:* May, 798–802
in childhood, possible inheritance of, *1969:* July, 930–933
oat-cell, of lung and mediastinum, *1968:* March, 323
of bone and soft tissue, amputation and disarticulation for, rehabilitation after, *1969:* May, 611–614
of breast, chemotherapy for, *1969:* Nov., 1273
surgery for, rehabilitation after, *1969:* May, 614–615
thermography in, *1970:* May, 606–611
of colon, radiation therapy for, *1968:* Jan., 206
surgery for, rehabilitation after, *1969:* May, 615–617
with chronic ulcerative colitis, *1969:* Sept., 1201
of face and mouth, rehabilitation after treatment, *1969:* May, 617

Carcinoma (*Continued*)
of kidney, and prolonged fever, *1970:* March, 387
of larynx, rehabilitation after treatment, *1969:* May, 617–618
of liver, primary, congenital abnormalities and, *1969:* July, 932
of lung, chemotherapy for, *1969:* Nov., 1273
detection of, *1970:* May, **549–553**
of prostate, radiation therapy for, *1968:* Jan., 206
of skin, inheritance of, *1969:* July, 928
of stomach, environmental factors in, *1968:* Nov., 1279
genetic factors in, *1968:* Nov., 1279
of testes, chemotherapy for, *1969:* Nov., 1272
rehabilitation after treatment, *1969:* May, 618–619
pain of, percutaneous cordotomy for, *1968:* Jan., 195
radiation therapy for, *1968:* Jan., 206
rehabilitation after treatment, *1969:* May, **607–624**
resistance, *1969:* July, 936
Cardiac. See also *Heart.*
Cardiac arrest, office treatment for, *1969:* March, 331
Cardiac arrhythmia. See *Arrhythmia, cardiac.*
Cardiac cachexia, complicating heart failure, *1970:* March, 319
Cardiac emergencies, in office practice, *1969:* March, **331–333**
Cardiac output, in shock, *1968:* Sept., 1050
Cardiac standstill, *1969:* March, 324
in pregnancy, *1969:* Sept., 1025–1028
Cardiogenic shock, after myocardial infarction, *1968:* Sept., 1073
treatment, *1969:* March, **309–313**
Cardiomyopathy, alcoholic, *1968:* Sept., **1183–1191**
Cardiospasm. See *Esophagus, achalasia.*
Cardiovascular system, adrenergic receptors in, *1968:* Sept., 1010
advanced renal disease and, *1968:* Sept., **1237–1247**
diseases, hypothyroidism and, *1968:* March, 440
nutrition and, *1970:* Nov., **1449–1454**
potassium therapy for, *1968:* Sept., **1103–1113**
recent advances in, symposium on, *1968:* Sept., **1007–1260**
disorders, in uremia, *1970:* March, 415–419
hyperdynamic states of, adrenergic receptor blockers and, *1968:* Sept., **1041–1048**
Caries, dental, diet and, *1970:* Nov., 1560
Carotid insufficiency syndrome, cerebrovascular disease and, *1970:* March, 353
Carotid sinus nerve, stimulation of, for angina pectoris, *1968:* Sept., 1036
Carpal tunnel syndrome, *1968:* Jan., 113; July, 778–779
Carriers, heterozygous, of hereditary metabolic disorders, detection of, *1969:* July, **857–874**
Cartilage, articular, destruction of, in rheumatoid arthritis, *1968:* May, 611
Casts, serial, in rehabilitation of hand, *1969:* May, 655
Cataplexy, narcolepsy and, *1968:* July, 784
Cataract, corneal grafting and, *1969:* Sept., 1106
corticosteroids and, *1969:* Sept., 1157
Catecholamines, adrenergic receptors and, *1968:* Sept., 1010
for cardiac arrhythmia, *1969:* March, 318
for cardiogenic shock, *1969:* March, 312
levels, in shock, *1968:* Sept., 1051
release, angiotensin and, *1968:* March, 268
tests, for pheochromocytoma, *1968:* Sept., 1220
urinary, tests for, drug effects on, *1969:* Jan., 212
Catheterization, cardiac. See under *Heart.*
subclavian vein, in intravenous hyperalimentation, *1970:* May, 578
Causalgia, *1968:* Jan., 148–151
Celiac disease. See *Sprue, nontropical.*
Cells. See also specific types.
adipose tissue, size and number, *1970:* Nov., 1536–1537
biology, in culture, *1969:* July, 796–798
Cajal-Retzius, *1970:* Nov., 1419
cultured, *1970:* May, **701–712**
future therapeutic uses, *1969:* July, 808
genetics of, *1969:* July, **795–811**
clinical diagnosis and, *1969:* July, 806–808
hybridization of, *1969:* July, 803–806
mutations found in, *1969:* July, 799–801
Cellulitis, penicillins for, *1970:* Sept., 1087
Central nervous system. See *Nervous system, central.*
Cephalexin, *1970:* Sept., **1229–1244**
clinical pharmacology, *1970:* Sept., 1236
spectrum of activity, *1970:* Sept., 1232
toxic reactions, *1970:* Sept., 1240–1242
Cephaloglycin, *1970:* Sept., 1217, 1223
Cephaloridine, *1970:* Sept., 1217, 1220–1223
nephrotoxicity, *1970:* Sept., 1222
Cephalosporins, *1970:* Sept., **1217–1228**
allergic reactions to, incidence of, *1970:* Jan., 62
Cephalothin (Keflin), *1970:* Sept., 1217, 1218–1220
for bacterial endocarditis, *1968:* Sept., 1098
for emergency treatment of infection, *1969:* March, 440
spectrum of activity, *1970:* Sept., 1129
Cerebellopontine angle syndrome, *1968:* July, **789–795**
aneurysm and, *1968:* July, 792
astrocytoma and, *1968:* July, 792, 793
eighth nerve neuroma and, *1968:* July, 789, 791
intracranial hemangioma and, *1968:* July, 793

Cerebellum, astrocytoma of, cerebellopontine angle syndrome and, *1968:* July, 793
lesions of, speech disturbances in, *1968:* July, 838–842
Cerebral amines, function, in movement disorders, *1969:* May, 636–637
Cerebral arteriosclerosis, pathogenesis, *1970:* March, 352
Cerebral atherogenesis, *1970:* March, 352
Cerebral crisis, *1969:* March, **293–300**
Cerebral ischemia, pathogenesis of, *1970:* March, 352–355
Cerebral palsy. See *Paralysis, cerebral.*
Cerebral vascular accident. See *Cerebrovascular disease.*
Cerebrospinal fluid, examination, in stroke, *1968:* Sept., 1198
Cerebrovascular disease, current concepts, *1970:* March, **349–360**
hemiplegia after, rehabilitation and, *1969:* May, 541
hemorrhagic, *1968:* Sept., **1193–1212**
causes of, *1968:* Sept., 1200–1204
cerebrospinal fluid examination in, *1968:* Sept., 1198
hypertension and, *1968:* Sept., 1204–1206
preventive measures, *1968:* Sept., 1209
treatment for, *1968:* Sept., 1207–1209
vs. occlusive, *1968:* Sept., 1193
speech disorders and, *1969:* May, 566
Cerebrovascular insufficiency, vs. brain tumor, *1969:* March, 297
Cerebrum, disorders of, chronic renal failure and, *1968:* July, 845–846
metabolic abnormalities and, *1968:* July, 846
Cervical block, in office, *1968:* Jan., 181
Cervical collar, for neck and shoulder pain, *1969:* May, 521
Cervical rib syndrome, *1968:* July, 777
Cervical root, pain and, *1968:* July, 773–776
herniated disk and, *1968:* July, 775
spinal cord hypertrophy and, *1968:* July, 775
Cervical root and plexus, palpation, in neck and shoulder pain, *1969:* May, 514
CGD (chronic granulomatous disease of childhood), *1969:* July, 910
Chair rest. See under *Rest.*
Charcot-Marie-Tooth disease, *1968:* July, 903
Chediak-Higashi syndrome, genetics and detection, *1969:* July, 914–915
infections in, *1970:* May, 720
Chemicals, chromosome breakage and, *1969:* Nov., 1252
mutations and, *1969:* Nov., 1243
in cell culture material, *1969:* Nov., 1250
in experimental mammals, *1969:* Nov., 1248
in somatic tissue, *1969:* Nov., 1251
skin necrosis and, *1969:* March, 266–268
Chemotaxis, leukocyte, disorder of, serum inhibitor and, *1970:* May, 719
Chemotherapeutic agents, effects on laboratory values, *1969:* Jan., 219
Chemotherapy of neoplastic disease, bases of, *1969:* Nov., **1265–1278**
Chest pain, coronary arteriography in, *1970:* July, 982
postoperative, *1968:* Jan., **91–101**
Chiasm, optic, lesions of, pupillary reflexes in, *1968:* July, 877
Childbirth, natural, *1968:* Jan., 145
Childhood, early, malnutrition in, *1970:* Nov., 1419
Children, diarrheal disease in, *1970:* March, **443–453**
meningitis in, ampicillin for, *1970:* Sept., 1149
otitis media in, ampicillin for, *1970:* Sept., 1148
penicillins for, *1970:* Sept., 1087
streptomycin dosage in, *1970:* Sept., 1166
pain relief in, *1968:* Jan., **131–136**
Chloramphenicol, *1970:* Sept., **1187–1197**
allergic reactions to, incidence, *1970:* Jan., 63
as alternate to penicillins, *1970:* Sept., 1193
avoiding, for emergency treatment of infection, *1970:* March, 440
blood dyscrasias from, *1970:* Sept., 1189, 1190
clinical indications, *1970:* Sept., 1191–1194
spectrum of activity, *1970:* Sept., 1189, 1193
Chlordiazepoxide (Librium), for pain, *1968:* Jan., 52
Chloride, tests for, drug effects on, *1969:* Jan., 212
Chloromycetin. See *Chloramphenicol*
Chloroquine (Aralen), for rheumatoid arthritis, *1968:* May, 761
retinopathy, fluorescein angiography of fundus in, *1968:* July, 866
Chlorpromazine (Thorazine), for pain, *1968:* Jan., 51
Chlorpropamide (Diabinese), hypoglycemia and, *1969:* March, 465; *1970:* March, 536
Chlortetracycline, *1970:* Sept., 1174, 1175
Cholangiography, percutaneous transhepatic, *1970:* July, **875–879**
Cholecystitis, diet and, *1970:* Nov., 1362
pain pattern in, *1968:* Jan., 105
Cholecystokinin-pancreozymin, structure, secretion, and action, *1968:* Nov., 1301
Cholera, tetracyclines for, *1970:* Sept., 1179
Cholera-like syndrome and pancreatic islet cell tumors, *1970:* May, **567–575**
Cholestasis, benign, recurrent, familial, *1968:* Nov., 1422
intrahepatic, *1968:* Nov., 1421
familial, *1968:* Nov., 1275
Cholesterol, blood, tests for, *1968:* Nov., 1432
concentration, tests for, *1970:* July, **1029–1035**
control of, dietary, *1968:* Sept., 1251
drug, *1968:* Sept., 1253–1259
input and output, *1968:* Sept., 1250

Cholesterol (*Continued*)
plasma, atherosclerotic cardiovascular disease and, *1970:* Nov., 1450
transport, physiology of, *1970:* Nov., 1384–1386
serum, coronary heart disease and, *1968:* Sept., 1249, 1250
tests for, drug effects on, *1968:* Jan., 212
Cholestyramine, for hypercholesterolemia, *1968:* Sept. 1255
Choloxin. See *Dextrothyroxine.*
Chordae tendineae, rupture of, complicating heart failure, *1970:* March, 320
Choreoathetosis, speech disturbances in, *1968:*July, 838–842
Choreoretinitis, fluorescein angiography of fundus in, *1968:* July, 861
Choriocarcinoma, chemotherapy for, *1969:* Nov., 1272
Choroid, hemangioma of, fluorescein angiography of fundus in, *1968:* July, 858
tumor of, metastatic, fluorescein angiography of fundus in, *1968:* July, 864
Choroiditis, fluorescein angiography of fundus in, *1968:* July, 861
Chromaffin tissue, glucagon and, *1970:* Jan., 186
Chromium, nutritional importance, *1970:* Nov., 1520–1523
Chromophobe adenoma, endocrine glands and, *1968:* July, 830–834
symptoms and signs of, early, *1968:* July, **827–834**
Chromosomes, abnormal, in abortuses, *1969:* July, 779, 780
etiology of, *1969:* July, 788
radiation-induced, *1969:* July, 969
analysis, in clinical medicine, *1970:* July, **1009–1027**
prenatal, *1969:* July, 789
cell culture and, *1969:* July, 806
anomalies of, abortion and, *1969:* Sept., 1040
etiology of, *1969:* Sept., 1047
breakage, chemical agents and, *1969:* Nov., 1252
effects of mutagens on, *1969:* Nov., 1246
Rh, *1969:* Sept., 1068
Chrysotherapy, for rheumatoid arthritis, *1968:* May, **733–738**
juvenile, *1968:* May, 586
Chylomicronemias, eruptive xanthomas with, *1970:* Nov., 1387
treatment, *1970:* Nov., 1604
Chylomicrons, plasma transport, *1970:* Nov., 1384
Circle of Willis, aneurysms of, hemorrhagic stroke and, *1968:* Sept., 1200, 1204
Cirrhosis, alcohol and, *1969:* Nov., 1421
ascites and, vs. intractable heart disease, *1970:* March, 314
biliary, primary, autoimmunity and, *1968:* Nov., 1289
steatorrhea in, *1970:* Nov., 1458
hepatic, mineral metabolism in, *1970:* Nov., 1461
Cirrhosis (*Continued*)
Laennec's, ascites in, basis of therapy for, *1969:* Nov., 1359–1365
esophageal varices and, *1968:* Nov., 1458
malnutrition and, *1970:* March, 469
of liver, genetic factors in, *1968:* Nov., 1278
implications of current research in, *1968:* Nov., 1405
in alcoholics, *1968:* Nov., **1445–1455**
incidence and susceptibility, *1968:* Nov., 1448
recognition, *1968:* Nov., 1450
therapy, *1968:* Nov., 1452
serum protein changes in, *1969:* Jan., 149, 150
Citanest. See *Propitocaine.*
Citrullinemia, fibroblast cultures in, *1970:* May, 704
Climate, rheumatoid arthritis and, *1968:* May, 484
Clindamycin and clinimycin, *1970:* Sept., 1300
Clinical chemistry, in community hospital laboratory, *1969:* Jan., 12
Clofibrate (Atromid S, CPIB), for hypercholesterolemia, *1968:* Sept., 1256
for hyperlipoproteinemia, *1970:* Nov., 1605–1612
side-effects, *1970:* Nov., 1611
Clomiphene (Clomid), for amenorrhea, *1968:* March, 354
Clostridia infections, erythromycin for, *1970:* Sept., 1208
tetracyclines for, *1970:* Sept., 1180
Clotting, blood. See *Coagulation.*
Clotting factors, *1969:* Jan., 62
deficiencies, tests for, *1969:* Jan., 72
Cloxacillin, *1970:* Sept., **1127–1143**
clinical indications, *1970:* Sept., 1133
for emergency treatment of infection, *1969:* March, 440
preparations and dosage, *1970:* Sept., 1136, 1137
serum protein-binding, *1970:* Sept., 1117
spectrum of activity, *1970:* Sept., 1129
toxic reactions, *1970:* Sept., 1135
Clubbing, cyanosis and, due to right-to-left shunts, *1970:* May, 625
of fingers and toes, hyperthyroidism and, *1968:* March, **393–398**
CNS. See *Nervous system, central.*
Coagulation, disorders of, obstetric, *1969:* Sept., **1085–1096**
disseminated intravascular, *1969:* March, **301–307;** Nov., 1319
diagnosis and treatment of, *1970:* May, **555–565**
skin necrosis and, *1969:* March, 265
fibrinolysis and, intravascular, syndrome of, diagnosis, *1970:* July, 898
mechanism of, *1969:* March, 301
oral contraception and, *1970:* Jan., 167
processes in, *1969:* Nov., **1309–1320**
tests for, *1969:* Jan., 63; Nov., 1313–1316; *1970:* July, 893–897

Coagulation (*Continued*)
tests for, in community hospital laboratory, *1969:* Jan., 15
Coagulopathy, consumption, *1969:* Nov., 1319
Coarctation of aorta. See under *Aorta.*
Cocaine, in office, *1968:* Jan., 178
Codman's jog and wince test, in neck and shoulder pain, *1969:* May, 515
Coenzyme supplementation, in treatment of inherited metabolic disorders, *1969:* July, 949
Colchicine, for gout, *1970:* March, 439
basis of action of, *1969:* Nov., 1337
Cold therapy, for neck and shoulder pain, *1969:* May, 518
Colistin (Coly-Mycin), *1970:* Sept., **1267–1276.** See also *Polymyxin E.*
clinical indications, *1970:* Sept., 1273
clinical pharmacology, *1970:* Sept., 1268
for emergency treatment of infection, *1969:* March, 441
spectrum of activity, *1970:* Sept., 1270
Colitis, granulomatous. See *Granulomatous colitis.*
ulcerative. See *Ulcerative colitis.*
Collagen diseases. See *Connective tissue disorders.*
Collagen formation, nutrition and, *1970:* Nov., 1498
Colon, carcinoma of, radiation therapy for pain, *1968:* Jan., 206
surgery for, rehabilitation after, *1969:* May, 615–617
with chronic ulcerative colitis, *1969:* Sept., 1201
Crohn's disease of. See *Granulomatous colitis.*
cytological examination, *1968:* Nov., 1325
diverticula of, low-residue diet for, *1970:* Nov., 1360
Marfan's syndrome and, *1968:* Nov., 1277
hemorrhage, causes, *1969:* March, 418
polyposis of, familial, inheritance, *1968:* Nov., 1274
Color blindness, as example of polymorphism, *1969:* July, 891
Colostomy, care of, *1969:* May, 616
Coly-Mycin. See *Colistin.*
Coma, diabetic, hyperosmolar, *1969:* Nov., 1371–1372
hyperosmolar hyperglycemic nonketotic, *1970:* May, **683–689**
hepatic, management, *1968:* Nov., **1475–1481.** See also *Hepatic coma.*
myxedema, *1968:* March, 445
Community health, newer approaches to, *1970:* May, **671–682**
rehabilitation medicine and, *1969:* May, **719–733**
Compazine. See *Prochlorperazine.*
Complement system, rheumatoid arthritis inflammation and, *1968:* May, 628–629
Computers in medicine, history taking, *1970:* July, **825–833**
Computers (*Continued*)
Regional Medical Programs and, *1970:* Jan., 25
Congestive heart failure. See under *Heart, failure.*
Congo red test, for amyloid, *1968:* May, 650
Conjunctiva, topical analgesia, *1968:* Jan., 178
Conjunctivitis, inclusion, tetracyclines for, *1970:* Sept., 1179
mild, therapy for, *1969:* Sept., 1151
with arthritis, *1968:* May, 504
Connective tissue, changes, rheumatoid arthritis and, *1968:* May, 598–600
disorders, jejunal biopsy in, *1970:* July, 855
neurophysiology in, *1969:* May, 630–631
serum protein changes in, *1969:* Jan., 149, 150
Consumption-coagulopathy. See *Coagulation, disseminated intravascular.*
Contact lenses, *1969:* Sept., 1138–1140
Contraception, oral, amenorrhea and, *1968:* March, 343
amenorrhea and infertility and, *1969:* Sept., 1032–1035
current status of, *1970:* Jan., **163–171**
varicose veins and, *1968:* Sept., 1085
Convulsions. See *Seizures, convulsive.*
Cooley's anemia, hemoglobin synthesis in, *1969:* July, 880
Coombs antiglobulin test, *1969:* Jan., 56
COPD. See *Pulmonary disease, obstructive, chronic.*
Copper, deficiency, *1970:* Nov., 1512
metabolism, *1970:* Nov., 1511
Wilson's disease and, *1968:* July, **989–1001**
nutritional significance, *1970:* Nov., 1510–1514
Cordotomy, percutaneous, techniques and results, *1968:* Jan., **189–201**
Cornea, grafts, *1969:* Sept., 1103–1107
topical analgesia, *1968:* Jan., 178
transplantation, indications, *1969:* Sept., **1099–1107**
Coronary arteriography, indications for, *1970:* July, **979–995**
Coronary artery disease, hyperlipidemic states and, *1970:* Nov., 1599
serum lipid levels and, *1968:* Sept., **1249–1260**
Coronary care units, myocardial infarction and, *1968:* Sept., 1065
nurses and physicians for, Regional Medical Programs and, *1970:* Jan., 23–24
Corset, for low back pain, *1969:* May, 535
Corticosteroids, after kidney transplants, *1970:* Jan., 87
erythropoiesis and, *1968:* March, 237
for adrenal insufficiency, *1969:* March, 462
for allergy to antibiotics, *1970:* Jan., 71
for asthma, *1969:* March, 243, 244
for eye disorders, *1969:* Sept., 1146
complications, *1969:* Sept., 1155
for gout, *1969:* Nov., 1339
for herpes zoster, *1968:* Jan., 115

Corticosteroids (*Continued*)
for keratitis, *1969:* Sept., 1148, 1152
for malignant exophthalmos, *1969:* March, 471
for ophthalmologic complications of exophthalmic goiter, *1970:* Jan., 126
for pancreatitis, *1969:* March, 434
for rheumatoid arthritis, *1968:* May, 693, **739–746**
juvenile, *1968:* May, 585
for status asthmaticus, *1970:* March, 499
for viral hepatitis, *1970:* March, 460
immunosuppression and, *1969:* Nov., 1227
intraocular pressure and, *1969:* Sept., 1115
leukopoiesis and, *1968:* March, 240
maintenance dose after adrenalectomy, *1969:* March, 460
neurologic side effects, *1968:* July, 850
ocular inflammation, and viruses, *1969:* Sept., **1145–1160**
Corticotropin (ACTH), erythropoiesis and, *1968:* March, 237
for gout, *1969:* March, 456; *1970:* March, 439
for myasthenic crisis, *1969:* March, 288
secretion of, excess, *1968:* March, 359
tests of, *1969:* Jan., 82
tumors secreting, *1968:* March, 323
treatment, *1968:* March, 324
Cortisol, for hypertension due to adrenal hyperplasia, *1968:* Sept., 1229
insulin antagonism and, *1968:* March, 254
Cortisone. See *Corticosteroids.*
Cortisone suppression test, hyperparathyroidism and, *1968:* March, 458
Corynebacterium diphtheriae infection, penicillin for, *1970:* Sept., 1087
Costoclavicular syndrome, *1968:* July, 777
Coumarin anticoagulants, inherited resistance to, *1969:* July, 850
to prevent thromboembolism, *1969:* March, 348
Counseling, genetic, *1969:* July, **991–999**
detection of heterozygous carriers and, *1969:* July, 870
CPIB. See *Clofibrate.*
CPK. See *Creatine phosphokinase.*
Cranial nerve(s), chronic renal failure and, *1968:* July, 847
eighth, neuroma of, cerebellopontine angle syndrome and, *1968:* July, 789, 791
lesions of, at cerebellopontine angle, *1968:* July, **789–795**
pain originating in, *1968:* Jan., 111
pain transmission in, *1968:* Jan., 18
Craniofacial syndromes, deafness and, *1969:* July, 769
Creatine, metabolism of, myopathy and, *1968:* March, 247
Creatine phosphokinase (CPK), tests for, *1969:* Jan., 119–122
Creatinine, urinary, tests for, drug effects on, *1969:* Jan., 212
Creatinuria, myopathy and, *1968:* March, 247
Crigler-Najjar syndrome, *1968:* Nov., 1420
inheritance, *1968:* Nov., 1275
Critical matings, inheritance and, *1969:* July, 745
Crohn's disease, of colon. See *Granulomatous colitis.*
Crooke cell, pathophysiology, *1968:* March, 320
Cryoglobulinemia and cryofibrinogenemia, skin necrosis and, *1969:* March, 265
Cryoglobulins, *1970:* July, 924
Culdoscopy, in amenorrhea, *1968:* March, 351
Cushing's syndrome, adrenocortical tumors and, *1968:* March, 320
amenorrhea and, *1968:* March, 344
clinical pattern and pathological findings, *1968:* March, **313–326**
Crooke cell and, *1968:* March, 320
diagnosis, *1968:* March, 313; Sept., 1217, 1223
ectopic corticotropin-secreting tumor and, *1968:* March, 323
erythropoiesis in, *1968:* March, 238
hypophyseal tumors and, *1968:* March, 320
metabolic and nutritional aspects, *1970:* Nov., 1483–1486
muscle weakness and, *1968:* March, 245
pancreatic islet cell tumors and, *1968:* March, 304
tests for, *1970:* July, 1062
treatment, *1968:* March, 324
without tumor, *1968:* March, 323
CVA. See *Cerebrovascular disease.*
Cyanocobalamin. See *Vitamin* B_{12}.
Cyanosis, clubbing and, due to right-to-left shunts, *1970:* May, 625
in adults with congenital heart disease, cardiac catheterization in, *1970:* July, 976
Cyclazocine, analgesic properties, *1968:* Jan., 39
Cyclophosphamide (Cytoxan), for immunosuppression, *1969:* Nov., 1227
for rheumatoid arthritis, *1968:* May, 696, 750, 751
Cycloplegics, in retinoscopy and refraction, *1969:* Sept., 1136
Cystathionine synthetase deficiency, *1970:* Nov., 1437
Cystathioninuria, dietary control of, *1970:* Nov., 1438
Cystic fibrosis, bronchopulmonary lavage for, *1970:* May, 768
fibroblast cultures in, *1970:* May, 703
of pancreas, inheritance, *1968:* Nov., 1278
Cytellin. See *Sitosterol.*
Cytogenetics, abortion and, *1969:* July, **773–794**
carcinoma and, *1969:* July, 933–936
future of, *1969:* July, 1003
Cytology, exfoliative, in gastrointestinal disease, *1968:* Nov., **1315–1328**
diagnostic criteria, *1968:* Nov., 1316–1319
techniques, *1968:* Nov., 1315
Cytosine arabinoside, bases of action of, *1969:* Nov., 1267
chromosome breakage and, *1969:* Nov., 1252

Cytotoxic drugs, for rheumatoid arthritis, *1968:* May, 696, **747–757**
Cytoxan. See *Cyclophosphamide.*

DBI. See *Phenformin.*
DCI. See *Dichloroisoproterenol.*
Deafness, disease and, in infants, *1969:* July, 753
due to dihydrostreptomycin, *1970:* Sept., 1161
due to kanamycin, *1970:* Sept., 1249
in twins, *1969:* July, 755
pedigree analysis, *1969:* July, 757–765
prelingual, profound, genetic and environmental factors, *1969:* July, **741–772**
prevalence, *1969:* July, 751, 752
retrocochlear lesion and, *1968:* July, 790
risk of, for children of deaf parents, *1969:* July, 762
syndromes with, *1969:* July, 765–769
Defibrination syndrome. See *Coagulation, disseminated intravascular.*
Dehydration, hypertonic, *1969:* March, 413
in diabetic coma, *1970:* May, 691
kidney failure and, *1969:* March, 400
therapeutic, for hyponatremia, *1969:* March, 413
Dejerine-Sottas disease, *1968:* July, 903
Delirium, toxic, acute, *1969:* March, **275–279**
Deltoin. See *Methetoin.*
Demerol. See *Meperidine hydrochloride.*
Demethylchlortetracycline, *1970:* Sept., 1174, 1175
Dental health, nutrition and, *1970:* Nov., **1555–1565**
Depression, psychotic, somatic effects, *1969:* March, 283
Dermatomyositis, esophageal involvement, motility studies in, *1970:* July, 869
"Desensitization," for anaphylaxis, *1969:* March, 255
for allergy to antibiotics, *1970:* Jan., 70
Desoxyn. See *Methamphetamine.*
Development, mental, nutrition and, *1970:* Nov., **1413–1429**
Dexamethasone, for rheumatoid arthritis, *1968:* May, 743
Dexedrine. See *Dextroamphetamine.*
Dextran, for acute cerebral infarction, *1970:* March, 358
Dextroamphetamine (Dexedrine), for narcolepsy, *1968:* July, 783
Dextrostix, in office laboratory, *1969:* Jan., 7
Dextrothyroxine (Choloxin), for hypercholesterolemia, *1968:* Sept., 1254
for hyperlipoproteinemias, *1970:* Nov., 1610
Diabetes, acromegaly and, *1970:* Nov., 1477
chronic pancreatitis and, *1968:* Nov., 1488
insipidus, causes, *1968:* March, 384
nephrogenic, dietary control, *1970:* Nov., 1441
due to demethylchlortetracycline, *1970:* Sept., 1182
Diabetes (*Continued*)
mellitus, Addison's disease and, *1968:* March, 336
chromium and, *1970:* Nov., 1520–1523
complicating urinary tract infection, *1970:* March, 401
diet therapy in, *1970:* Nov., **1577–1587**
fluorescein angiography of fundus in, *1968:* July, 858
hypoglycemia and, *1970:* March, 541
hypoglycemia from drugs in, *1969:* March, **465–467**
juvenile, diet in, *1969:* Nov., 1374–1375
metabolic considerations in therapy for, *1969:* Nov., **1367–1378**
leg amputation and, *1969:* May, 674
neuropathy and, *1968:* July, 905
obesity and, *1970:* Nov., 1533
orthostatic hypotension and, *1968:* July, 812
parietal cell antibody and, *1968:* Nov., 1286
polyneuropathy and, *1968:* Jan., 112
pregnancy and, *1968:* March, 253
with hemiplegia, *1969:* May, 543
Diabetic coma, hyperosmolar, *1969:* Nov., 1371–1372
hyperglycemic nonketotic, *1970:* May, **683–699**
Diabinese. See *Chlorpropamide.*
Diagnostic procedures, sophisticated, symposium on, *1970:* July, **823–1070**
Dialysis. See also *Hemodialysis.*
for congestive heart failure, *1968:* Sept., 1176
neurologic complications, *1968:* July, 849
Dialysis disequilibrium syndrome, in uremia, *1970:* March, 414
Diamox. See *Acetazolamide.*
Diarrhea, after gastrointestinal surgery, *1969:* Nov., 1391
in islet cell tumors, *1970:* May, 567
infectious, *1968:* Nov., 1361
of travelers, *1970:* March, 448, 450
weanling, *1970:* Nov., 1501–1503
Diarrheal disease, acute, *1970:* March, **443–453**
Diathermy, shortwave, for neck and shoulder pain, *1969:* May, 517
Diazepam (Valium), for pain, *1968:* Jan., 52
for recurrent convulsions, *1968:* July, **977–987**
for status epilepticus, *1968:* July, 968
Diazoxide (Hyperstat), for hypertensive crisis, *1969:* March, 353
Dibenamine, blocking action, *1968:* Sept., 1011
Dibenzyline. See *Phenoxybenzamine.*
Dichloroisoproterenol (DCI), blocking action, *1968:* Sept., 1011
Dicloxacillin, *1970:* Sept., **1127–1143**
for emergency treatment of infection, *1969:* March, 440
preparations and dosage, *1970:* Sept., 1137, 1138
serum protein-binding, *1970:* Sept., 1117
spectrum of activity, *1970:* Sept., 1129

Dicoumarol, metabolism of, inherited variations in, *1969:* July, 849
Diet, abortion and, *1969:* July, 777
after myocardial infarction, *1968:* Sept., 1066
ascites in Laennec's cirrhosis and, *1969:* Nov., 1360
dental health and, *1970:* Nov., **1555–1565**
elemental, in surgical nutrition, *1970:* Nov., 1376
gout and, *1969:* Nov., 1339
hypertonic intravenous, administration of, *1970:* Nov., 1377–1381
in acid peptic disease, *1970:* Nov., 1357–1359
in blood lipid disorders, *1970:* Nov., **1383–1398**
in chronic pancreatitis, *1970:* March, 487
in coronary artery disease, *1970:* Nov., 1500
in diabetes mellitus, *1970:* Nov., **1577–1587**
in dumping syndrome, *1969:* Nov., 1408
in dysbetalipoproteinemia, *1970:* Nov., 1396
in gastrointestinal disorders, *1970:* Nov., **1357–1366**
in gout, *1970:* March, 441
in hereditary disorders, *1970:* Nov., **1431–1448**
in hyperbetalipoproteinemia, *1970:* Nov., 1391
in hyperlipidemia, *1970:* May, 663–665
in hyperlipoproteinemia, *1970:* Nov., 1396, 1604, 1609
in hypertriglyceridemia, *1970:* Nov., 1394
in juvenile diabetes mellitus, *1969:* Nov., 1374–1375
in liver disease, *1970:* March, 473–475
clinical aspects, *1970:* Nov., 1461–1468
in nontropical sprue, *1970:* May, 654
in refractory heart failure, *1968:* Sept., 1165
in uremia, *1970:* March, 425–428
iron requirements, *1970:* Nov., 1404
low-carbohydrate, in hyperlipoproteinemia, *1970:* Nov., 1608
low-cholesterol, *1968:* Sept., 1251
low-residue, uses, *1970:* Nov., 1359–1362
low-sodium, in congestive heart failure, *1970:* Nov., 1452
in liver disease, *1970:* Nov.. 1466
restrictions, in asthma, *1969:* March, 241
sources of iron in, *1970:* Nov., 1403
Diethylstilbestrol. See *Estrogens.*
Difficult medical problems, symposium on, *1970:* March, **279–542**
DiGeorge syndrome, *1969:* July, 910; *1970:* March, 286
Digitalis, cellular action of, *1970:* Jan., **221–234**
effects on heart, *1969:* Nov., 1281–1284
for alcoholic myocardiopathy, *1968:* Sept., 1187
for cardiac arrhythmia, basis of action of, *1969:* Nov., 1305
for cardiogenic shock, *1969:* March, 312
Digitalis (*Continued*)
for refractory heart failure, *1968:* Sept., 1164
for shock in myocardial infarction, *1970:* Jan., 241
in acute pulmonary edema, *1969:* March, 329
in chronic heart failure, *1970:* March, 324
intoxication, *1969:* Nov., 1283
newer concepts regarding, *1969:* Nov., **1279–1286**
to prevent congestive heart failure, *1969:* March, 346
Dihydrostreptomycin, deafness from, *1970:* Sept., 1161
Dilantin. See *Diphenylhydantoin.*
Diphenhydramine hydrochloride (Benadryl), for anaphylactic syndromes, *1969:* March, 256
Diphenylhydantoin (Dilantin), for cardiac arrhythmia, basis of action of, *1969:* Nov., 1303
for status epilepticus, *1968:* July, 968
for trigeminal neuralgia, *1968:* Jan., 112; July, 798
for ventricular premature beats, *1969:* March, 323
metabolism of, inherited variations in, *1969:* July, 846
2,3-Diphosphoglycerate, red cell, alterations in, clinical conditions with, *1970:* May, 736
hypoxemia and, *1970:* May, 733
Diphtheria, erythromycin for, *1970:* Sept., 1207
Diplococcus pneumoniae infections, tetracyclines for, *1970:* Sept., 1179
Disaccharidases, *1968:* Nov., 1356
deficiency, *1968:* Nov., **1355–1365**
clinical disorders associated with, *1968:* Nov., 1357–1362
Disaccharides, absorption, *1968:* Nov., 1355
intolerance, dietary control, *1970:* Nov., 1440
in celiac disease, *1970:* May, 652
Disarticulation, for malignant disease, rehabilitation after, *1969:* May, 611–614
Disease, abnormal response to fasting in, *1970:* Nov., 1373–1375
Disks, intervertebral, degeneration of, low back pain and, *1968:* Jan., 62
herniated, cervical root pain and, *1968:* July, 775
herniated lumbar thermography in, *1970:* May, 613
Disodium chromoglycate (Intal), for anaphylactic syndromes, *1969:* March, 256
Disseminated intravascular coagulation. See under *Coagulation.*
Diuretics. See also *Thiazides.*
effects on laboratory values, *1969:* Jan., 219
for acute pulmonary edema, *1969:* March, 327–328
for alcoholic myocardiopathy, *1968:* Sept., 1187
for ascites in Laennec's cirrhosis, *1969:* Nov., 1361

Diuretics (*Continued*)
for hypertension, *1968:* Sept., 1231
for refractory heart failure, *1968:* Sept., 1166
in chronic heart failure, *1970:* March, 325–328
thiazide, gout and, *1970:* March, 432
DNA-RBC test, for antinuclear factors, *1968:* May, 561
Dominance, genetic, *1969:* July, 743
Donor selection. See under *Transplantation.*
Dopamine, for shock in myocardial infarction, *1970:* Jan., 241
Doriden. See *Glutethimide.*
Down's syndrome, Australia antigen in, *1970:* May, 810
chromosomal abnormality in, *1970:* July, 1015
drug effects and, *1969:* July, 853
etiology, *1969:* Sept., 1047
mosaic, fibroblast cultures in, *1970:* May, 707
Doxycycline hyclate, *1970:* Sept., 1174, 1175
Driving, aids, for physically handicapped, *1969:* May, 689–692
behavior, psychological factors in physically handicapped, *1969:* May, 692–695
education, for physically handicapped, *1969:* May, **685–696**
Drowsiness, diurnal, *1968:* July, 781
Drugs, abortion and, *1969:* July, 776
addiction, *1968:* Jan., 34
malnutrition and, *1970:* Nov., **1567–1575**
agrypnotic. See *Agrypnotic drugs.*
antifungal. See *Antifungal drugs;* and specific names of drugs.
antihypertensive, vision and, *1969:* Sept., 1116
antimicrobial. See also under specific names.
choice of for various organisms, *1970:* Sept., 1162
efficacy of, symposium on, *1970:* Sept., **1075–1350**
antiprotozoal, effects on laboratory values, *1969:* Jan., 220
glaucoma and, *1969:* Sept., **1109–1121**
immunosuppressive, after kidney transplants, *1970:* Jan., 84
antibody synthesis and, *1969:* Nov., 1227
for autoimmune hemolytic anemia, *1969:* Nov., 1233
for chronic active hepatitis, *1969:* Nov., 1236
for chronic renal disease, *1969:* Nov., 1238
for idiopathic thrombocytopenic purpura, *1969:* Nov., 1234
for psoriasis, *1969:* Nov., 1237
for rheumatoid arthritis, *1969:* Nov., 1235
for systemic lupus erythematosus, *1969:* Nov., 1236
for ulcerative colitis, *1969:* Nov., 1237
oncogenic potential of, *1969:* Nov., 1232
metabolism, *1970:* Nov., 1567

Drugs (*Continued*)
reactions, delirium, *1969:* March, 276
serum sickness-like, *1970:* Sept., 1094
vs. juvenile rheumatoid arthritis of polyarticular onset, *1968:* May, 578
resistance, inherited, *1969:* July, 850–851
responses to, atypical, as examples of polymorphism, *1969:* July, 892
genetics and, *1969:* July, **839–855**
Dubin-Johnson syndrome, *1968:* Nov., 1422
inheritance, *1968:* Nov., 1276
Ductus arteriosus, patent, cardiac catheterization in, *1970:* July, 975–976
Dumping symptoms, after gastrointestinal surgery, *1969:* Nov., 1391
without peptic ulcer or gastrectomy, *1969:* Nov., 1406
Duodenum, cytological examination, *1968:* Nov., 1323
disorders of, pain patterns in, *1968:* Jan., 107
Dura, neuroanatomy, *1968:* Jan., 187
Dwarfism, hypopituitary, idiopathic, radioimmunoassay of gonadal hormones in, *1970:* July, 1055
Dymelor. See *Acetohexamide.*
Dyrenium. See *Triamterine.*
Dysarthria, cerebrovascular disease and, *1969:* May, 568
characteristics, *1969:* May, 565
neurologic disease and, *1968:* July, **835–844**
patterns, *1968:* July, 841–844
tests for, *1969:* May, 572
Dysautonomia, familial, drug effects and, *1969:* July, 853
Dysbetalipoproteinemia, diagnosis and diet therapy, *1970:* Nov., 1396
Dyslexia, diagnosis and counseling in, *1969:* Sept., **1123–1129**
Dyslipoproteinemias, diagnosis of, *1970:* Jan., **153–159**
Dyspepsia, diet and, *1970:* Nov., 1362
Dyspnea, anaphylaxis and, *1969:* March, 252
Dysrhythmia, after myocardial infarction, *1968:* Sept., 1067
Dystonia, speech disturbances in, *1968:* July, 838–842
Dystonia musculorum deformans, *1969:* May, 641–642
Dystrophy, muscular, creatine phosphokinase levels in, *1969:* Jan., 121
oculopharyngeal, inheritance, *1968:* Nov., 1275
sympathetic, post-traumatic, *1968:* Jan., 152
reflex, *1968:* Jan., 127

EACA. See *Epsilon-aminocaproic acid.*
Ear, middle, infections. See *Otitis media.*
toxic reactions. See *Ototoxic reactions.*
Echoencephalography, in diagnosis of intracranial disorders, *1969:* Jan., 159–174; March, 294
Ecology, nutritional, *1970:* Nov., 1505–1508

Ecthyma gangrenosum, *1969:* March, 272
Edecrin. See *Ethacrynic acid.*
Edema. See also *Lymphedema.*
angioneurotic, anaphylaxis and, *1969:* March, 252
in liver disease, dietary control, *1970:* Nov., 1466
laryngeal, anaphylaxis and, *1969:* March, 252
of hand, *1969:* May, 646
pulmonary, acute, management, *1969:* March, **327–330**
after myocardial infarction, *1968:* Sept., 1072
Education, continuing, current concepts and future needs, *1970:* Jan., **5–18**
Edwards' syndrome, chromosomal abnormality in, *1970:* July, 1018
EECG. See *Echoencephalography.*
Elbow, examination, in hemiplegic patient, *1969:* May, 549
in rheumatoid arthritis, *1968:* May, 496
surgery, *1968:* May, 724
Elderly. See *Aged persons.*
Electrocardiogram, in hyperkalemia, *1969:* March, 411
in pulmonary embolism, *1969:* March, 368; *1970:* March, 364
Electrocardiography, abnormalities in, coronary arteriography in, *1970:* July, 984
Electroencephalogram, abnormalities in, techniques for activating, *1968:* July, 952–953
artifacts in, biologic, *1968:* July, 941
in chronic renal failure, *1968:* July, 846–847
localization of seizure origin by, *1968:* July, 953–957
of fetus, *1968:* July, 946
patterns in, clinical significance, *1968:* July, **933–940,** 949–951
positive spikes in, 14 and 6 per second, *1968:* July, 933–934
small sharp spikes in, *1968:* July, 934–939
Electroencephalography, extracerebral, *1968:* July, **941–948**
in evaluation of seizures, *1968:* July, **949–957**
Electrolytes, deficiencies, after gastrointestinal surgery, *1969:* Nov., 1399–1401
fluids and, disturbances, *1969:* March, **407–415**
in diabetic acidosis, *1969:* Nov., 1368
Electromyography, *1968:* July, 943
in low back pain, *1969:* May, 530
Electron microscopy, muscle disease and, *1968:* July, **909–931.** See also under *Muscles.*
Electronystagmography, *1968:* July, 944
Electro-oculogram, *1968:* July, 945
Electrophoresis. See also *Immunoelectrophoresis.*
in diagnosis of hyperlipidemia, *1970:* July, 1031, 1033
in diagnosis of syndromes associated with hyperglobulinemia, *1970:* July, 922–936
in study of plasma lipoproteins, *1970:* Jan., 153
Electrophoresis (*Continued*)
in tests of serum alkaline phosphatase, *1969:* Jan., 116, 117
of hemoglobin, in anemia, *1969:* Jan., 49
of serum proteins, *1969:* Jan., **147–157**
zone, *1969:* Jan., 152–154
paper, in classification of hyperlipoproteinemias, *1970:* Nov., 1601, 1602
Electrophysiology, cellular, antiarrhythmic therapy and, *1969:* Nov., 1297–1299
Electroretinography, *1968:* July, 944, 945
Elemental diets, in surgical nutrition, *1970:* Nov., 1376
Elements, trace, caries-inhibiting, *1970:* Nov., 1558
Embolectomy, for arterial block, *1969:* March, 338
pulmonary, *1970:* March, 372–374
Embolism, arterial, skin necrosis and, *1969:* March, 263
fat, skin necrosis and, *1969:* March, 265
pulmonary, *1969:* March, **341–350**
complicating heart failure, *1970:* March, 317
diagnosis, *1969:* March, **365–373**
management of, *1970:* March, **361–377**
postoperative chest pain and, *1968:* Jan., 95
prevention of, *1970:* March, 366–368
roentgen findings, *1969:* March, **375–383**
surgical management of, *1970:* March, 372–374
vs. intractable heart failure, *1970:* March, 312
sudden arterial occlusion and, *1969:* March, 335
Embolus, prosthetic heart valves and, *1968:* Sept., 1134
Emergencies, cardiac, in office practice, *1969:* March, **331–333**
medical, symposium on, *1969:* March, **237–477**
psychiatric, *1969:* March, **281–284**
Emotional disturbances, from illness or operation, *1969:* March, 277
Emphysema, pulmonary, vs. intractable heart failure, *1970:* March, 314
Encephalopathy, hepatic. See *Hepatic coma.*
hypertensive, *1969:* March, **351–360**
Endocarditis, bacterial, causes, *1968:* Sept., 1091, 1092
changing patterns, *1968:* Sept., **1091–1101**
complications, *1968:* Sept., 1099
diagnosis, *1968:* Sept., 1094
emergency treatment, *1969:* March, 444
oxacillin and cloxacillin for, *1970:* Sept., 1133
penicillins for, *1970:* Sept., 1089
prevention, *1968:* Sept., 1096, 1097
prophylaxis for, *1970:* Sept., 1106
rare types, *1968:* Sept., 1093
streptomycin for, *1970:* Sept., 1164, 1165
treatment, *1968:* Sept., 1097
enterococcal, treatment of, *1970:* Sept., 1150

Endocarditis (*Continued*)
prolonged fever and, *1970:* March, 382–384
prosthetic heart valves and, *1968:* Sept., 1136
staphylococcal, antibacterials for comparative effectiveness, *1970:* Sept., 1280
Endocrine glands. See also names of glands.
chromophobe adenoma and, *1968:* July, 830–834
disorders of, hematopoiesis and, *1968:* March, **231–241**
laboratory aids in, *1969:* Jan., **79–95**
neurophysiology in, *1969:* May, 626–628
nutrition and, *1970:* Nov., **1473–1494**
secondary hypertension and, *1968:* Sept., 1214
symposium on, *1968:* March, **229–472**
functions, malnutrition and, *1970:* Nov., 1490
pregnancy and, *1968:* March, **253–262**
secretions, osteoporosis and, *1970:* Jan., 147–149
Endometrium, biopsy of, in amenorrhea, *1968:* March, 350
Energy cost studies, during rehabilitation in chronic obstructive pulmonary disease, *1969:* May, 597
Energy expenditure, increased, in disease and injury, *1970:* Nov., 1374
nitrogen loss and, *1970:* Nov., 1371
Enteritis, candidal, nystatin for, *1970:* Sept., 1335
regional. See *Regional enteritis.*
Enterobacter infections, choice of therapy for, *1970:* Sept., 1162
Enterococcus infections, choice of therapy for, *1970:* Sept., 1162
Environment, control, for asthma, *1969:* March, 241
mutagens of, detection of, *1969:* Nov., **1243–1256**
Enzymes, defects, nutritional problems and, *1970:* Nov., 1431–1433
deficiencies, congenital, *1968:* Nov., 1276
diagnosis by cell culture, *1969:* July, 807
in cultured human cells, *1969:* July, 799–801
induction and inhibition, in treatment of inherited metabolic disorders, *1969:* July, 955
lysosomal, rheumatoid arthritis and, *1968:* May, 600–601
replacement, in treatment of inherited metabolic disorders, *1969:* July, 953
serum, in chronic pancreatitis, *1970:* March, 481
in pulmonary embolism, *1970:* March, 365
tests for, reliability and value of, *1969:* Jan., **115–135**
variants, as examples of polymorphism, *1969:* July, 894
Ephedrine, for asthma, *1969:* March, 242, 243
for orthostatic hypotension, *1968:* July, 814
for shock, *1968:* Sept , 1085
Epidural space, anatomy, *1968:* Jan., 209
Epigastric artery, rupture, *1969:* March, **361–363**
Epikeratoprosthesis, *1969:* Sept., 1107
Epilepsy, electroencephalographic patterns in, *1968:* July, 933–934
treatment, general rules, *1968:* July, 973–974
vs. orthostatic hypotension, *1968:* July, 811
Epinephrine, for anaphylaxis, *1969:* March, 256
for status asthmaticus, *1970:* March, 498, 500
for Stokes-Adams syncope, *1969:* March, 333
Epiplants, corneal, *1969:* Sept., 1107
Epsilon-aminocaproic acid, for disseminated intravascular clotting, *1969:* March, 306
Equanil. See *Meprobamate.*
Erb's palsy, complicating hemiplegia, *1969:* May, 545
Ergotamine, blocking action, *1968:* Sept., 1011
Erysipelas, penicillins for, *1970::* Sept., 1087
Erysipelothrix infections of animals, rheumatoid arthritis and, *1968:* May, 667–669
Erythema nodosum, with ulcerative colitis, *1968:* May, 508
Erythroblastosis fetalis, *1969:* Sept., 1066
Erythrocytes, enzymes, deficiencies, drug effects and, *1969:* July, 852
in rheumatoid arthritis, sedimentation rate, *1968:* May, 543
survival, *1968:* May, 528
indices, iron deficiency and, *1970:* July, 907
metabolism, genetic disorders of, *1969:* July, **813–826**
normal, *1969:* July, 813–816
oxygen transport by, *1970:* May, 787
heredity and environment and, *1970:* May, **731–743**
substitutes for, *1970:* May, **787–795**
Erythromycin, *1970:* Sept., **1199–1215**
allergic reactions to, incidence of, *1970:* Jan., 63
as alternate to penicillin, *1970:* Sept., 1205
clinical indications, *1970:* Sept., 1204–1207
preparations, and dosage, *1970:* Sept., 1209
spectrum of activity, *1970:* Sept., 1200
toxic reactions, *1970:* Sept., 1204
Erythropathy(ies), drugs and chemicals causing, *1969:* Jan., 59
Erythropoiesis, endocrine effects on, *1968:* March, 232–238
Erythropoietin, current status of, *1970:* Jan., **173–181**
Escherichia coli infections, choice of therapy for, *1970:* Sept., 1162
Esophagitis, candidal, nystatin for, *1970:* Sept., 1335
Esophagoscopy, emergency, in bleeding esophageal varices, *1968:* Nov., 1460
Esophagus, achalasia, intravenous hyperalimentation for, *1970:* May, 585
motility studies in, *1970:* July, 867

Esophagus (*Continued*)
cytological examination, *1968:* Nov., 1319
diseases, implications of current research in, *1968:* Nov., 1269
hemorrhage, causes, *1969:* March, 418
motility studies, *1970:* July, **863–873**
neuromuscular abnormalities of, *1970:* July, 867–871
varices, bleeding, diagnosis and treatment, *1968:* Nov., **1457–1474**
prophylactic portacaval anastomosis and, *1968:* Nov., 1470
Estrogen-progesterone test, in amenorrhea, *1968:* March, 349
Estrogens, erythropoiesis and, *1968:* March, 233, 234
for hypercholesterolemia, *1968:* Sept., 1259
for hypothalamic amenorrhea, *1968:* March, 340
for ovarian failure, *1968:* March, 346
insulin antagonism and, *1968:* March, 254
Ethacrynic acid (Edecrin), for ascites in Laennec's cirrhosis, *1969:* Nov., 1362
for hypertension, *1968:* Sept., 1232
for pulmonary edema, *1969:* March, 327
for refractory heart failure, *1968:* Sept., 1171
Ethambutol (Myambutol), *1970:* Sept., **1317–1325**
Ethanol, metabolism, *1970:* Nov., 1568
metabolism, as model for other drugs, *1969:* Nov., **1413–1423**
Ethchlorvynol (Placidyl), for pain, *1968:* Jan., 49
Ether, as enema, for status asthmaticus, *1970:* March, 500
Ethinamate (Valmid), for pain, *1968:* Jan., 49
Ethyl alcohol, for trigeminal neuralgia, *1968:* July, 799
Excretion, disturbed, in hemiplegic patient, *1969:* May, 557–558
Exercise, adrenergic receptor blockers and, *1968:* Sept., 1043
for low back pain, *1969:* May, 538
for neck and shoulder pain, *1969:* May, 518
in rehabilitation of hand, *1969:* May, 652
to promote venous return, *1969:* March, 345
Exertional headache, benign, *1968:* July, **801–808**
Exophthalmos, malignant, *1969:* March, **469–477**
progressive, transantral orbital decompression for, *1968:* March, **399–407**
Expectorants, for asthma, *1969:* March, 241, 243
Extremities. See also *Arm; Leg.*
amputations, for malignant disease, rehabilitation after, *1969:* May, 612
local analgesia of, in office, *1968:* Jan., 180
trauma, thromboembolism and, *1969:* March, 347
Eyes. See also *Vision* and under names of disorders and parts of eye.

Eyes (*Continued*)
accommodation of, amplitude of, *1969:* Sept., 1140
cataracts, corneal grafting and, *1969:* Sept., 1106
common disorders and injuries, symposium on, *1969:* Sept., **1097–1168**
disorders, corticosteroids for, *1969:* Sept., 1146
complications, *1969:* Sept., 1155
5-iodo,2-deoxyuridine for, *1969:* Sept., 1152
staphylococcal, *1969:* Sept., 1149
viral, *1969:* Sept., 1150–1155
fundus of, fluorescein angiography, *1968:* July, **853–869**
herpes zoster and, *1969:* Sept., 1154
infections, chloramphenicol for, *1970:* Sept., 1192
staphylococcal, *1969:* Sept., 1149
tetracyclines for, *1970:* Sept., 1179
inflammation, viruses and corticosteroids, *1969:* Sept., **1145–1160**
muscle balance of, as part of refraction, *1969:* Sept., 1134
pressure in, drugs and, *1969:* Sept., **1109–1121**
rhegmae in, significance and treatment of, *1969:* Sept., 1165
toxic reactions, to ethambutol, *1970:* Sept., 1319
tumor metastases to, radiation therapy for pain, *1968:* Jan., 206
Eyeglasses, bifocal, for children, *1969:* Sept., 1137
contact lenses, *1969:* Sept., 1138–1140
indications for, *1969:* Sept., **1131–1144**

FABRY'S disease, fibroblast cultures in, *1970:* May, 703
genetics and, *1969:* July, 834–835
Face, carcinoma of, rehabilitation after treatment, *1969:* May, 617
Facial nerve, cerebellopontine angle lesions and, *1968:* July, 789
Family history, rheumatoid arthritis and, *1968:* May, 489–490
Fanconi syndrome, due to tetracyclines, *1970:* Sept., 1182
Fasting, as test for hypoglycemia, *1968:* March, 284
metabolic response to, *1970:* Nov., 1367–1373
Fats, absorption, medium chain triglycerides and, *1970:* Nov., 1376
normal, *1968:* Nov., 1342
studies, *1968:* Nov., 1350
body requirements, for diabetics, *1970:* Nov., 1579
body stores, measuring, *1970:* Nov., 1368
malabsorption, in liver disease, *1970:* Nov., 1457
metabolism, in liver disease, *1970:* Nov., 1458
Fatty acids, free, thyrotoxicosis and, *1970:* Nov., 1481

Fear, cardiovascular response to, adrenergic receptor blockers and, *1968:* Sept., 1043
Febrile convulsions, medical treatment for, *1968:* July, 967
Feet. See *Foot.*
Felty's syndrome, *1968:* May, 529
Ferrous sulfate, for iron deficiency, *1970:* Nov., 1407
Fertility, oral contraception and, *1969:* Sept., 1032–1035
Fetus, and newborn, newer studies in, *1969:* Sept., **1051–1062**
  brain growth, critical periods in, *1970:* Nov., 1419
  death of, *1969:* Sept., 1089
Fever, as reaction to antibiotics, *1970:* Jan., 61
  complicating heart failure, *1970:* March, 319
  juvenile rheumatoid arthritis and, *1968:* May, 570, 575, 577
  Mediterranean, *1970:* March, 392
  oxygen consumption and, *1970:* Nov., 1374
  penicillin toxicity and, *1970:* Sept., 1093
  prolonged and perplexing, *1970:* March, **379–396**
  psychogenic, *1970:* March, 392
  relapsing, tetracyclines for, *1970:* Sept., 1179
Fibrillation, atrial, *1969:* March, 321
    chronic, *1970:* March, 325
    paroxysmal, office treatment for, *1969:* March, 333
    propranolol for, *1968:* Sept., 1020, 1023
    treatment, *1969:* March, 321
  ventricular, *1969:* March, 324
    primary, after myocardial infarction, *1968:* Sept., 1064
Fibrinolysins, for pulmonary embolism, *1970:* March, 369
Fibrinolysis, primary, vs. disseminated intravascular clotting, *1969:* March, 305; *1970:* May, 557
  tests for, *1970:* July, 896
Fibroblast cultures, in genetic disorders, *1970:* May, **701–712**
Fibrosis, cystic. See *Cystic fibrosis.*
Fingers, clubbing of, hyperthyroidism and, *1968:* March, **393–398**
  paresthesia in, *1968:* July, 774
    thoracic outlet syndromes and, *1968:* July, 777
Fluids, and electrolytes, depletion, in pyloric obstruction, therapy for, *1968:* Nov., 1333
    disturbances, *1969:* March, **407–415**
    in status asthmaticus, *1970:* March, 499, 500
  body, normal relationships, *1970:* May, 688–693
  restriction, in refractory heart failure, *1968:* Sept., 1165
  therapy, for diabetic coma, *1970:* May, 693
Fluorescein angiography, of ocular fundus, *1968:* July, **853–869**
Fluorescein string test, in gastrointestinal hemorrhage, *1969:* March, 420
Fluoride, bone metabolism and, *1970:* Nov., 1559
  metabolism, osteoporosis and, *1970:* Jan., 146–147
  tooth development and, *1970:* Nov., 1557
Fluorochemicals, as erythrocyte substitute, *1970:* May, 789–794
5-Fluorodeoxyuridine, chromosome breakage and, *1969:* Nov., 1252
9-α-Fluorohydrocortisone, for orthostatic hypotension, *1968:* July, 814
5-Fluorouracil, bases of action of, *1969:* Nov., 1267
Flutter, atrial, *1969:* March, 321
    office treatment for, *1969:* March, 333
    propranolol for, *1968:* Sept., 1023
Folate, absorption, studies, *1968:* Nov., 1351
  assay, in megaloblastic-macroovalocytic anemias, *1970:* May, 635
  deficiency, *1970:* May, 639
    etiology and pathogenesis of, *1970:* May, 641
Folic acid antagonists, bases of action of, *1969:* Nov., 1267
  for immunosuppression, *1969:* Nov., 1227
Folic acid therapy, for tropical sprue, *1968:* Nov., 1379
Follicle-stimulating hormone, radioimmunoassay for, *1970:* July, **1049–1059**
Foods, intolerance, in infancy, dietary management, *1970:* Nov., 1440
  iron content, *1970:* Nov., 1403
  tolerances, in liver disease, *1970:* Nov., 1468
Foot, deformities, in spina bifida and myelomeningocele, *1969:* May, 504
  examination, in hemiplegic patient, *1969:* May, 555
  in rheumatoid arthritis, *1968:* May, 498
    surgery, *1968:* May, 729
Free fatty acids, thyrotoxicosis and, *1970:* Nov., 1481
Friedreich's ataxia, *1968:* July, 900
Fructosemia, dietary control, *1970:* Nov., 1439
Fundus of eye, fluorescein angiography, *1968:* July, **853–869**
Funduscopy, in miliary tuberculosis, *1970:* March, 380
Fungus infections, griseofulvin for, *1970:* Sept., **1339–1345**
  nystatin for, *1970:* Sept., **1329–1337**
Furosemide (Lasix), for ascites in Laennec's cirrhosis, *1969:* Nov., 1362
  for hypertension, *1968:* Sept., 1232
  for refractory heart failure, *1968:* Sept., 1172

GALACTOSE-kinase insufficiency, in galactosemia, *1970:* Nov., 1439
Galactose-1-phosphate uridyl transferase deficiency, dietary control, *1970:* Nov., 1438
Galactosemia, detection of carriers, *1969:* July, 859
  dietary control, *1970:* Nov., 1438

Galactosemia (*Continued*)
inheritance and gastrointestinal manifestations, *1968:* Nov., 1278
Gallbladder, inflammation, diet and, *1970:* Nov., 1362
Gammopathy, monoclonal, *1969:* Jan., 151
benign, *1970:* July, 923
Ganglion cells, dorsal root, degeneration, *1968:* July, 900
Gangliosidosis, generalized, genetics and, *1969:* July, 835–836
Gangrene, bacterial, *1969:* March, 271
vascular disease and, *1969:* March, 264
Gantrisin. See *Sulfisoxazole.*
Gardner's syndrome, inheritance of, *1968:* Nov., 1274; *1969:* July, 925
Gastrectomy, malnutrition caused by, *1968:* Nov., 1400
Gastric. See also *Stomach.*
Gastric analysis, *1968:* Nov., **1305–1313**
in megaloblastic-macroovalocytic anemias, *1970:* May, 633
Gastric atony, vs. pyloric obstruction, *1968:* Nov., 1329
Gastric cooling, for hemorrhage, *1969:* March, 423
Gastric retention, vs. pyloric obstruction, *1968:* Nov., 1329
Gastric secretion, clinical aspects, *1968:* Nov., **1305–1313**
tests, *1968:* Nov., 1307
Gastrin, effects, *1968:* Nov., 1270
gastrointestinal disease and, *1968:* Nov., 1299
implications of current research on, *1968:* Nov., 1269
structure, secretion, and action, *1968:* Nov., 1298
Gastroenterology, implications of current research in, *1968:* Nov., **1269–1272**
Gastrointestinal hormones, implications of current research in, *1968:* Nov., 1269
Gastrointestinal tract, carcinoid tumor of, chemotherapy for, *1969:* Nov., 1275
carcinoma of, chemotherapy for, *1969:* Nov., 1274
disorders, autoimmune mechanisms and, *1968:* Nov., **1285–1295**
clinical nutrition and, *1968:* Nov., **1397–1402**
complicating immunosuppression, *1969:* Nov., 1232
cytological examination in, *1968:* Nov., **1315–1328**
diet in, *1970:* Nov., **1357–1366**
due to lincomycin, *1970:* Sept., 1299
food intolerances and, *1970:* Nov., 1440–1441
genetic aspects, *1968:* Nov., **1273–1283**
function, altered, inheritance, *1968:* Nov., 1275
symposium on, *1968:* Nov., **1265–1501**
with extragastrointestinal symptoms, genetic factors in, *1968:* Nov., 1276
hemorrhage, from ulcer, *1969:* March, 427–428
obscure, *1969:* March, **417–423**
Gastrointestinal tract (*Continued*)
obstruction, from ulcer, *1969:* March, 426–427
surgery on, nutritional problems after, *1969:* Nov., **1389–1402**
Gastroscopy, emergency, in bleeding esophageal varices, *1968:* Nov., 1463
Gaucher's disease, genetics and, *1969:* July, 828–832
Gene frequencies, estimation of, detection of heterozygous carriers and, *1969:* July, 870
Gene transformation, in treatment of inherited metabolic disorders, *1969:* July, 956
Genetic counseling, *1969:* July, **991–999**
detection of heterozygous carriers and, *1969:* July, 870
Genetic disorders, fibroblast cultures in, *1970:* May, **701–712**
nutritional management, *1970:* Nov., **1431–1448**
Genetic factors, in gastrointestinal disease, *1968:* Nov., **1273–1283**
Genetic mapping, future of, *1969:* July, 1003
Genetics, carcinoma and, *1969:* July, **923–939**
cultural adaptation and, *1969:* July, **977–990**
cultured human somatic cells and, *1969:* July, **795–811**
clinical diagnosis and, *1969:* July, 806–808
deafness and, *1969:* July, **741–772**
detection of heterozygous carriers, clinical uses, *1969:* July, 868–871
human, future of, *1969:* July, **1001–1011**
in clinical medicine, symposium on, *1969:* July, **739–1011**
pregnancy wastage and, *1969:* Sept., **1039–1050**
principles, *1969:* July, 741–744
resistance to infection and, *1969:* July, **903–922**
response to drugs and, *1969:* July, **839–855**
rheumatoid arthritis and, *1968:* May, 489–490
sphingolipidoses and, *1969:* July, **827–838**
Genitourinary system, infection, emergency treatment, *1969:* March, 445
tuberculosis, *1969:* March, **449–453**
Gentamicin, *1970:* Sept., **1305–1315**
allergic reactions to, incidence of, *1970:* Jan., 63
clinical indications, *1970:* Sept., 1312
in mixture, synergistic effects, *1970:* Sept., 1309
ototoxicity, *1970:* Sept., 1312
spectrum of activity, *1970:* Sept., 1306, 1309
German measles. See *Rubella.*
Giardiasis, jejunal biopsy and, *1970:* July, 859
Gigantism, *1968:* March, 376
Gilbert's syndrome, *1968:* Nov., 1420
Glands. See under names of glands.

Glasses. See *Eyeglasses.*
Glaucoma, angle-closure, *1969:* Sept., 1110–1115
drug effects and, *1969:* July, 853
corticosteroids and, *1969:* Sept., 1156
drugs and, *1969:* Sept., **1109–1121**
Globin, synthesis, defects, *1969:* Jan., 53
Globulin, antilymphocyte (ALG). See *Antilymphocyte globulin.*
immune, for prophylaxis of infectious hepatitis, *1970:* March, 463
Glomerular filtration rate, regulation, *1968:* March, 269
Glomerulonephritis, chronic, immunosuppression for, *1969:* Nov., 1238
Glucagon, for acute pulmonary edema, *1969:* March, 330
for chronic heart failure, *1970:* March, 324
physiologic role and therapeutic use, *1970:* Jan,, **183–190**
Glucagon test, in hypoglycemia, *1968:* March, 285
Glucagonoma, *1968:* March, 298
Glucocorticoids, disorders, metabolic and nutritional aspects, *1970:* Nov., 1483–1490
osteoporosis and, *1970:* Jan., 147–148
tests of, *1969:* Jan., 89
Glucose, intolerance, in intravenous hyperalimentation, *1970:* May, 583
metabolism, clinical evaluation, *1970:* Nov., 1540
disorders, obesity and, *1970:* Nov., 1533
nitrogen-sparing effect, *1970:* Nov., 1373
tests for, drug effects on, *1969:* Jan., 212
tolerance, abnormal, chromium and, *1970:* Nov., 1520–1523
Glucose tolerance test, hypersomatotropism and, *1968:* March, 372
in hypoglycemia, *1968:* March, 285
need for standardization, *1970:* Nov., 1540
Glucose-galactose malabsorption, dietary control, *1970:* Nov., 1440
Glucosephosphate isomerase deficiency, *1969:* July, 821
Glucose-6-phosphate dehydrogenase deficiency, *1969:* July, 817
Glutethimide, for pain, *1968:* Jan., 49
N-glycine, in measurement of protein synthesis, *1970:* Nov., 1481
Glycogenosis, fibroblast cultures in, *1970:* May, 706
Glycosides, cardiac, for arrhythmia, *1969:* March, 316
cellular action of, *1970:* Jan., **221–234**
Glycosuria, in diabetic coma, *1970:* May, 690
Goiter, causes, *1968:* March, 409
clinical aspects, *1968:* March, 411
deafness and, *1969:* July, 765
exophthalmic, autoimmunity and, *1970:* Jan., 120–123
choice of treatment for, *1970:* Jan., 123–126
malignant exophthalmos and, *1969:* March, 469
ophthalmologic complications, *1970:* Jan., 126–127
Goiter (*Continued*)
exophthalmic, radioactive iodine therapy for, *1968:* March, 425
laboratory tests in, *1968:* March, 412
single and multinodular, management, *1968:* March, **409–415**
therapy for, *1968:* March, 413
thyroid function tests in, *1970:* July, 1043
toxic. See *Hyperthyroidism.*
Gold sodium thiomalate (Myochrysine), for rheumatoid arthritis, *1968:* May, 691, 735
Gold therapy, for rheumatoid arthritis, *1968:* May, 691, **733–738**
juvenile, *1968:* May, 586
Gold thioglucose (Solganol), for rheumatoid arthritis, *1968:* May, 691, 735
Gonadotropin, assay of, in amenorrhea, *1968:* March, 349
secretion of, decreased, *1968:* March, 363
excess, *1968:* March, 359
tests of, *1969:* Jan., 84
Gonorrhea, newer drugs for, *1970:* Sept., 1150
penicillins for, *1970:* Sept., 1090
tetracyclines for, *1970:* Sept., 1180
Goodpasture's syndrome, autoimmunity and, *1970:* Jan., 100
bronchopulmonary lavage for, *1970:* May, 768
Gout, *1970:* March, **431–441.** See also *Arthritis, gouty.*
acute, *1969:* March, **455–457**
treatment, *1969:* Nov., 1337
clinical manifestations, *1969:* Nov., 1334–1337
diet and, *1969:* Nov., 1339
tophaceous, *1969:* Nov., 1336
treatment, physiologic and biochemical basis for, *1969:* Nov., **1331–1347**
Graft vs. host assay, in tissue typing, *1970:* Jan., 46
Grafts, corneal, *1969:* Sept., 1102–1107
rejection, management of, *1970:* Jan., 88
mechanism of, *1970:* Jan., 53–54
Granulocytopathies, genetics and detection, *1969:* July, 910–913
Granulocytopoiesis. See *Leukopoiesis.*
Granuloma, rheumatoid, in rheumatoid arthritis, *1968:* May, 616
Granulomatous colitis, *1968:* Nov., 1387–1392; *1969:* Sept., 1209
prolonged fever and, *1970:* March, 391
Granulomatous disease, chronic, infection in, *1970:* May, 714–717
of childhood, *1969:* July, 910
Graves' disease. See *Goiter, exophthalmic.*
Gray baby syndrome, due to chloramphenicol, *1970:* Sept., 1190
Griseofulvin, *1970:* Sept., **1339–1345**
effect on porphyrin disturbances, *1970:* Sept., 1341
spectrum of activity, *1970:* Sept., 1339
Growth hormone. See *Hormone, growth; Somatotropin.*
Guanethidine (Ismelin), for hypertension, *1968:* Sept., 1233
Guillain-Barré syndrome, *1968:* Jan., 115

Guillain-Barré-Strohl syndrome, *1968:* July, 900
Gynecography, in amenorrhea, *1968:* March, 351

HABILITATION, in spina bifida and myelomeningocele, *1969:* May, 506
Haemophilus influenzae infections, choice of therapy for, *1970:* Sept., 1162
erythromycin in, *1970:* Sept., 1207
Hand, examination, in hemiplegic patient, *1969:* May, 550
in rheumatoid arthritis, examination, *1968:* May, 495
surgery, *1968:* May, 719
rehabilitation of, principles, *1969:* May, **645–658**
Hand-shoulder-arm syndrome, *1968:* Jan., 155
Hashimoto's thyroiditis, autoimmunity and, *1970:* Jan., 121
Head, injury, complicating intracranial disorders, *1969:* March, 293
other injuries and, *1969:* March, 295
local analgesia of, in office, *1968:* Jan., 180
trauma to, echoencephalography in diagnosis of, *1969:* Jan., 163
Headache, chronic renal failure and, *1968:* July, 848
exertional, benign, *1968:* July, **801–808**
sudden, intracranial hemorrhage and, *1968:* Sept., 1158
Hearing. See also *Deafness.*
disturbed. See also *Ototoxic reactions to drugs.*
cerebellopontine angle lesions and, *1968:* July, 789
chronic renal failure and, *1968:* July, 847
in hemiplegic patient, *1969:* May, 557
Heart, arrest. See *Cardiac arrest.*
arrhythmias. See *Arrhythmias.*
atrioventricular conduction in, drugs to enhance, *1969:* March, 318
auscultation of, *1969:* Jan., 104–109
beats, ectopic, drugs to depress, *1969:* March, 318
supraventricular, after myocardial infarction, *1968:* Sept., 1067
premature, atrial and nodal, *1969:* March, 321
ventricular, *1969:* March, 323
propranolol for, *1968:* Sept., 1025
block, *1969:* March, 324–325
after myocardial infarction, *1968:* Sept., 1069
atrioventricular, with paroxysmal atrial tachycardia, *1969:* March, 322
bundle branch, *1969:* March, 325
permanent, causes of and surgery for, *1968:* Sept., 1126–1127
catheterization, in pulmonary embolism, *1969:* March, 369
indications for, *1970:* July, **973–978**
defect in, deafness and, *1969:* July, 767
denervated, function of, *1970:* Jan., 109–110

Heart (*Continued*)
disease, amyloid and other types, vs. alcoholic myocardiopathy, *1968:* Sept., 1186
atherosclerotic, myocardial infarction and, *1968:* Sept., 1061
coronary. See *Coronary artery disease.*
diagnosis, modern bedside methods in, *1969:* Jan., **97–113**
ill-defined, coronary arteriography in, *1970:* July, 986
prosthetic extremity and, *1969:* May, 661
effects of digitalis on, *1969:* Nov., 1281–1284
electrical slowing of, *1970:* Jan., **247–259**
failure, after myocardial infarction, *1968:* Sept., 1071
congestive, as factor in thromboembolism, *1969:* March, 342
dialysis for, *1968:* Sept., 1176
dietary control, *1970:* Nov., 1452
differential diagnosis, *1970:* March, 312–315
hypertrophy and, *1970:* Jan., 218
in uremia, *1970:* March, 416
office treatment for, *1969:* March, 332
venous tone in, *1968:* Sept., 1081
intractable, *1970:* March, **309–332**
acute, management of, *1970:* March, 321–323
chronic, management of, *1970:* March, 323–329
complications, *1970:* March, 316–320
refractory, *1968:* Sept., **1157–1182**
factors in, *1968:* Sept., 1157–1162
glucagon and, *1970:* Jan., 186
hypertrophy, cellular and subcellular basis of, *1970:* Jan., **211–220**
involvement, in juvenile rheumatoid arthritis, *1968:* May, 573
murmurs, *1969:* Jan., 108
pacemakers, in prevention and treatment of tachyarrhythmias, *1969:* Nov., **1287–1295**
paired ventricular stimulation by, *1970:* Jan., **247–259**
radioisotope scanning, dual channel, *1969:* Jan., 199
rate, slowed, after myocardial infarction, *1968:* Sept., 1069
sounds, *1969:* Jan., 105
electronic recording of, *1969:* Jan., 109
transplantation of, hemodynamic observations after, *1970:* Jan., **107–113**
manifestations of rejection after, *1970:* Jan., 110–111
valves, diseases of, coronary arteriography in, *1970:* July, 988
incompetence, *1970:* Jan., **261–274**
prosthetic, arrhythmias and, *1968:* Sept., 1138
failure, *1968:* Sept., 1135
hemolytic anemia and, *1968:* Sept., 1138
infection and, *1968:* Sept., 1136
management of patients with, *1968:* Sept., **1133–1143**
pregnancy and, *1968:* Sept., 1139

Heart (*Continued*)
valves, tricuspid, stenosis of, complicating heart failure, *1970:* March, 319
Heat therapy, for low back pain, *1969:* May, 532
for neck and shoulder pain, *1969:* May, 517
in rehabilitation of hand, *1969:* May, 654
Heavy chain disease, *1970:* July, 923
Heinz body anemia, *1969:* Jan., 54
Hemangioma, intracranial, cerebellopontine angle syndrome and, *1968:* July, 793
of choroid, fluorescein angiography of fundus in, *1968:* July, 858
Hematinics, inadequacy of, *1970:* Nov., 1407–1408
Hematocrit, in rheumatoid arthritis, *1968:* May, 527
Hematologic disorders, in uremia, *1970:* March, 419–421
Hematology, in office laboratory, *1969:* Jan., 6
Hematoma, intracerebral, treatment for, *1968:* Sept., 1208
intracerebral or subdural, rehabilitation after, *1969:* May, **677–684**
subdural, chronic, *1969:* March, 296
Hematopoiesis, disturbed, as reaction to antibiotics, *1970:* Jan., 61
endocrine function and, *1968:* March, **231–241**
Hematuria, tests for, *1969:* Jan., 29
Heme, synthesis, defects, *1969:* Jan., 48
Hemicorporectomy, rehabilitation after, *1969:* May, 608
Hemiplegia, behavior modification in, *1969:* May, 580–583
denial of disability in, *1969:* May, 579
left vs. right, mental disturbances in, *1969:* May, 577–580
perceptual and intellectual problems, rehabilitation and, *1969:* May, **575–583**
rehabilitation, complications, *1969:* May, **541–559**
traumatic, driver training and, *1969:* May, 686, 688
Hemochromatosis, hereditary aspects, *1968:* Nov., 1276
Hemoconcentration, as factor in thromboembolism, *1969:* March, 342
Hemodialysis, hepatitis and, *1970:* March, 464
Hemoglobin, abnormalities of, oxygen dissociation curve in, *1970:* May, 737
electrophoresis, in anemia, *1969:* Jan., 49
fetal, red cell 2,3-diphosphoglycerate levels in, *1970:* May, 739
inherited variants, drug effects and, *1969:* July, 852
structure and genetics, *1969:* July, 875–878
synthesis, genetic control of, thalassemia syndromes and, *1969:* July, **875–886**
intracellular mechanisms, *1969:* July, 878–880
Hemoglobinopathies, *1969:* Jan., 53
as examples of polymorphism, *1969:* July, 892
Hemoglobinuria, paroxysmal nocturnal, *1969:* Jan., 55
Hemolytic anemia. See under *Anemia.*
Hemorrhage, esophageal varices and, diagnosis and treatment, *1968:* Nov., **1457–1474**. See also *Esophagus, varices, bleeding.*
gastrointestinal, complicating immunosuppression, *1969:* Nov., 1232
from ulcer, *1969:* March, 427–428
obscure, *1969:* March, **417–423**
in disseminated intravascular coagulation, *1970:* May, 557
intracranial, echoencephalography in diagnosis of, *1969:* Jan., 165
spontaneous, *1969:* March, 300
therapy for, *1970:* March, 356
iron loss from, *1969:* March, 423
laboratory aids in recognition of, *1969:* Jan., **61–78**
prosthetic heart valves and, *1968:* Sept., 1135
subarachnoid, acute, *1968:* Sept., 1194
in hemiplegia, *1969:* May, 543
Hemorrhagic stroke, *1968:* Sept., **1193–1212**
Hemostatis, mechanism of, *1969:* Nov., 1309–1311
evaluation of, *1970:* July, **889–902**
Henderson equation, *1970:* Nov., 1544
Heparin, for arterial block, *1969:* March, 337, 338
for disseminated intravascular coagulation; *1969:* March, 306; *1970:* May, 563, 564
for "impending coronary syndrome," *1968:* Sept., 1062
for pulmonary embolism, *1970:* March, 368
Hepatic. See also *Liver.*
Hepatic coma, ammonia toxicity and, *1968:* Nov., 1477
dietary control, *1970:* Nov., 1464–1468
management, *1968:* Nov., **1475–1481**
trials of treatment, *1968:* Nov., 1479
Hepatitis, active, chronic, immunosuppression for, *1969:* Nov., 1236
acute alcoholic, nutritional management, *1970:* Nov., 1464
cholangiolitic, *1968:* Nov., 1421
diet and, *1970:* Nov., 1363
lupoid, autoimmunity and, *1968:* Nov., 1290
malnutrition and, *1970:* March, 469
viral, *1970:* March, **455–466**
Australia antigen and, *1970:* May, **805–817**
dietary management, *1970:* Nov., 1462–1464
serum ornithine carbamyl transferase activity in, *1969:* Jan., 129
serum protein changes in, *1969:* Jan., 149, 150
Hepatolenticular degeneration, *1968:* July, 989
inheritance and gastrointestinal manifestations, *1968:* Nov., 1278
Hepatology, implications of current research in, *1968:* Nov., **1403–1406**

Hepatoma, alpha-fetoprotein in, *1970:* May, 798–802
malnutrition and, *1970:* March, 470
Hepatotoxic reactions, to erythromycin estolate, *1970:* Sept., 1204
to tetracyclines, *1970:* Sept., 1181
Hereditary disorders. See also *Genetics; Inheritance.*
nutritional management, *1970:* Nov., **1431–1448**
renal manifestations, dietary center, *1970:* Nov., 1441–1443
Heredity. See *Genetics; Inheritance.*
Heredopathia atactica polyneuritiformis. See *Refsum's disease.*
Heritability, *1969:* July, 984
Hernia, diaphragmatic, esophageal motility studies in, *1970:* July, 871
Herniated disk, cervical root pain and, *1968:* July, 775
Herpes simplex keratitis, corticosteroids in, *1969:* Sept., 1148, 1150
Herpes zoster, of eye, *1969:* Sept., 1154
pain in, *1968:* Jan., 115
Heteronuclear lines of cultured human cells, *1969:* July, 796
Hexokinase deficiency, *1969:* July, 820
Hiatal hernia, esophageal motility studies in, *1970:* July, 871
Hicks, foot ulcer of, *1968:* July, 899
Hip, deformities, in spina bifida and myelomeningocele, *1969:* May, 504
examination, in hemiplegic patient, *1969:* May, 552
in low back pain, *1969:* May, 530
fracture, complicating hemiplegia, *1969:* May, 552
in rheumatoid arthritis, *1968:* May, 501
surgery, *1968:* May, 725
Histamine, anaphylaxis and, antagonists for, *1969:* March, 256
as mediator of anaphylaxis, *1969:* March, 251
rheumatoid arthritis inflammation and, *1968:* May, 625
Histamine test, for pheochromocytoma, *1968:* Sept., 1220
of gastric secretion, *1968:* Nov., 1307–1310
Histocompatibility antigens. See *Antigens, transplantation.*
Histoplasmosis, of adrenal glands, *1968:* March, 329
History, medical, taking, computer-aided, *1970:* July, **825–833**
HL-A locus, *1970:* Jan., 52
Hodgkin's disease, chemotherapy for, *1969:* Nov., 1271
immunological deficiency and, *1970:* March, 298
lymphography in, *1970:* July, 940
Home, planning, for physically handicapped, *1969:* May, **703–711**
Homocystinuria, dietary control, *1970:* Nov., 1437
Homonuclear lines of cultured human cells, *1969:* July, 796
Hormones. See also under name of hormone.
adenohypophyseal, secretion of, decreased, *1968:* March, 362
excess, *1968:* March, 359
antidiuretic, renal response, defect in, *1970:* Nov., 1441
secretion, deficient, polyuria and, *1968:* March, 384
disorders, *1968:* March, **381–391**
inappropriate, *1968:* March, 388–390, July, **817–826**
gastrointestinal, *1968:* Nov., **1297–1303**
implications of current research in, *1968:* Nov., 1269
growth. See also *Somatotropin.*
diabetogenic nature, *1970:* Nov., 1477
disorders, metabolic and nutritional aspects, *1970:* Nov., 1474–1480
excess of, long-term nutritional effects, *1970:* Nov., 1476
imbalanced, abortion and, *1969:* July, 776
pituitary. See *Hormones, adenohypophyseal.*
sex, erythropoiesis and, *1968:* March, 232
thyroid, preparations, *1968:* March, 434, 439
secretion, normal, *1968:* March, 431
variations in, *1968:* March, 437
Horner's pupil, *1968:* July, 879
HPL. See *Lactogen, human placental.*
Human cell cultures, *1970:* May, **701–712**
Humoral agent, deficiency, defect of phagocytosis due to, *1970:* May, 717–719
Hunter's syndrome and Hurler's syndrome, studies on cultured cells, *1969:* July, 802
Hurler's disease, fibroblast cultures in, *1970:* May, 703
Hybridization of cultured human cells, *1969:* July, 803–806
Hydantoins, for seizures, *1968:* July, 963
Hydatidiform degeneration, *1969:* Sept., 1044
Hydatidiform mole, chromosome abnormalities and, *1969:* July, 786
Hydralazine (Apresoline), for hypertension, *1968:* Sept., 1233
for hypertensive encephalopathy, *1969:* March, 352, 358
neurologic side effects, *1968:* July, 850
Hydrarthrosis, intermittent, vs. rheumatoid arthritis, *1968:* May, 510
Hydrocephalus, with myelomeningocele, neurosurgical management, *1969:* May, 494
Hydrocortisone, for heart block, *1969:* March, 325
for rheumatoid arthritis, *1968:* May, 743
Hydroxychloroquine (Plaquenil), for rheumatoid arthritis, *1968:* May, 761
17-Hydroxycorticosteroids, tests of, *1969:* Jan., 89
drug effects on, *1969:* Jan., 212
Hydroxyproline, urinary, hyperparathyroidism and, *1968:* March, 458
in diagnosis of metabolic bone disease, *1970:* July, 1067

5-Hydroxytryptamine, rheumatoid arthritis inflammation and, *1968:* May, 625
Hyperabduction syndrome, *1968:* July, 777
Hyperalimentation, intravenous, *1970:* May, **577-589**
Hyperbetalipoproteinemia, diagnosis and diet therapy, *1970:* Nov., 1390-1391
treatment, *1970:* Nov., 1393
Hyperbilirubinemia, neonatal, treatment of, *1969:* Sept., 1058
Hypercalcemia, causes of, *1970:* March, 519
hyperparathyroidism and, *1970:* Jan., 132
prolonged, in hyperparathyroidism, *1970:* March, 513-514
Hypercholesterolemia, essential familial, treatment, *1970:* Nov., 1604
familial, treatment, *1970:* Nov., 1393
therapy for, diet, *1968:* Sept., 1251-1253
drug, *1968:* Sept., 1253-1259
Hyperchylomicronemia, diagnosis and diet therapy, *1970:* Nov., 1393, 1394
Hypercortisonism, with rheumatoid arthritis, *1968:* May, 740-742
Hypercreatinemia, myopathy and, *1968:* March, 247
Hypercupremia, *1970:* Nov., 1511
Hyperdynamic states of cardiovascular system, adrenergic receptor blockers and, *1968:* Sept., **1041-1048**
Hyperglobulinemia, syndromes associated with diagnosis of, *1970:* July, **917-938**
Hyperglycemia, in diabetic coma, *1970:* May, 687
Hyperkalemia, *1969:* March, 411
cardiovascular effects of, *1968:* Sept., 1241
causes of, *1968:* Sept., 1243
Hyperkinetic heart syndrome, adrenergic receptor blockers and, *1968:* Sept. 1044
Hyperlipemia. See also *Hyperlipoproteinemia.*
acute pancreatitis and, *1968:* Nov., **1493-1501**
exogenous, diagnosis and diet therapy, *1970:* Nov., 1394
mixed, atherosclerotic cardiovascular disease and, *1970:* Nov., 1450
Hyperlipidemia, coronary artery disease and, *1970:* Nov., 1599
in atherosclerosis, dietary and drug treatment of, *1970:* May, **657-669**
tests for, *1970:* July, **1029-1035**
treatment, *1970:* Nov., **1599-1613**
Hyperlipoproteinemias. See also *Hyperlipemia.*
characteristic alterations in, *1970:* Nov., 1392
chemotherapy, *1970:* Nov., 1605-1612
classification, *1970:* Nov., 1390-1397, 1601-1604
clinical, *1970:* May, 660
clinical features, *1970:* Nov., 1603
diagnosis, *1970:* Jan., 154-156
diet therapy for, *1970:* Nov., 1604, 1609
familial, dietary control, *1970:* Nov., 1442
treatment, *1970:* Nov., 1393
low-carbohydrate diet in, *1970:* Nov., 1608
Hyperlipoproteinemias (*Continued*)
mixed, diagnosis and diet therapy, *1970:* Nov., 1395
paper electrophoresis in, *1970:* Nov., 1601, 1602
physical findings, *1970:* Nov., 1387-1391
tests for, *1970:* Nov., 1386-1387
Hypernatremia, *1969:* March, 413-415
Hypernephroma, and prolonged fever, *1970:* March, 386
Hyperopia, *1969:* Sept., 1135
Hyperosmolar hyperglycemic nonketotic diabetic coma, *1970:* May, **683-699**
Hyperoxia, after cardiopulmonary resuscitation, *1969:* March, 395
Hyperparathyroidism, primary, *1970:* March, **511-529**
diagnosis, *1968:* March, **451-462**
simplified approach to, *1970:* Jan., **131-139**
secondary to uremia, *1970:* March, 422
tests for, *1970:* July, 1062
treatment, *1970:* Jan., 137-138
Hyperphenylalaninemia, dietary control of, *1970:* Nov., 1435
Hyperprebetalipoproteinemia, chemotherapy, *1970:* Nov., 1607
diagnosis and therapy, *1970:* Nov., 1391-1394
Hypersensitivity, penicillin, *1970:* Sept., 1092-1097
Hypersomatotropism, diagnosis, *1968:* March, **371-380**
Hypersplenism, in rheumatoid arthritis, *1968:* May, 529
Hyperstat. See *Diazoxide.*
Hypertension, cerebrovascular disease and, *1970:* March, 350
encephalopathy (crisis) in, *1969:* March, **351-360**
fluorescein angiography of fundus in, *1968:* July, 859
hemorrhagic stroke and, *1968:* Sept., 1204-1206
in hemiplegia, *1969:* May, 543
in uremia, *1970:* March, 418
portal assessment, *1968:* Nov., 1414
primary, therapy for, *1968:* Sept., 1230-1233
pulmonary, cardiac catheterization in, *1970:* July, 976
renal, treatment, *1968:* Sept., 1230
secondary, causes, *1968:* Sept., 1214
diagnosis of, progress in, *1968:* Sept., **1213-1226**
treatment, *1968:* Sept., 1227-1230
vs. primary (essential), *1968:* Sept., 1213
skin ulcers and, *1969:* March, 262
toxemia of pregnancy and, *1968:* Sept., 1234
treatment of, recent advances in, *1968:* Sept., **1227-1236**
vs. alcoholic myocardiopathy, *1968:* Sept., 1186
with renal insufficiency, *1968:* Sept., 1234
Hyperthyroidism, Addison's disease and, *1968:* March, 335, 336

Hyperthyroidism (*Continued*)
cardiovascular effects of, adrenergic receptor blockers and, *1968:* Sept., 1046
clubbing of fingers and toes in, *1968:* March, **393–398**
erythropoiesis and, *1968:* March, 235
exophthalmos with, surgery for, *1968:* March, **399–407**
hypocholesterolemia in, *1970:* Nov., 1481
laboratory diagnosis, *1970:* July, **1037–1047**
leukopoiesis and, *1968:* March, 239
metabolic and nutritional aspects, *1970:* Nov., 1480–1482
periosteal bone formation in, *1968:* March, **393–398**
red cell 2,3 diphosphoglycerate and, *1970:* May, 736
Hypertriglyceridemia, endogenous, diagnosis and diet therapy, *1970:* Nov., 1391–1394
treatment, *1970:* Nov., 1604
Hyperuricemia, asymptomatic, treatment of, *1969:* Nov., 1343–1344
control of, *1969:* Nov., 1340–1343
after gout attack, *1969:* March, 457
mechanisms of production of, *1969:* Nov., 1332
treatment of, physiologic and biochemical basis for, *1969:* Nov., **1331–1347**
Hyperventilation, vs. intractable heart failure, *1970:* March, 313
Hypnosis, for pain, *1968:* Jan., **217–224**
essential elements, *1968:* Jan., 218
hazards, *1968:* Jan., 222
in labor, *1968:* Jan., 145
Hypnotics, nonbarbiturate, for pain, *1968:* Jan., 49
Hypoadrenalism, idiopathic, parietal cell antibody and, *1968:* Nov., 1286
Hypoaldosteronism, familial, dietary control, *1970:* Nov., 1442
Hypocholesterolemia, in hyperthyroidism, *1970:* Nov., 1481
Hypofibrinogenemia, acquired, *1969:* March, 301
Hypogammaglobulinemia, acquired (late-onset), *1970:* March, 294
arthritis of, vs. juvenile rheumatoid arthritis, *1968:* May, 578
pernicious anemia and, *1970:* May, 640
Hypoglycemia, causes, *1968:* March, 283
clinical approaches, *1970:* March, **531–542**
drug-induced, in diabetes mellitus, *1969:* March, **465–467**
iatrogenic, in juvenile diabetes mellitus, *1969:* Nov., 1372
insulinoma and, tolbutamide and leucine tests in, *1968:* March, **283–294**
leucine-sensitive, dietary control of, *1970:* Nov., 1436
post gastrectomy, *1970:* March, 540
pregnancy and, *1968:* March, 256
Hypogonadism, radioimmunoassay of gonadal hormones in, *1970:* July, 1056
zinc deficiency and, *1970:* Nov., 1517
Hypokalemia, after gastrointestinal surgery, *1969:* Nov., 1400
cardiovascular effects of, *1968:* Sept., 1241
clinical manifestations, *1968:* Sept., 1104
hypertension and, *1968:* Sept., 1216
in liver disease, *1970:* Nov., 1466
with alkalosis, *1969:* March, 409–410
Hypolipoproteinemias, diagnosis of, *1970:* Jan., 156–157
Hyponatremia, *1969:* March, 412–413
after gastrointestinal surgery, *1969:* Nov., 1399
recognition, *1968:* July, 817
Hypophosphatemia, hyperparathyroidism and, *1970:* Jan., 134
Hypophysectomy, for malignant exophthalmos, *1969:* March, 472
Hypophysis. See *Pituitary gland.*
Hypopigmentation, deafness and, *1969:* July, 767
Hypopituitarism, amenorrhea and, *1968:* March, 342
metabolic and nutritional aspects, *1970:* Nov., 1478
Hyposensitization, for asthma, *1969:* March, 241
Hypotension, after myocardial infarction, *1968:* Sept., 1072
anaphylaxis and, *1969:* March, 252
orthostatic, *1968:* July, **809–816**
venous tone in, *1968:* Sept., 1082
Hypotensive drugs, effects on laboratory values, *1969:* Jan., 219
Hypothalamus, amenorrhea and, *1968:* March, 340
in regulation of adenohypophyseal hormone secretion, *1968:* March, 358
Hypothermia, esophagogastric, for bleeding esophageal varices, *1968:* Nov., 1466
for upper gastrointestinal hemorrhage, *1969:* March, 423
in neonates, *1969:* Sept., 1057
Hypothyroidism. See also *Myxedema.*
Addison's disease and, *1968:* March, 334, 336
after radioactive iodine therapy, *1968:* March, **417–429**
cardiovascular disease and, *1968:* March, 440
erythropoiesis and, *1968:* March, 235
laboratory diagnosis of, *1970:* July, **1037–1047**
metabolic and nutritional aspects, *1970:* Nov., 1482
thyroid function tests in, *1970:* July, 1043
treatment, evaluation of, *1968:* March, 441
primary, *1968:* March, 431
Hypoventilation, hypoxia due to, *1970:* May, 617
Hypovolemia, from pancreatitis, *1969:* March, 432
Hypoxemia, red cell 2,3-diphosphoglycerate and, *1970:* May, 733
Hypoxia, cardiovascular response to, adrenergic receptor blockers and, *1968:* Sept., 1044

Hypoxia (*Continued*)
pathophysiology of, *1970:* May, 617–624
perinatal, *1969:* Sept., 1056
Hysterical neurosis, *1969:* March, 282

ICF syndrome, diagnosis of, *1970:* July, 898
Icterus. See *Jaundice.*
Icterus intermittens juvenalis, *1968:* Nov., 1420
IDU (5-iodo,2-deoxyuridine), for eye disorders, *1969:* Sept., 1152
I.F. See *Intrinsic factor.*
Ileitis, "backwash," *1968:* Nov., 1387
regional (terminal, distal). See *Regional enteritis.*
Ileocolitis, *1968:* Nov., 1387; *1969:* Sept., 1207
Illiterates, testing vision in, *1969:* Sept., 1133
Immune response, abortion and, *1969:* July, 777
afferent limb of, concept of, *1970:* May, 714
disorders of, *1970:* May, 714–720
antibody-mediated, *1969:* Nov., 1225–1227
cell-mediated, *1969:* Nov., 1228
disorders of. See *Immunologic deficiency diseases.*
injection therapy for allergy and, *1969:* Nov., 1260
lymphoid cells and, *1970:* March, 282
thymus and, *1970:* March, 281
Immunity. See also *Autoimmunity* and *Immunosuppression.*
alterations in, rheumatoid arthritis and, *1968:* May, 594–598
rheumatoid arthritis inflammation and, *1968:* May, 630–631
tissue, biological significance of, *1970:* Jan., 55
tissue typing and, *1970:* Jan., **43–58**
Immunization, injection therapy for allergy and, *1969:* Nov., 1261
programs, for children with spina bifida, *1969:* May, 491
Immunoelectrophoresis, in diagnosis of syndromes associated with hyperglobulinemia, *1970:* July, 927–936
of serum proteins, *1969:* Jan., 154–156
Immunoglobulin A, deficiency of, isolated, *1970:* March, 291
Immunoglobulins, abnormalities, diagnosis of, *1970:* July, **917–938**
selective, *1969:* July, 907
deficiencies, in celiac disease, *1970:* May, 651
human, *1969:* March, 249, 250
increased, causes, *1969:* Jan., 151
Immunohematology, in community hospital laboratory, *1969:* Jan., 14
Immunologic deficiency, with thrombopenia and eczema, *1969:* July, 909
Immunologic deficiency diseases, *1969:* July, 907–910; *1970:* March, **281–307**
cell-mediated, *1970:* March, 284, 286–288
combined type, *1970:* March, 288–290
Immunologic deficiency diseases (*Continued*)
humoral, *1970:* March, 284–286
partial, *1970:* March, 291–296
secondary, *1970:* March, 296–298
Immunologic tolerance, *1970:* Jan., 54–55
Immunoserology, in community hospital laboratory, *1969:* Jan., 16
Immunosuppression. See also *Drugs, immunosuppressive.*
after kidney transplantation, *1970:* Jan., 85–86
clinical uses of, *1969:* Nov., **1225–1241**
hazards of, *1969:* Nov., 1231–1233
malignant disease and, *1970:* March, 299–300
Impending coronary syndrome, *1968:* Sept., 1062
Implants, corneal, *1969:* Sept., 1107
Imuran. See *Azathioprine.*
Inborn errors of metabolism, nutritional management of, *1970:* Nov., **1431–1448**
INCAP, studies on nutrition, *1970:* Nov., 1424
Incontinence, bladder and bowel, in children with spina bifida, *1969:* May, 491
in hemiplegic patient, *1969:* May, 557–558
Inderal. See *Propranolol.*
Indomethacin, for gout, *1970:* March, 439
for rheumatoid arthritis, *1968:* May, 694
Infantile paralysis. See *Poliomyelitis.*
Infantile spasms, medical treatment for, *1968:* July, 967
Infants, iron deficiency in, *1970:* Nov., 1402. See also *Anemia, iron deficiency.*
kanamycin dosage for, *1970:* Sept., 1249
newborn, and fetus, newer studies in, *1969:* Sept., **1051–1062**
intravenous hyperalimentation in, *1970:* May, 580
pernicious anemia in, dietary management, *1970:* Nov., 1445
total parenteral nutrition for, methods, *1970:* Nov., 1377–1381
Infarction, myocardial. See under *Myocardium.*
Infection, as cause of rheumatoid arthritis, *1968:* May, **673–676**
bacterial, diarrhea and, *1970:* March, 445–446
emergency treatment, *1969:* March, **437–447**
penicillins for, *1970:* Sept., 1086–1091
peritonitis during antibiotic therapy, *1969:* March, 442
shock during antibiotic therapy, *1969:* March, 442
skin necrosis and, *1969:* March, 270, 272
superinfection during antibiotic therapy, *1969:* March, 441
complicating immunosuppression, *1969:* Nov., 1232
complicating kidney transplantation, *1970:* Jan., 89
diarrheal, *1970:* March, **443–453**
enhanced susceptibility to, *1970:* May, **713–722**

Infection (*Continued*)
genitourinary, emergency treatment, *1969:* March, 445
in malnourished subjects, *1970:* Nov., **1495–1508**
in pancreatitis, *1969:* March, 434
intra-abdominal, and prolonged fever, *1970:* March, 384–386
maternal, abortion and, *1969:* July, 775
resistance, inherited defects in, *1969:* July, **903–922**
resistance factors, nutrition and, *1970:* Nov., 1499
serum protein changes in, *1969:* Jan., 150
surgical, ampicillin for, *1970:* Sept., 1153
viral. See *Viral infections.*
Infectious mononucleosis. See *Mononucleosis, infectious.*
Infertility, in "normal" couple, *1969:* Sept., 1019–1022
oral contraception and, *1969:* Sept., 1032–1035
Inheritance. See also *Genetics.*
autosomal recessive, of metabolic disorders, detection by direct measurements, *1969:* July, 857
mendelian patterns, in carcinoma and precancerous diseases, *1969:* July, 924–930
modes of, *1969:* July, 745
Injection therapy, for allergy, immunologic basis of, *1969:* Nov., **1257–1264**
Injuries. See names of parts or organs.
nutrition after, *1970:* Nov., 1373–1375
Institute of Nutrition of Central America (INCAP), studies on nutrition, *1970:* Nov., 1424
Insulin, administration, in diabetic acidosis, *1969:* Nov., 1368
biosynthesis of, *1970:* Jan., 191–192
excess, hypoglycemia and, *1970:* March, 535
for chronic pancreatitis, *1970:* March, 487
osteoporosis and, *1970:* Jan., 148
plasma, assay of, in hypoglycemia, *1968:* March, 285
protein synthesis and, *1970:* Jan., **201–207**
resistance, in juvenile diabetes mellitus, *1969:* Nov., 1375
resistance, obesity and, *1970:* Nov., 1534
secretion, *1968:* March, 284
Insulin antagonism, pregnancy and, *1968:* March, 254
Insulin test, of gastric secretion, *1968:* Nov., 1309
Insulin tolerance test, hypersomatotropism and, *1968:* March, 372
in hypoglycemia, *1968:* March, 285
Insulinoma, *1968:* March, 300
hypoglycemia and, *1970:* March, 537
tolbutamide and leucine tests in, *1968:* March, **283–294**
Intal. See *Disodium chromoglycate.*
Intercostal block, in office, *1968:* Jan., 180
Interferon, nutritional deficiency and, *1970:* Nov., 1499
Interventricular septum, rupture of, after myocardial infarction, *1968:* Sept., 1074
Intervertebral disk, herniated, cervical root pain and, *1968:* July, 775
Intestines. See also *Bowels.*
disorders of. See also names of disorders.
growth retardation and, *1969:* Sept., 1204
inflammatory, clinical observations on, *1969:* Sept., **1195–1217**
nonspecific, *1968:* Nov., **1387–1396**
prolonged fever and, *1970:* March, 391
nephrolithiasis and, *1969:* Sept., 1205
fistulas, medium chain triglycerides in, *1970:* Nov., 1375
hemorrhage, causes, *1969:* March, 418
malabsorption in. See *Malabsorption.*
obstruction, pregnancy and, *1969:* Sept., 1022–1025
parasites, jejunal biopsy and, *1970:* July, 859
polyps of, inheritance, *1968:* Nov., 1274
small, biopsy of, *1970:* July, **851–862**
Intracranial disorders, acute, *1969:* March, **293–300**
Intracranial hemorrhage, spontaneous, *1969:* March, 300
Intraocular pressure, drugs and, *1969:* Sept., **1109–1121**
Intravenous alimentation, *1970:* Nov., 1377–1381
Intravenous hyperalimentation, *1970:* May, **577–589**
Intrinsic factor, assay of, in megaloblastic-macroovalocytic anemias, *1970:* May, 637
Iodide, intravenous, for status asthmaticus, *1970:* March, 499
Iodine, body, measurement with whole-body counter, *1969:* Jan., 208
deficiency, goiter and, *1968:* March, 409
protein-bound, thyroid function and, *1968:* March, 464
thyroid function and, factors in interpretation, *1970:* Jan., 117
thyroid therapy and, *1968:* March, 442
radioactive, biologic effects, *1968:* March, 419
dosage, *1968:* March, 417
radioactive, for exophthalmic goiter, *1970:* Jan., 125
for thyrotoxicosis, *1968:* March, **417–429**
post-therapy management, *1968:* March, 423
principles of therapy, *1968:* March, 422–427
uptake in thyroid disorders, *1969:* Jan., 85
uptake test, *1968:* March, 464
uptake test, factors in interpretation, *1970:* Jan., 118
5-Iodo,2-deoxyuridine, for eye disorders, *1969:* Sept., 1152
IPPB. See *Breathing, intermittent positive pressure.*
Iron, absorption, *1970:* Nov., 1402
normal, *1968:* Nov., 1343
studies, *1968:* Nov., 1351
blood content of, decreased, *1969:* Jan., 48

Iron (*Continued*)
body, distribution, *1970:* Nov., 1401
measurement, *1970:* July, 909, 912
with whole-body counter, *1969:* Jan., 208
body, requirements, *1970:* Nov., 1404
deficiency, after gastrointestinal surgery, *1969:* Nov., 1397
anemia of, *1970:* Nov., 1406–1412. See also *Anemias, iron deficiency.*
diagnosis of, *1970:* July, **903–915**
diagnosis, and therapy, *1970:* Nov., 1405–1410
evaluation, marrow biopsy in, *1970:* Nov., 1405
hypothyroidism and, *1968:* March, 237
prevention, *1970:* Nov., 1410
loss, from hemorrhage, *1969:* March, 423
metabolism, *1970:* Nov., **1400–1406**
in rheumatoid arthritis, *1968:* May, 529
oral dosage, *1970:* Nov., 1408
parenteral, *1970:* Nov., 1409
tests of, drug effects on, *1969:* Jan., 212
therapeutic, as diagnostic test, *1970:* July, 912–913
Irradiation. See *Radiation; Roentgen.*
Ischemia, cardiac, transient, myocardial infarction and, *1968:* Sept., 1062
cerebral, pathogenesis of, *1970:* March, 352–355
renal, *1969:* March, 399
transient attacks, cerebrovascular disease and, *1970:* March, 351
therapy for, *1970:* March, 356
ISD. See *Isosorbide dinitrate.*
Islet cells of pancreas. See under *Pancreas.*
Ismelin. See *Guanethidine.*
Isoenzyme studies, in alcoholic muscle disease, *1970:* May, 726
Isoniazid, metabolism of, inherited variations in, *1969:* July, 842–844
Isoproterenol (Isuprel), as aerosol, for respiratory insufficiency in anaphylaxis, *1969:* March, 256
for heart block, *1969:* March, 325
for shock, *1968:* Sept., 1085
in myocardial infarction, *1970:* Jan., 240
for slow ventricular rate, *1968:* Sept., 1070
for status asthmaticus, *1970:* March, 500
Isosorbide dinitrate, for intractable angina, *1970:* March, 335–336, 338–342
Isoxazolyl penicillins, *1970:* Sept., **1127–1143**
Isuprel. See *Isoproterenol.*

JAFFE'S tests, in Horner's pupil, *1968:* July, 879, 880
Jaundice, age of patient and cause, *1968:* Nov., 1424
cholestatic, of pregnancy, *1968:* Nov., 1422
classification, *1968:* Nov., 1420
differential diagnosis, *1968:* Nov., **1417–1444**
drug-induced, *1968:* Nov., 1422
hepatic, *1968:* Nov., 1420, 1421
Jaundice (*Continued*)
hepatocanalicular, *1968:* Nov., 1420, 1421
hepatocellular, *1968:* Nov., 1420, 1421
intrahepatic cholestatic, due to erythromycin estolate, *1970:* Sept., 1204
mode of onset and cause, *1968:* Nov., 1425
neonatal, deafness and, *1969:* July, 755
nonhemolytic, hereditary, *1968:* Nov., 1420
pain and, *1968:* Nov., 1426
physical examination and, *1968:* Nov., 1426
posthepatic, *1968:* Nov., 1420, 1423
prehepatic, *1968:* Nov., 1420
production, *1968:* Nov., 1420, 1421
retention, *1968:* Nov., 1420
Jejunum, biopsy of, *1970:* July, **851–862**
Jellyfish venom, skin necrosis and, *1969:* March, 267
Joint space, narrowing of, in rheumatoid arthritis, *1968:* May, 660
Joints, disarticulation, for malignant disease, rehabilitation after, *1969:* May, 611–614
in rheumatoid arthritis, ankylosis, *1968:* May, 614
aspiration, *1968:* May, 539
effusion, *1968:* May, 609
examination, *1968:* May, 494
inflammatory changes, *1968:* May, 611
lymphoid nodules, *1968:* May, 610
malalignment, *1968:* May, 660
vs. ankylosing spondylitis, *1968:* May, 518
of hand, stiffness, *1969:* May, 646–651
of spine, osteoarthritis of, low back pain and, *1968:* Jan., 62
pathologic changes in, rheumatoid arthritis and, *1968:* May, 607–616
peripheral, in ankylosing spondylitis, *1968:* May, 522
soft tissue changes in, rheumatoid arthritis and, *1968:* May, 656
subluxation of, in rheumatoid arthritis, *1968:* May, 660
JRA. See *Arthritis, rheumatoid, juvenile.*

KALIURESIS, thiazide diuretics and, *1969:* Nov., 1325
Kallikrein, formation of bradykinin and, *1968:* March, 266
Kallikrein-kininogen-kinin system, rheumatoid arthritis inflammation and, *1968:* May, 624
Kanamycin, *1970:* Sept., **1245–1256**
administration and dosage, *1970:* Sept., 1246, 1248, 1253
allergic reactions to, incidence of, *1970:* Jan., 63
bacteria resistant to, *1970:* Sept., 1250
clinical indications, *1970:* Sept., 1251
for emergency treatment of infection, *1969:* March, 440
in infants, *1970:* Sept., 1249
Karyotyping, *1970:* July, 1011–1013
Kasabach-Merritt syndrome, skin necrosis and, *1969:* March, 265
Kayexalate. See *Polystyrene sulfonate.*

Keflin. See *Cephalothin.*
Keratitis, corticosteroids for, *1969:* Sept., 1148–1155
Keratoconjunctivitis, epidemic, treatment of, *1969:* Sept., 1155
Keratoconus, keratoplasty in, *1969:* Sept., 1103
Keratoplasty, *1969:* Sept., 1102–1107
Keratoprostheses, *1969:* Sept., 1107
Keratosis blenorrhagica, with arthritis, *1968:* May, 504
Ketonuria, branched-chain. See *Maple syrup urine disease.*
Kidney. See also *Renal.*
carbuncle, and prolonged fever, *1970:* March, 386
carcinoma of, prolonged fever and, *1970:* March, 387
circulation in, angiotensin and, *1968:* March, 269–275
colic, hyperparathyroidism and, *1970:* March, 514–515
disease, ampicillin in patients with, *1970:* Sept., 1146, 1154
cardiovascular aspects of, *1968:* Sept., **1237–1247**
chronic, immunosuppression for, *1969:* Nov., 1238
diagnosis, office procedures in, *1969:* Jan., **25–35**
due to methicillin, *1970:* Sept., 1122
polycystic, hypertension and, *1968:* Sept., 1217
polyuria in, *1968:* March, 384
secondary hypertension and, *1968:* Sept., 1214
unilateral, diagnosis of, *1968:* Sept., 1221
failure, acute, *1969:* March, **397–405**
chronic, neurologic complications of, *1968:* July, **845–851**
due to cephaloridine, *1970:* Sept., 1222
intravenous hyperalimentation for, *1970:* May, 586
methicillin in patients with, *1970:* Sept., 1118
function, in liver disease, dietary control, *1970:* Nov., 1467
genetic disorders, dietary control, *1970:* Nov., 1441–1443
infarction of, lactate dehydrogenase activity in, *1969:* Jan., 125
insufficiency, hypertension and, *1968:* Sept., 1234
ischemia, *1969:* March, 399
renin-angiotensin system and, *1968:* March, 270
necrosis, tubular, *1969:* March, 402–404
systemic lupus erythematosus and, *1970:* Jan., 96
toxic reactions. See *Nephrotoxic reactions.*
transplantation of, complications of, *1970:* Jan., 88
dialysis and, *1970:* Jan., 75–77
donor selection in, *1970:* Jan., 79–83
medical criteria for, *1970:* Jan., 78
patient selection and management in, *1970:* Jan., **75–94**
Kidney (*Continued*)
transplantation of, postoperative care, *1970:* Jan., 84
preparation for, *1970:* Jan., 83
tuberculosis of, *1969:* March, 452
tubular necrosis of, acute, after transplantation, *1970:* Jan., 89
tumors, hypertension and, *1968:* Sept., 1217
prolonged fever and, *1970:* March, 386
vascular disease, dietary control, *1970:* Nov., 1453
Kinesis. See *Movement.*
Klebsiella infections, choice of therapy for, *1970:* Sept., 1162
Klinefelter's syndrome, chromosomal abnormality in, *1970:* July, 1018
radioimmunoassay of gonadal hormones in, *1970:* July, 1056
Knee, deformities, in spina bifida and myelomeningocele, *1969:* May, 504
examination, in hemiplegic patient, *1969:* May, 554
in rheumatoid arthritis, *1968:* May, 499
surgery, *1968:* May, 726
Kwashiorkor, *1968:* Nov., 1361

LABOR, pain relief in, *1968:* Jan., **137–146**
Laboratory, in community hospital, continuing medical education and, *1969:* Jan., 20
facilities of, *1969:* Jan., 17
organization of, *1969:* Jan., 12
role of, *1969:* Jan., **11–23**
standardization and quality control, *1969:* Jan., 19
office, current place of, *1969:* Jan., **3–9**
facilities and equipment for, *1969:* Jan., 4
in kidney disease, *1969:* Jan., **25–35**
in lung function tests, *1969:* Jan., **37–45**
tests adaptable to, *1969:* Jan., 5
Laboratory diagnosis, advances in, symposium on, *1969:* Jan., **1–231**
Labstix system, for urinalysis, *1969:* Jan., 6
Lactase deficiency, *1968:* Nov., 1358
after gastrointestinal surgery, *1969:* Nov., 1394
causes, *1969:* Sept., 1184
Lactic dehydrogenase, serum, tests for, *1968:* Nov., 1410, 1431; *1969:* Jan., 122–128
Lactogen, human placental, insulin antagonism and, *1968:* March, 254
Laennec's cirrhosis. See *Cirrhosis.*
Landry's paralysis, *1968:* July, 901
Language. See *Speech.*
Largon. See *Propriomazine.*
Laryngectomy, speech after, *1969:* May, 617–618
Larynx, carcinoma of, rehabilitation after treatment, *1969:* May, 617–618
edema, anaphylaxis and, *1969:* March, 252
topical analgesia, *1968:* Jan., 178
Lasix. See *Furosemide.*

Lateral sclerosis, amyotrophic, speech disturbances in, *1968:* July, 838–842
LATS. See *Long-acting thyroid stimulator.*
Lavage, bronchopulmonary, *1970:* May, **755–771**
LDH. See *Lactic dehydrogenase.*
LDL. See *Lipoproteins, low density.*
Lee-White test, *1969:* Jan., 64
Leg, amputation, prosthesis for, immediate fitting, *1969:* May, **665–676**
rehabilitation after, *1969:* May, 674–676
deformities, in spina bifida and myelomeningocele, *1969:* May, 504
examination, in hemiplegic patient, *1969:* May, 551–556
local analgesia of, in office, *1968:* Jan., 180
nerve blocks in, *1968:* Jan., 125
orthoses, new concepts in, *1969:* May, **585–592**
thrombophlebitis, complicating hemiplegia, *1969:* May, 553
Leprosy, *1968:* July, 904
Leriche syndrome, *1968:* Jan., 63
Lesch-Nyhan syndrome, studies on cultured cells, *1969:* July, 802
Leucine-sensitive hypoglycemia, dietary control of, *1970:* Nov., 1436
Leucine tolerance test, in hypoglycemia, *1968:* March, 286–293
Leukemia, chemotherapy for, *1969:* Nov., 1270
chromosomal abnormality in, *1970:* July, 1021–1023
lymphatic, chronic, immunological deficiency and, *1970:* March, 299
vs. juvenile rheumatoid arthritis of acute onset, *1968:* May, 575
Leukocytes, chemotaxis, disorder of, serum inhibitor and, *1970:* May, 719
polymorphonuclear, in rheumatoid arthritis inflammation, *1968:* May, 629
Leukocytosis, in rheumatoid arthritis, *1968:* May, 543
juvenile, *1968:* May, 570
Leukodystrophy, metachromatic, nerve biopsy in diagnosis, *1968:* July, 891
Leukopenia, with rheumatoid arthritis, *1968:* May, 529
Leukopoiesis, endocrine effects on, *1968:* March, 238–240
Levodopa, for Parkinsonism, *1970:* May, 775–784
Levophed. See *Norepinephrine.*
Levoprome. See *Methotrimeprazine.*
Levothyroxine, for hyperlipoproteinemias, *1970:* Nov., 1610
Librium. See *Chlordiazepoxide.*
Lidocaine (Xylocaine), after myocardial infarction, *1968:* Sept., 1064
for cardiac arrhythmia, basis of action of, *1969:* Nov., 1301
for epidural anesthesia, *1968:* Jan., 212
in office, *1968:* Jan., 175, 178
intravenous, for ventricular arrhythmia, *1969:* March, 323
Lincomycin, *1970:* Sept., **1295–1303**
Lipase, pancreatic, congenital absence, *1968:* Nov., 1275
Lipemia, treatment, *1970:* Nov., 1393
Lipid storage diseases, genetics and, *1969:* July, **827–838**
Lipids, alterations, in atherosclerotic cardiovascular disease, *1970:* Nov., 1450
disorders, diagnosis and dietary treatment, *1970:* Nov., **1383–1398**
genetic, dietary control, *1970:* Nov., 1442–1443
plasma, in hyperlipoproteinemia, *1970:* Nov., 1386–1387
vs. lipoproteins, *1970:* May, 657
plasma transport, physiology of, *1970:* Nov., 1384–1386
serum levels of, control of, dietary, *1968:* Sept., 1252–1253
drug, *1968:* Sept., 1253–1259
coronary artery disease and, *1968:* Sept., **1249–1260**
Lipoproteinemias. See also specific types.
broad-beta, diagnosis and diet therapy, *1970:* Nov., 1396
Lipoproteins. See also *Hyperlipemias; Lipemias.*
beta, deficiency, congenital, *1968:* Nov., 1277
plasma transport, *1970:* Nov., 1385
blood, myocardial infarction and, *1968:* Sept., 1061
electrophoretic properties, *1970:* Nov., 1602
low density (LDL), plasma transport, *1970:* Nov., 1385
plasma, abnormal, diagnosis of, *1970:* Jan., **153–159**
physicochemical properties, *1970:* Nov., 1384
prebeta, plasma transport, 1970: Nov., 1385
transport, disorders, diagnosis and dietary treatment, *1970:* Nov., **1383–1398**
very low density (VLDL), *1970:* Nov., 1385
Listeria monocytogenes infections, choice of therapy for, *1970:* Sept., 1163
tetracylines for, *1970:* Sept., 1180
Liver, abscess, and prolonged fever, *1970:* March, 384
as source of lipoproteins, *1970:* Nov., 1384
biopsy, needle, *1968:* Nov., 1415
carcinoma, primary, congenital abnormalities and, *1969:* July, 932
cirrhosis. See *Cirrhosis.*
disease, acute, dietary control, *1970:* Nov., 1462–1464
alcohol and, *1969:* Nov., 1419–1422
androgenic steroids in, *1970:* Nov., 1456
carbohydrate metabolism in, *1970:* Nov., 1457
chronic, dietary control, *1970:* Nov., 1464–1468
classification, *1968:* Nov., 1415
complicating immunosuppression, *1969:* Nov., 1232
diagnostic procedures, *1968:* Nov., **1407–1416**
diet and, *1970:* Nov., 1363
dietary control in, clinical aspects, *1970:* 1461–1468

Liver (*Continued*)
disease, fat malabsorption in, *1970:* Nov., 1457
food tolerances in, *1970:* Nov., 1468
hypoglycemia and, *1970:* March, 533
intestinal disorders and, *1969:* Sept., 1203
metabolic defects in, *1970:* Nov., 1455
nitrogen balance in, *1970:* Nov., 1456
nutrition and, *1970:* Nov., **1455–1472**
nutritional deficiencies in, *1970:* March, **467–477**
obstructive, 5′-nucleotidase levels in, *1969:* Jan., 129
potassium deficiency in, *1970:* Nov., 1466
protein metabolism in, *1970:* Nov., 1456
renal function in, dietary control, *1970:* Nov., 1467
serum ornithine carbamyl transferase activity in, *1969:* Jan., 129
serum protein changes in, *1969:* Jan., 149, 150
steatorrhea in, *1970:* Nov., 1458
symposium on, *1968:* Nov., **1265–1501**
vitamin deficiency in, *1970:* Nov., 1459–1461
dysfunction, constitutional, *1968:* Nov., 1320
function of, oral contraception and, *1970:* Jan., 166
tests of, drug effects on, *1969:* Jan., 214
inflammation. See *Hepatitis.*
physiology, implications of current research in, *1968:* Nov., 1403
scanning, *1968:* Nov., 1412
dual channel, *1969:* Jan., **189–203**
toxic reactions to drugs. See *Hepatotoxicity.*
tumors, malnutrition and, *1970:* March, 470
prolonged fever and, *1970:* March, 389
Lofenalac, in phenylketonuria, *1970:* Nov., 1433
Long-acting thyroid stimulator, tests for, *1969:* Jan., 88
Lordosis, lumbar, increased, low back pain and, *1969:* May, 527
Low back, anatomic considerations, *1969:* May, 525–528
pain, evaluation and medical management, *1969:* May, **525–540**
Low-residue diet, uses, *1970:* Nov., 1359–1362. See also *Diet.*
LSD. See *Lysergic acid diethylamide.*
L-Thyroxine. See *Hormones, thyroid.*
L-Triiodothyronine. See also *Hormones, thyroid.*
uptake test, *1968:* March, 468
Lucey-Driscoll syndrome, *1968:* Nov., 1421
Lundh test, in chronic pancreatitis, *1968:* Nov., 1491
Lungs. See also *Pulmonary.*
abscess, penicillins in, *1970:* Sept., 1088
capacity, tests of, *1969:* Jan., 40
carcinoma of, chemotherapy for, *1969:* Nov., 1273
detection of, *1970:* May, **549–553**
Lungs (*Continued*)
carcinoma of, rehabilitation after treatment, *1969:* May, 618–619
diseases, diffuse, transbronchoscopic lung biopsy in, *1970:* July, **951–959**
expiratory velocity, tests of, *1969:* Jan., 43
function tests, during rehabilitation in chronic obstructive pulmonary disease, *1969:* May, 596
in office, *1969:* Jan., **37–45**
in pulmonary embolism, *1969:* March, 369
infections, antimicrobials for, *1970:* Sept., 1192
gram-negative, gentamicin for, *1970:* Sept., 1313
lesions, discrete, transthoracic needle aspiration of, *1970:* July, **961–971**
in rheumatoid arthritis, *1968:* May, 619
oat-cell carcinoma, *1968:* March, 323
scanning, in pulmonary embolism, *1969:* March, 378; *1970:* March, 365
tuberculosis, without radiologic evidence, *1970:* March, 381
Lupus erythematosus, systemic, antinuclear factor tests in, *1968:* May, 559
autoimmunity and, *1970:* Jan., 95–100
esophageal involvement, motility studies in, *1970:* July, 869
immunosuppression for, *1969:* Nov., 1236
reactions to antibiotics resembling, *1970:* Jan., 61
vs. rheumatoid arthritis, *1969:* May, 560, 562
juvenile, *1968:* May, 575
Luteinizing hormone, radioimmunoassay for, *1970:* July, **1049–1059**
Lymph nodes, hyperplasia, in rheumatoid arthritis, *1968:* May, 619
Lymphadenopathy, in rheumatoid arthritis, *1968:* May, 493
juvenile, *1968:* May, 570
Lymphangiectasia, intestinal, *1970:* March, 296
jejunal biopsy in, *1970:* July, 858
Lymphangitis, penicillins for, *1970:* Sept., 1087
Lymphedema, of arm, after radical mastectomy, *1969:* May, 615
Lymphoblast cell lines, *1970:* May, 709
Lymphocyte transfer test, in tissue typing, *1970:* Jan., 46
Lymphocytes, immune response and, *1969:* Nov., 1228
Lymphocytotoxicity test, in tissue typing, *1970:* Jan., 47–50
Lymphography, in lymphoma, *1970:* July, **939–949**
Lymphoid cells, immune response and, *1970:* March, 282
Lymphoma, immunosuppression and, *1969:* Nov., 1232
lymphography in, *1970:* July, **939–949**
prolonged fever and, *1970:* March, 387
small bowel involvement, jejunal biopsy in, *1970:* July, 856, 857

Lymphopenia, in infants, immunologic deficiency and, *1970:* March, 288
Lymphopoiesis. See *Leukopoiesis.*
Lymphosarcoma, chemotherapy for, *1969:* Nov., 1271
Lysergic acid diethylamide (LSD), chromosome breakage and, *1969:* Nov., 1253
Lysosomes, activities, *1968:* May, 635–637
in pathogenesis of rheumatoid arthritis, *1968:* May, **635–641**
in rheumatoid arthritis, *1968:* May, 626–628
inflammation and, *1968:* May, 637

"M" PROTEINS, *1969:* Jan., 151
Macroglobulinemia, serum protein changes in, *1969:* Jan., 152
Waldenström's, electrophoresis in diagnosis, *1970:* July, 923
Macrolide antibiotics, allergic reactions to, incidence of, *1970:* Jan., 63
Maddox rod test, *1969:* Sept., 1135
Magnesium, concentration of, cardiovascular system and, *1968:* Sept., 1244
deficiency, after gastrointestinal surgery, *1969:* Nov., 1400
Malabsorption, *1968:* Nov., **1339–1354**
after gastrointestinal surgery, *1969:* Nov., 1392
clinical observations on, *1969:* Sept., **1169–1194**
glucose-galactose, dietary control, *1970:* Nov., 1440
in celiac disease, *1970:* May, 650
inheritance, *1968:* Nov., 1276
of fats, in liver disease, *1970:* Nov., 1457
Malalignment of joints, in rheumatoid arthritis, *1968:* May, 660
Malignant disease. See *Tumors, malignant.*
Malingering, pathologic, *1968:* Jan., 156
Malleomyces pseudomellei infections, choice of therapy for, *1970:* Sept., 1163
Malnutrition, alcoholism and, *1970:* Nov., **1567–1575**
brain growth and, *1970:* Nov., 1414–1419
brain weight and, *1970:* Nov., 1419
cyclic nature of problem, *1970:* Nov., 1426
drug addiction and, *1970:* Nov., **1567–1575**
endocrine function and, *1970:* Nov., 1490–1491
gastrointestinal disease and, *1968:* Nov., 1398
in hemiplegic patient, *1969:* May, 544
infectious disease and, *1970:* Nov., **1495–1508**
liver disease and, *1970:* March, **467–477**
mental development and, *1970:* Nov., **1413–1429**
peripheral neuropathy and, *1970:* March, 473
polyneuropathy and, *1968:* Jan., 112
Manganese, nutritional significance of, *1970:* Nov., 1525–1527
Mannitol response test, in diagnosis of kidney failure, *1969:* March, 401
Maple syrup urine disease, dietary control of, *1970:* Nov., 1435
genetic variants, *1970:* Nov., 1436
Marfan's syndrome, fibroblast cultures in, *1970:* May, 703
gastrointestinal manifestations and genetic factors, *1968:* Nov., 1277
Massage, for neck and shoulder pain, *1969:* May, 518
in rehabilitation of hand, *1969:* May, 655
Mathematical genetics, future of, *1969:* July, 1005
Mating, patterns of, genetic consequences, *1969:* July, 978–980
MBC. See *Minimum bactericidal concentration.*
MDM. See *Minor determinant mixture.*
Mean corpuscular hemoglobin concentration, in differentiation of anemias, *1969:* Jan., 47
Mean corpuscular volume, in differentiation of anemias, *1969:* Jan., 50
Measles, German. See *Rubella.*
in malnourished children, *1970:* Nov., 1503–1505
Median nerve, compression, *1968:* July, 778–779
Mediastinum, oat-cell carcinoma, *1968:* March, 323
Medical education, evaluation of, *1970:* May, **591–602**
Medical emergencies, symposium on, *1969:* March, **237–477**
Medicine, modern challenges in, symposium on, *1970:* Jan., **1–274**
new developments in, symposium on, *1970:* May, **547–817**
Medionecrosis, cystic, and aneurysmal dilatation of ascending aorta, *1968:* Sept., **1145–1156**
Medium chain triglycerides. See under *Triglycerides.*
Megaloblastic-macroovalocytic anemias, tests in, *1970:* May, 632–640
Melanoma, malignant, fluorescein angiography of fundus in, *1968:* July, 863
inheritance of, *1969:* July, 928
Melioidosis, chloramphenicol for, *1970:* Sept., 1192
Meniere's disease, streptomycin for, *1970:* Sept., 1164
Meninges, irritation of, chronic renal failure and, *1968:* July, 848
Meningitis, bacterial, emergency treatment, *1969:* March, 443
in children, ampicillin for, *1970:* Sept., 1149
penicillins for, *1970:* Sept., 1088
deafness and, *1969:* July, 754
kanamycin for, *1970:* Sept., 1254
Menstruation, cessation, *1968:* March, **339–355.** See also *Amenorrhea.*
disorders of, oral contraception and, *1970:* Jan., 167
Mental development, nutrition and, *1970:* Nov., **1413–1429**
Mental disturbances, in hemiplegia, rehabilitation and, *1969:* May, **575–583**

Mental tests, for hemiplegic patients, *1969:* May, 576
Meperidine hydrochloride (Demerol), for pain, in children, *1968:* Jan., 134
in labor, *1968:* Jan., 140
Mephenesin (Tolseram, Tolserol), for trigeminal neuralgia, *1968:* July, 798
Mephentermine (Wyamine), for shock, *1968:* Sept., 1085
Mepivacaine, for epidural anesthesia, *1968:* Jan., 212
Meprobamate (Equanil, Miltown) for pain, *1968:* Jan., 51
Meralluride, for ascites in Laennec's cirrhosis, *1969:* Nov., 1362
6-Mercaptopurine, bases of action, *1969:* Nov., 1267
for immunosuppression, *1969:* Nov., 1227
Mestinon. See *Pyridostigmine bromide.*
Metabolic acidosis. See *Acidosis, metabolic.*
Metabolic alkalosis. See *Alkalosis, metabolic.*
Metabolism, alcohol, *1970:* Nov., 1568
amino acids. See *Amino acids, metabolism.*
bone. See *Bone, metabolism.*
calcium, disorders of, in uremia, *1970:* March, 421–425
carbohydrate. See *Carbohydrates, metabolism.*
cellular, disorders of, in cultured human cells, *1969:* July, 799–801
cerebral, in cerebral ischemia, *1970:* March, 354–355
changes in, rheumatoid arthritis and, *1968:* May, 601
chromium, *1970:* Nov., 1521
copper, *1970:* Nov., 1511
Wilson's disease and, *1968:* July, **989–1001**
creatine, myopathy and, *1968:* March, 247
disorders of, diagnosis by cell culture, *1969:* July, 807
hereditary, detection of heterozygous carriers, *1969:* July, **857–874**
treatment, *1969:* July, **941–963**
in liver disease, *1970:* Nov., 1455
low back pain and, *1968:* Jan., 66
neurophysiology in, *1969:* May, 626–628
obesity and, *1970:* Nov., **1533–1542**
with intracranial disorders, *1969:* March, 293
drug, *1970:* Nov., 1567
inherited variations in, *1969:* July, 842–851
erythrocytes, genetic disorders of, *1969:* July, **813–826**
normal, *1969:* July, 813–816
growth hormone and, *1970:* Nov., 1474
in disease and injury, *1970:* Nov., 1371, 1373–1375
inborn errors of, nutritional management, *1970:* Nov., **1431–1448**
iodide, pregnancy and, *1968:* March, 257
iron, *1970:* Nov., **1400–1406**
juvenile diabetes mellitus and, therapeutic considerations, *1969:* Nov., **1367–1378**
Metabolism (*Continued*)
laboratory tests of, thyroid therapy and, *1968:* March, 443
potassium myopathy and, *1968:* March, 249
starvation and, *1970:* Nov., 1367–1373
steroid, pregnancy and, *1968:* March, 259–261
trace elements and, current concepts, *1970:* Nov., **1509–1542**
water and electrolyte, abnormalities of, cerebral disorders and, *1968:* July, 846
zinc, *1970:* Nov., 1514
Metachromasia; cellular, fibroblast cultures in, *1970:* May, 703
Metachromatic leukodystrophy, genetics and, *1969:* July, 833–834
Metalloenzymes, zinc, *1970:* Nov., 1514
Metaraminol (Aramine), for cardiogenic shock, *1968:* Sept., 1085; *1969:* March, 313
Metatarsophalangeal joints, in rheumatoid arthritis, *1968:* May, 498
Methacycline, *1970:* Sept., 1174, 1175
Methamphetamine (Desoxyn), for narcolepsy, *1968:* July, 782
Methemoglobinemia, congenital, *1969:* July, 822
from acetophenetidin, *1969:* July, 848
Methetoin (Deltoin), for seizures, *1968:* July, 972
Methicillin, *1970:* Sept., **1113–1125**
for bacterial endocarditis, *1968:* Sept., 1098
for emergency treatment of infection, *1969:* March, 440
in patients with renal failure, *1970:* Sept., 1118
nephritis due to, *1970:* Sept., 1122
spectrum of activity, *1970:* Sept., 1114, 1129
Methimazole, for exophthalmic goiter, *1970:* Jan., 124
Methotrexate (Amethopterin), bases of action, *1969:* Nov., 1267
chromosome breakage and, *1969:* Nov., 1252
for immunosuppression, *1969:* Nov., 1227
for rheumatoid arthritis, *1968:* May, 750, 754
Methotrimeprazine (Levoprome), analgesic properties, *1968:* Jan., 39
for pain, *1968:* Jan., 50
Methoxamine (Vasoxyl), for shock, *1968:* Sept., 1085
Methyldopa (Aldomet), for hypertension, *1968:* Sept., 1232
for hypertensive encephalopathy, *1969:* March, 358
Methylmalonic acidemia, dietary control, *1970:* Nov., 1444
fibroblast cultures in, *1970:* May, 705
Methylphenidate (Ritalin), for narcolepsy, *1968:* July, 782
for orthostatic hypotension, *1968:* July, 814
Methylprednisone, for rheumatoid arthritis, *1968:* May, 743

Methyprylon (Noludar), for pain, *1968:* Jan., 49
Metopirone. See *Metyrapone.*
Metycaine. See *Piperocaine.*
Metyrapone (Metopirone), for ascites in Laennec's cirrhosis, *1969:* Nov., 1362
MIC. See *Minimum inhibitory concentration.*
Microorganisms, skin necrosis and, *1969:* March, 268–273
Microradiography, in diagnosis of metabolic bone disease, *1970:* July, 1063
Middle ear, infection. See *Otitis media.*
Miltown. See *Meprobamate.*
Mineralocorticoids, tests of, *1969:* Jan., 91
Minerals, metabolism, in liver disease, *1970:* Nov., 1461
trace, current concepts, *1970:* Nov., **1509–1542**
Minimum bactericidal concentration (MBC), *1970:* Sept., 1113
Minimum inhibitory concentration (MIC), *1970:* Sept., 1113
Minnesota Multiphasic Personality Inventory (MMPI), automated, *1970:* July, **835–849**
Minocycline, *1970:* Sept., 1174, 1175
Minor determinant mixture (MDM), in skin tests for penicillin allergy, *1970:* Sept., 1094, 1097
Mitral insufficiency, causes of and surgery for, *1968:* Sept., 1116–1122
Mitral valve, disease, cardiac catheterization in, *1970:* July, 974–975
incompetence, *1970:* Jan., **261–274**
Mixed lymphocyte culture, in tissue typing, *1970:* Jan., 50–52
MMPI. See *Minnesota Multiphasic Personality Inventory.*
Mogadon. See *Nitrazepam.*
Mole, hydatidiform, chromosome abnormalities and, *1969:* July, 786
uterine, *1969:* Sept., 1044
Molybdenum, nutritional significance of, *1970:* Nov., 1527
Monamine oxidase cells, *1970:* Nov., 1419
Mongolism. See *Down's syndrome.*
Mononucleosis, infectious, ampicillin in, rash with, *1970:* Sept., 1154
neuropathy and, *1968:* July, 902
vs. Guillain-Barré-Strohl syndrome, *1968:* July, 901
Morphine, for pain, in children, *1968:* Jan., 134
in labor, *1968:* Jan., 140
Morphine sulfate, for pain after myocardial infarction, *1968:* Sept., 1065
to relieve anxiety in heart failure, *1970:* March, 321
Motility, esophageal, implications of current research in, *1968:* Nov., 1269
Motion. See *Movement* and *Range of motion.*
Mouth, carcinoma of, rehabilitation after treatment, *1969:* May, 617
Movement, disorders, *1969:* May, **633–644**
Mucolytic agents, for status asthmaticus, *1970:* March, 500
Mucoviscidosis, inheritance and gastrointestinal manifestations, *1968:* Nov., 1278
Multiple endocrine adenomatosis, *1968:* March, 303
Multiple myeloma. See *Myeloma, multiple.*
Multiple nevoid basal cell cancer syndrome, inheritance of, *1969:* July, 926
Murmurs, heart, *1969:* Jan., 108
Murphy-Pattee test for thyroxine, *1970:* July, 1044
Muscle(s), abnormalities, chronic renal failure and, *1968:* July, 848–849
in spina bifida and myelomeningocele, *1969:* May, 502, 504
diseases. See also *Myopathy; Myotonia.*
alcoholic, *1970:* May, **723–730**
creatine phosphokinase levels in, *1969:* Jan., 121
ultrastructural reactions in, *1968:* July, **909–931**
glycogen sequestration, *1968:* July, 926–928
mitochondria, *1968:* July, 922–926
Z disk, *1968:* July, 910–922
of calf, contracture, complicating hemiplegia, *1969:* May, 556
palpation, in neck and shoulder pain, *1969:* May, 514
relaxants, for neck and shoulder pain, *1969:* May, 517
stretch reflex, cervical root pain and, *1968:* July, 775
wasting of, endocrine disorders and, *1968:* March, **243–252**
weak, cervical root pain and, *1968:* July, 774
neurophysiology in evaluation of, *1969:* May, **625–632**
Muscular dystrophy. See under *Dystrophy.*
Mutagens, environmental, detection of, *1969:* Nov., 1243–1256
Mutations, chemicals and, *1969:* Nov., 1243
in cell culture material, *1969:* Nov., 1250
in experimental mammals, *1969:* Nov., 1248
in somatic tissue, *1969:* Nov., 1251
genetic, radiation and, *1969:* July, **965–976**
in cultured human cells, *1969:* July, 799–801
Myambutol. See *Ethambutol.*
Myasthenia, aggravation by drugs, *1969:* March, 285
Myasthenia gravis, crisis in, *1969:* March, **285–291**
speech disturbances in, *1968:* July, 839
Mycobacterial infections, nontuberculous, ethambutol for, *1970:* Sept., 1324
skin necrosis and, *1969:* March, 272
Mycoplasma infections of animals, rheumatoid arthritis and, *1968:* May, 667–669, **677–686**
Mycoplasma pneumoniae infections, tetracyclines for, *1970:* Sept., 1179
Mycoplasmas, rheumatoid arthritis and, *1968:* May, 675
Mycotic infections, skin necrosis and, *1969:* March, 272

Mydriatic agents, complicating diagnosis of intracranial disorders, *1969:* March, 293
Myelination, malnutrition and, *1970:* Nov., 1417
Myelography, in low back pain, *1969:* May, 531
Myeloma, multiple, chemotherapy for, *1969:* Nov., 1271
electrophoresis in diagnosis, *1970:* July, 922
immunological deficiency and, *1970:* March, 299
neuropathy and, *1968:* July, 906
plasmacytic. See *Myeloma, multiple.*
serum protein changes in, *1969:* Jan., 152
Myelomeningocele, management, *1969:* May, **487–509**
Myeloproliferative syndromes, chromosomal abnormalities in, *1970:* July, 1023
Myocardiopathy, alcoholic, *1968:* Sept., **1183–1191**
Myocardium, contractility, drugs to increase, *1969:* March, 316
contraction, cellular events of, *1970:* Jan., 224–225
damaged, creatine phosphokinase levels with, *1969:* Jan., 120
excitation, cellular events of, *1970:* Jan., 222–224
infarction, acute, management, *1968:* Sept., **1061–1075**
arrhythmia and, *1969:* March, **315–326**
propranolol for, *1968:* Sept., 1025
blood lipoproteins and, *1968:* Sept., 1061
complications of, surgery for, *1968:* Sept., **1115–1131**
consequences, *1968:* Sept., 1063–1064
drugs to prevent arrhythmia after, *1969:* March, 319
etiology, *1968:* Sept., 1061–1062
hemodynamic effects and results of therapy, *1970:* Jan., **235–246**
office treatment for, *1969:* March, 332
postoperative chest pain and, *1968:* Jan., 91, 98
prodromata, *1968:* Sept., 1062–1063
insufficiency, in hemiplegia, *1969:* May, 543
oxygen demands of, propranolol and, *1968:* Sept., 1032
revascularization, coronary arteriography after, *1970:* July, 991–993
for intractable angina, *1970:* March, 343–346
Myochrysine. See *Gold sodium thiomalate.*
Myopathy(ies). See also *Muscles.*
primary, neurophysiology in, *1969:* May, 628–629
steroid, *1968:* March, 245–246
biochemical mechanisms, *1968:* March, 249
thyrotoxic, chronic, *1968:* March, 243–245
Myopia, *1969:* Sept., 1135–1139
Myositis, in rheumatoid arthritis, *1968:* May, 619
Myotonia, neurophysiology in, *1969:* May, 629
Myxedema. See also *Hypothyroidism.*
parietal cell antibody and, *1968:* Nov., 1286
treatment, *1968:* March, **431–450**
evaluation, *1968:* March, 441
vs. intractable heart disease, *1970:* March, 314
Myxedema coma, *1968:* March, 445

NAFCILLIN, for emergency treatment of infection, *1969:* March, 440
serum protein-binding, *1970:* Sept., 1117
spectrum of activity, *1970:* Sept., 1129
Naffziger's test, in low back pain, *1969:* May, 530
Nalidixic acid (NegGram), in urinary tract infections, *1970:* Sept., **1347–1350**
Nalorphine (Nalline), analgesic properties, *1968:* Jan., 38
Naphthylamidase, serum, tests for, *1969:* Jan., 128
Narcolepsy, treatment, *1968:* July, **781–787**
Narcotics, dependence on, *1968:* Jan., 33–36
duration of action, *1968:* Jan., 42
for pain, *1968:* Jan., **33–45**
postoperative, *1968:* Jan., 85
in children, *1968:* Jan., 132
in labor, *1968:* Jan., 140
metabolism, *1970:* Nov., 1569
oral administration, *1968:* Jan., 41
potency and efficacy, *1968:* Jan., 39
regulations for use, *1968:* Jan., 36
selection, *1968:* Jan., 39–44
Nasal cavity, topical analgesia, *1968:* Jan., 178
Nasogastric suction, for pyloric obstruction, *1968:* Nov., 1333
Natural childbirth, *1968:* Jan., 145
Neck, dissection, radical, rehabilitation after, *1969:* May, 618
injuries to, flexion-extension, *1968:* July, 775
pain, evaluation and conservative management, *1969:* May, **511–524**
restricted movement, *1968:* July, 774
Necrosis, types, *1969:* March, 259
NegGram. See *Nalidixic acid.*
Neomycin, allergic reactions to, incidence of, *1970:* Jan., 63
for diarrheal disease, *1970:* March, 449, 451
for hypercholesterolemia, *1968:* Sept., 1255
malabsorption, *1969:* Sept., 1179
sprue-like syndrome from, *1970:* Nov., 1458
Neonatology, *1969:* Sept., 1057
Neoplasms. See *Carcinoma; Tumors.*
Neostigmine, parenteral, for myasthenic crisis, *1969:* March, 288
Neo-Synephrine. See *Phenylephrine.*
Nephritis, glomerular, chronic, immunosuppression for, *1969:* Nov., 1238
methicillin, *1970:* Sept., 1122

Nephrolithiasis, in gout, *1970:* March, 435–436
intestinal disorders and, *1969:* Sept., 1205
Nephropathy. See *Kidney, diseases.*
Nephrosis, idiopathic (lipoid), immunosuppression for, *1969:* Nov., 1238
Nephrotic syndrome, electrophoresis in diagnosis, *1970:* July, 925
vs. intractable heart disease, *1970:* March, 315
Nephrotoxic reactions, to cephaloridine, *1970:* Sept., 1222
to polymyxins, *1970:* Sept., 1263
to sodium colistimethate, *1970:* Sept., 1271
to tetracyclines, *1970:* Sept., 1182
to vancomycin, *1970:* Sept., 1281
Nerves, biopsy, *1968:* July, **885–893**
blocks, in treatment of pain in extremities, *1968:* Jan., **123–129**
cranial, chronic renal failure and, *1968:* July, 847
eighth, neuroma of, cerebellopontine angle syndrome and, *1968:* July, 789, 791
lesions of, at cerebellopontine angle, *1968:* July, 789–795
pain originating in, *1968:* Jan., 111
pain transmission in, *1968:* Jan., 18
fibers, conduction velocities, *1969:* May, 627
optic, lesions of, pupillary reflexes in, *1968:* July, 877
peripheral, bony tunnel syndromes and, *1968:* Jan., 113
diseases of. See *Neuropathy, peripheral.*
pain originating in, *1968:* Jan., 112
pain reception and, *1968:* Jan., 15
trauma to, *1968:* Jan., 113
spinal, pain transmission in, *1968:* Jan., 16
root lesions, *1968:* Jan., 114
Nervous system, autonomic, renin-angiotensin system and, *1968:* March, 275
central, disease, deafness and, *1969:* July, 754
pituitary function and, *1968:* March, **357–369**
in uremia, *1970:* March, 413
drugs acting on, effects on laboratory values, *1969:* Jan., 217
malignant disease involving, rehabilitation after treatment, *1969:* May, 619–620
penicillin toxicity and, *1970:* Sept., 1093
disorders. See also *Neuropathy.*
hypoglycemia and, *1970:* March, 532
motor speech signs in, *1968:* July, **835–844**
orthostatic hypotension and, *1968:* July, 812, 813
pupil in, *1968:* July, **871–884**
symposium on, *1968:* July, **771–1001**
vs. inappropriate secretion of antidiuretic hormone, *1968:* July, 824
in normal movement, *1969:* May, 634–636
pain originating in, *1968:* Jan., **111–121**
neurolytic substances for, *1968:* Jan., 164
Nervous system (*Continued*)
peripheral, chronic renal failure and, *1968:* July, 847–848
sympathetic, adrenergic receptor blockers and, *1968:* Sept., **1049–1060**
toxic reactions, to polymyxins, *1970:* Sept., 1263
Nethalide. See *Pronetalol.*
Neuralgia, postherpetic, *1968:* Jan., 115
percutaneous cordotomy for pain in, *1968:* Jan., 196
radiation therapy for pain of, *1968:* Jan., 204
post-traumatic, percutaneous cordotomy for, *1968:* Jan., 197
trigeminal, *1968:* Jan., 111
medical treatment, *1968:* July, **797–800**
Neuritis, brachial, paralytic, *1968:* July, 776–777
febrile, acute, *1968:* July, 901
shoulder girdle, *1968:* July, 776–777
Neuroblastoma, congenital abnormalities and, *1969:* July, 932
Neurofibromatosis, inheritance of, *1969:* July, 924
gastrointestinal manifestations and, *1968:* Nov., 1278
Neurohumors, in regulation of adenohypophyseal hormone secretion, *1968:* March, 357
Neurologic disorders, secondary hypertension and, *1968:* Sept., 1214
Neurolytic agents, for pain, *1968:* Jan., **161–171**
techniques of administering, *1968:* Jan., 168
Neuroma, of eighth cranial nerve, cerebellopontine angle syndrome and, *1968:* July, 789, 791
Neuropathy, carcinomatous sensory, *1968:* July, 900
Charcot-Marie-Tooth type, *1968:* July, 903
congenital sensory, *1968:* July, 899
Dejerine-Sottas type, *1968:* July, 903
hereditary sensory radicular, *1968:* July, 899
hypertrophic, *1968:* July, 903
ischemic, *1968:* July, 905
peripheral, causes, *1968:* July, 896
diagnosis and classification, *1968:* July, **895–908**
dorsal root ganglion cell type, *1968:* July, 899–900
in uremia, *1970:* March, 412
malnutrition and, *1970:* March, 473
symptoms, *1968:* July, 895
with predominantly motor symptoms, *1968:* July, 900–904
with predominantly sensory symptoms, *1968:* July, 904–906
primary, neurophysiology in, *1969:* May, 630
Refsum type, *1968:* July, 904
traction or pressure, complicating hemiplegia, *1969:* May, 544, 554
Neurophysiology, in evaluation of weakness, *1969:* May, **625–632**

Neurosis, hysterical, *1969:* March, 282
Neurosurgery, for spina bifida and myelomeningocele, *1969:* May, 493–496
Neurotoxic reactions, to polymyxins, *1970:* Sept., 1263
Neutral third party test, in tissue typing, *1970:* Jan., 46
Neutrophils, function, disorder of, in chronic granulomatous disease, *1970:* May, 714–717
in rheumatoid arthritis inflammation, *1968:* May, 629
Newborn. See under *Infant.*
Nicotinic acid, for hypercholesterolemia, *1968:* Sept., 1258
Niemann-Pick disease, genetics and, *1969:* July, 832–833
Nitrazepam (Mogadon), for seizures, *1968:* July, 972
Nitrofurantoin, neurologic side effects, *1968:* July, 850
Nitrogen, balance, in Addison's disease, *1970:* Nov., 1487
in Cushing's syndrome, *1970:* Nov., 1485
loss, energy expenditure and, *1970:* Nov., 1371–1373
extrarenal, in disease and injury, *1970:* Nov., 1374
glucose and, *1970:* Nov., 1373
metabolism, abnormal, in disease, *1970:* Nov., 1373–1375
in liver disease, *1970:* Nov., 1456
mustards, for immunosuppression, *1969:* Nov., 1227
for rheumatoid arthritis, *1968:* May, 696, 750
Nitroglycerin, for intractable angina, *1970:* March, 334–335
Nitrous oxide analgesia, in labor, *1968:* Jan., 141
Nodules, subcutaneous, in rheumatoid arthritis, *1968:* May, 493
Noludar. See *Methyprylon.*
Nontropical sprue. See *Sprue, nontropical.*
Norepinephrine (Levophed), adrenergic receptors and, *1968:* Sept., 1010
for shock, *1968:* Sept., 1084
in myocardial infarction, *1970:* Jan., 240
for vascular collapse in anaphylaxis, *1969:* March, 256
Normal-infertile couple, *1969:* Sept., 1019–1022
Novobiocin, *1970:* Sept., **1282–1287**
Novocaine. See *Procaine.*
NP-Lx test, for antinuclear factors, *1968:* May, 561
Nuclear fusion, of cultured human cells, *1969:* July, 804
5′-Nucleotidase, serum, tests for, *1969:* Jan., 128–129
Nucleus pulposus, herniated, sciatica and, *1968:* Jan., 184
Nutramigen, for galactosemia, *1970:* Nov., 1439
Nutrition, abortion and, *1969:* July, 777
acromegaly and, *1970:* Nov., 1475
after gastrointestinal surgery, *1969:* Nov., **1389–1402**
Nutrition (*Continued*)
body composition and fuel supplies, *1970:* Nov., 1367–1373
brain function and, *1970:* Nov., 1421–1428
clinical, current concepts, symposium on, *1970:* Nov., **1357–1613**
gastrointestinal disease and, *1968:* Nov., **1397–1402**
deficiencies. See also *Malnutrition.*
amenorrhea and, *1968:* March, 341
in liver disease, *1970:* March, **467–477**
dental health and, *1970:* Nov., **1555–1565**
disturbances, in endocrine disorders, *1970:* **1473–1494**
endocrine disease and, *1970:* Nov., **1473–1494**
for pyloric obstruction, *1968:* Nov., 1334
in aged persons, *1970:* Nov., **1589–1597**
in cardiovascular disease, *1970:* Nov., **1449–1454**
in hereditary disorders, *1970:* Nov., **1431–1448**
in intravenous hyperalimentation, *1970:* May, 581, 582
in liver disease, *1970:* Nov., **1455–1472**
clinical aspects, *1970:* Nov., 1461–1468
mental development and, *1970:* Nov., **1413–1429**
osteoporosis and, *1970:* Jan., 144–147
parenteral, total, *1970:* Nov., 1377–1381
surgical, *1970:* Nov., **1367–1381**
methods of treatment, *1970:* Nov., 1375–1381
tooth development and, *1970:* Nov., 1556–1559
Nutritional anemias, recent advances in, *1970:* May, **631–645**
Nutritional ecology, *1970:* Nov., 1505–1508
Nystatin, *1970:* Sept., **1329–1337**

OBESITY, adipose tissue growth in, *1970:* Nov., 1536–1539
amenorrhea and, *1968:* March, 342
diabetes mellitus and, *1970:* Nov., 1533
edema and, vs. intractable heart failure, *1970:* March, 313
metabolic studies of, *1970:* Nov., **1533–1542**
newer concepts of, *1970:* May, **745–754**
therapeutic considerations, *1970:* Nov., 1540
types of, *1970:* Nov., 1537
Obstetrics, coagulation problems in, *1969:* Sept., **1085–1096**
Occupational therapy, in rehabilitation of hand, *1969:* May, 656
Ocular toxicity, to ethambutol, *1970:* Sept., 1319
Office laboratory. See under *Laboratory.*
Oliguria, causes, *1969:* March, 399
Onycholysis, treatment of, *1970:* Sept., 1336
Ophthalmoscopy, direct and indirect, for retinal detachments, *1969:* Sept., 1162
Optic nerve, lesions, pupillary reflexes in, *1968:* July, 877

Oral cavity, topical analgesia, *1968:* Jan., 178
disease, diet and, *1970:* Nov., 1559–1563
Oral health, nutrition and, *1970:* Nov., **1555–1565**
Orbit, decompression of, in exophthalmos, *1968:* March, **399–407**; *1969:* March, 472
Organic brain syndrome, *1969:* May, 558
Organomercurial diuretics, for ascites in Laennec's cirrhosis, *1969:* Nov., 1362
for refractory heart failure, *1968:* Sept., 1167
Orinase. See *Tolbutamide.*
Ornithine carbamyl transferase, serum, tests for, *1969:* Jan., 129–130
Orotic aciduria, hereditary, dietary control, *1970:* Nov., 1443
studies on cultured cells, *1969:* July, 803
Orthopedic surgery, for deformities in spina bifida and myelomeningocele, *1969:* May, 505
for rheumatoid arthritis, *1968:* May, **717–731**
Orthoses. See also specific names, as *Cervical collar.*
for low back pain, *1969:* May, 536
for neck and shoulder pain, *1969:* May, 521–522
hand, *1969:* May, 656
leg, hydropneumatic, *1969:* May, 591
new concepts in, *1969:* May, **585–592**
plastic spiral, *1969:* May, 586–588
supracondylar knee-ankle, *1969:* May, 588–590
Orthostatic hypotension, *1968:* July, 809–816
Ospolot. See *Sulthiame.*
Osteitis fibrosa cystica, hyperparathyroidism and, *1970:* March, 514
Osteoarthritis, hand in, *1968:* May, 495
of synovial joints of spine, low back pain and, *1968:* Jan., 62
Osteoarthrosis, secondary, in rheumatoid arthritis, *1968:* May, 663
Osteodystrophy, renal, *1970:* March, 421–422
tests for, *1970:* July, 1062
Osteogenic sarcoma, thermography in, *1970:* May, 612
Osteomalacia, tests for, *1970:* July, 1062
Osteomyelitis, kanamycin for, *1970:* Sept., 1254
lincomycin for, *1970:* Sept., 1298
oxacillin and cloxacillin for, *1970:* Sept., 1134
penicillins for, *1970:* Sept., 1090
vertebral, low back pain and, *1968:* Jan., 63
Osteoporosis, bone metabolism and, *1970:* Jan., **141–152**
in rheumatoid arthritis, *1968:* May, 656
low back pain and, *1968:* Jan., 66
post-traumatic, *1968:* Jan., 153
primary, tests for, *1970:* July, 1062
Otitis media, acute, in children, ampicillin for, *1970:* Sept., 1148
deafness and, *1969:* July, 754
penicillins for, *1970:* Sept., 1087
Ototoxic reactions, to dihydrostreptomycin, *1970:* Sept., 1161
to gentamicin, *1970:* Sept., 1312
to kanamycin, *1970:* Sept., 1247, 1249
to vancomycin, *1970:* Sept., 1281
Ouabain, for cardiac arrhythmia, *1969:* March, 318, 321
Ovarian hyperthecosis syndrome, *1968:* March, 345
Ovary(ies), carcinoma of, chemotherapy for, *1969:* Nov., 1273
radiation therapy for pain of, *1968:* Jan., 206
chromophobe adenoma and, *1968:* July, 830
disorders of, amenorrhea and, *1968:* March, 345
tumors of, amenorrhea and, *1968:* March, 345
Overeating, situational determinants of, *1970:* May, 747
Oxacillin, clinical indications, *1970:* Sept., 1133
for bacterial endocarditis, *1968:* Sept., 1098
for emergency treatment of infection, *1969:* March, 440
preparations and dosage, *1970:* Sept., 1136, 1137
spectrum of activity, *1970:* Sept., 1129
toxic reactions, *1970:* Sept., 1135
Oxazolidinediones, for seizures, *1968:* July, 963
Oxygen, arterial. See *Blood, gases.*
consumption, fever and, *1970:* Nov., 1374
thyroxine and, *1970:* Nov., 1481
therapy, after myocardial infarction, *1968:* Sept., 1066
for cardiopulmonary resuscitation, *1969:* March, 390
for status asthmaticus, *1970:* March, 501
transport by erythrocytes, *1970:* May, 787
heredity and environment and, *1970:* May, **731–743**
Oxygenation, fetal, measurement of, *1969:* Sept., 1056
Oxytetracycline, *1970:* Sept., 1174, 1175

PACEMAKER, cardiac, electrical, for slow ventricular rate, *1968:* Sept., 1070
in prevention and treatment of tachyarrhythmias, *1969:* Nov., **1287–1295**
paired ventricular stimulation by, *1970:* Jan., **247–259**
Paget's disease, low back pain and, *1968:* Jan., 67
tests for, *1970:* July, 1062
Pain. See also specific regions, as *Abdomen; Chest.*
and its clinical management, symposium on, *1968:* Jan., **1–224**
asymbolia for, *1968:* Jan., 117
brachial, neurologic disorders and, *1968:* July, **773–779**
cervical root, *1968:* July, 773–776

Pain (*Continued*)
epidural anesthesia for, *1968:* Jan., **209-215**
experimental, production of, *1968:* Jan., 27
vs. pathologic, *1968:* Jan., 23
hypnosis for relief of, *1968:* Jan., **217-224**
in extremities, differential neural blockade for, *1968:* Jan., **123-129**
in pregnancy and labor, relief of, *1968:* Jan., **137-146**
insensitivity to, congenital, *1968:* July, 899
low back, *1968:* Jan., **55-71**
evaluation and medical management, *1969:* May, **525-540**
measurement of, clinical, *1968:* Jan., **23-32**
narcotics for, *1968:* Jan., **33-45**
neck and shoulder, evaluation and conservative management, *1969:* May, **511-524**
neurologic substance of, *1968:* Jan., **111-121**
neurolytic agents in relief of, *1968:* Jan., **161-171**
patterns of, classic, *1968:* Jan., 104-108
phantom limb, *1968:* Jan., 118; *1969:* May, 662
postoperative, factors in, *1968:* Jan., 82
in chest, *1968:* Jan., **91-101**
in children, *1968:* Jan., 133
incisional, *1968:* Jan., 108
prevention of, *1968:* Jan., **73-80**
reactions to, *1968:* Jan., 74
treatment, *1968:* Jan., **81-90**
radiation therapy, *1968:* Jan., **203-207**
reception, peripheral, *1968:* Jan., 15
receptors, stimulation of, *1968:* Jan., 6
relief, in children, *1968:* Jan., **131-136**
in office, *1968:* Jan., **173-181**
sedatives and tranquilizers for, *1968:* Jan., **47-53**
stimulation of, *1968:* Jan., 3-4
surgical diseases and, *1968:* Jan., **103-109**
sympathectomy for relief of, *1968:* Jan., **147-159**
sympathetic vs. somatic, nerve blocks and, *1968:* Jan., 123
thalamic, *1968:* Jan., 116
transmission and central projection of, *1968:* Jan., **15-21**
Palsy. See *Paralysis.*
Pancreas, carcinoma of, radiation therapy for, *1968:* Jan., 205
cystic fibrosis of, fibroblast cultures in, *1970:* May, 703
inheritance, *1968:* Nov., 1278
disease of, diagnostic tests, *1968:* Nov., **1483-1492**
pain pattern in, *1968:* Jan., 106
function, tests of, *1970:* March, 483
islet cells, histochemical characteristics, *1968:* March, 296
hyperplasia, *1968:* March, 299
tumors. See also *Glucagonoma; Insulinoma.*
cholera-like syndrome and, *1970:* May, **567-575**
Pancreas (*Continued*)
islet cells, tumors, endocrine syndromes with, *1968:* March, **295-312**
hormone overproduction by, *1968:* March, 304-309
hypoglycemia and, *1970:* March, 537
laboratory tests for, *1968:* March, **283-294**
Zollinger-Ellison syndrome and, *1968:* March, 301
scanning, *1970:* March, 486; July, 881-888
radioisotope, dual channel, *1969:* Jan., **189-203**
Pancreatitis, acute, diagnostic tests, *1968:* Nov., 1483
hyperlipemia and, *1968:* Nov., **1493-1501**
medical management, *1969:* March, **431-435**
chronic, *1970:* March, **479-492**
diagnostic tests, *1968:* Nov., 1487
malabsorption in, *1969:* Sept., 1176
radiation therapy for, *1968:* Jan., 204
Pancreatography, *1970:* March, 485
Pannus formation, rheumatoid arthritis and, *1968:* May, 611
Papillary muscle, dysfunction, after myocardial infarction, *1968:* Sept., 1074
surgery for, *1968:* Sept., 1116
rupture, surgery for, *1968:* Sept., 1119
Papilledema, fluorescein angiography of fundus in, *1968:* July, 860
Paracentesis, for ascites in Laennec's cirrhosis, *1969:* Nov., 1359-1365
Paralysis, ascending, acute, *1968:* July, 901
bulbar, speech disturbances in, *1968:* July, 838-841
cerebral, *1969:* May, 642-643
Erb's, complicating hemiplegia, *1969:* May, 545
infantile. See *Poliomyelitis.*
Landry's, *1968:* July, 901
pseudobulbar, diabetes mellitus and, *1969:* May, 543
speech disturbances in, *1968:* July, 838-841
Parasites, intestinal, jejunal biopsy and, *1970:* July, 859
Parathormone. See *Parathyroid hormone.*
Parathyroid glands, function, *1970:* March, 511-512
Parathyroid hormone, osteoporosis and, *1970:* Jan., 149
radioimmunoassay, hyperparathyroidism and, *1970:* Jan., 136-137
Paresthesia, in fingers, *1968:* July, 774
thoracic outlet syndromes and, *1968:* July, 777
Parkinsonism, *1969:* May, 637-641
amantidine for, *1970:* May, 784
levodopa for, *1970:* May, 775-784
newer medical treatments for, *1970:* May, **773-785**
speech disturbances in, *1968:* July, 838-842
Paronychia, treatment, *1970:* Sept., 1336

Parotitis, surgical, radiation therapy for, *1968:* Jan., 204
Partial thromboplastin time test, *1970:* July, 894
Pasteurella infections, choice of therapy for, *1970:* Sept., 1163
tetracyclines for, *1970:* Sept., 1179
Patau's syndrome, chromosomal abnormality in, *1970:* July, 1016
Patent ductus arteriosus, cardiac catheterization in, *1970:* July, 975–976
Pathology, tests, in community hospital laboratory, *1969:* Jan., 16
Patient Inventory Questionnaire, *1970:* July, 828
PBI. See *Iodine, protein-bound.*
Pedigree, genetic, *1969:* July, 744–745
in study of deafness, *1969:* July, 757–765
Pellagra, neuropathy and, *1968:* July, 904
Pelvis, examination of, in amenorrhea, *1968:* March, 348
Pelvospondylitis ossificans. See *Spondylitis, ankylosing.*
Pemphigus vulgaris, autoimmunity and, *1970:* Jan., 100–104
Pendred's syndrome, *1969:* July, 765
Penicillin, allergic reactions, *1970:* Sept., 1092–1097
contaminants and, *1970:* Jan., 64
incidence of, *1970:* Jan., 62
prevention of, *1970:* Jan., 66–68
skin tests in, *1970:* July, **997–1007**
benzathine, hypersensitivity reactions, *1970:* Sept., 1094
biosynthesis of, *1970:* Sept., 1082
clinical indications, *1970:* Sept., 1086–1091
for bacterial endocarditis, *1968:* Sept., 1098
G, for emergency treatment of infection, *1969:* March, 440
spectrum of activity, *1970:* Sept., 1103, 1129
toxic reactions, *1970:* Sept., 1093
vs. methicillin, *1970:* Sept., 1114
isoxazolyl, *1970:* Sept., **1127–1143**
natural, *1970:* Sept., **1081–1099**
penicillinase-resistant, *1970:* Sept., 1130
pharmacology, *1970:* Sept., 1083
phenoxyalkyl, *1970:* Sept., 1101–1111
prophylactic use, *1970:* Sept., 1091, 1106
protein-binding activity in, *1970:* Sept., 1094, 1905, 1131
extent and significance, *1970:* Sept., 1117
renal excretion, *1970:* Sept., 1084, 1105
semisynthetic, for staphylococcal infections, *1970:* Sept., 1118–1121
serum concentrations, *1970:* Sept., 1083, 1084, 1104
structure, *1970:* Sept., 1082, 1101, 1102
synthetic, for emergency treatment of infection, *1969:* March, 440
toxic reactions, *1970:* Sept., 1092–1097
V, *1970:* Sept., 1101–1111
preparations and dosage, *1970:* Sept., 1105
Penicillin (*Continued*)
V, spectrum of activity, *1970:* Sept., 1103
toxic reactions, *1970:* Sept., 1108
Penicilloylation, *1970:* Sept., 1094, 1095
Pentagastrin test, of gastric secretion, *1968:* Nov., 1308
Pentazocine, analgesic properties of, *1968:* Jan., 39
Pentolinium (Ansolysen), for hypertensive encephalopathy, *1969:* March, 352, 355
Peptic ulcer, acute manifestations, management, *1969:* March, **425–429**
belladonna for, physiology and pharmacology of, *1969:* Nov., **1379–1388**
diet and, *1970:* Nov., 1357–1359
disaccharidase deficiency and, *1968:* Nov., 1362
gastric secretion and, *1968:* Nov., 1305
multiple endocrine adenomatosis and, *1968:* Nov., 1278
perforated, *1969:* March, 425–426
Perception, in hemiplegia, rehabilitation and, *1969:* May, **575–583**
Pericarditis, constrictive, vs. intractable heart disease, *1970:* March, 315
tuberculous, *1970:* March, 381
uremic, *1970:* March, 415
and cardiac tamponade, *1968:* Sept., 1237–1241
Pericardium, diseases of, cardiac catheterization in, *1970:* July, 977
Perinatology, *1968:* Sept., 1055
Periosteum, bone formation at, hyperthyroidism and, *1968:* March, **393–398**
rheumatoid arthritis and, *1968:* May, 663
Peritonitis, during antibiotic therapy for bacterial infection, *1969:* March, 442
periodic, vs. juvenile rheumatoid arthritis of acute onset, *1968:* May, 575
Perlèche, nystatin for, *1970:* Sept., 1334
Pernicious anemia. See under *Anemia.*
Personality, assessment, automated, *1970:* July, **835–849**
Pertussis, erythromycin for, *1970:* Sept., 1207
Peutz-Jeghers syndrome, inheritance of, *1968:* Nov., 1274
Phagocytosis, defect of, due to humoral agent deficiency, *1970:* May, 717–719
nutrition and, *1970:* Nov., 1498
Phalen's maneuver, *1968:* July, 778
Phantom limb pain, *1968:* Jan., 118; *1969:* May, 662
Pharmacogenetics, *1969:* July, **839–855**
III-IV Pharyngeal pouch syndrome, *1970:* March, 286
Pharyngitis, bacterial, efficiency of penicillins for, *1970:* Sept., 1086
streptococcal, oxacillin and cloxacillin in, *1970:* Sept., 1134
Pharynx, topical analgesia of, *1968:* Jan., 178
Phenergan. See *Promethazine.*
Phenethicillin, *1970:* Sept., 1101–1111
indications for, *1970:* Sept., 1106
spectrum of activity, *1970:* Sept., 1103

Phenformin, for juvenile diabetes mellitus, *1969:* Nov., 1375
Phenobarbital sodium, for status epilepticus, *1968:* July, 968
Phenol, as neurolytic agent, *1968:* Jan., 163
Phenolsulphonphthalein test, *1969:* Jan., 33
drug effects on, *1969:* Jan., 212
Phenoxyalkyl penicillins, *1970:* Sept., 1101–1111
Phenoxybenzamine (Dibenzyline), blocking action of, *1968:* Sept., 1011
for hypertension, *1968:* Sept., 1229
for hypertensive encephalopathy, *1969:* March, 353
preoperative, for pheochromocytoma, *1969:* Nov., 1354
Phenoxyethylpenicillin. See *Phenethicillin.*
Phenoxymethylpenicillin. See *Penicillin V.*
Phentolamine (Regitine), blocking action of, *1968:* Sept., 1011
for hypertensive encephalopathy, *1969:* March, 353
Phentolamine test, for pheochromocytoma, *1968:* Sept., 1219
Phenylalanine hydroxylase defect, *1970:* Nov., 1433
Phenylbutazone (Butazolidin), for gout, *1969:* March, 456; *1970:* March, 439
basis of action, *1969:* Nov., 1338
for rheumatoid arthritis, *1968:* May, 694
metabolism of, inherited variations in, *1969:* July, 849
site of action, *1968:* Jan., 8
Phenylephrine (Neo-Synephrine), for shock, *1968:* Sept., 1085
Phenylketonuria, detection of carriers, *1969:* July, 863
nutritional management, *1970:* Nov., 1433–1435
Phenylthiocarbamide, tasters and nontasters, as examples of polymorphism, *1969:* July, 891
Pheochromocytoma, adrenergic receptor blockers and, *1968:* Sept., 1044
rationale and indications, *1969:* Nov., **1349–1358**
cardiac arrhythmias and, propranolol for, *1968:* Sept., 1026
hypertension and, *1968:* Sept., 1219
nutritional disturbances in, *1970:* Nov., 1488
treatment of, *1968:* Sept., 1229
Philadelphia Pulmonary Neoplasm Research Project, *1970:* May, **549–553**
PHLA. See *Post-heparin lipolytic activity.*
Phonocardiograms, *1969:* Jan., 109
in pulmonary embolism, *1969:* March, 368
Phosphates, excretion, hyperparathyroidism and, *1968:* March, 454
in prevention of dental caries, *1970:* Nov., 1561
tubular reabsorption of, hyperparathyroidism and, *1970:* Jan., 135
Phosphoglycerate kinase deficiency, *1969:* July, 821
Phosphohexose isomerase deficiency, *1969:* July, 821
Phospholipids, in plasma lipid transport, *1970:* Nov., 1384
Phosphorus, serum, hyperparathyroidism and, *1968:* March, 453
hypersomatotropism and, *1968:* March, 371
tubular reabsorption, hyperparathyroidism and, *1968:* March, 455; *1970:* March, 524
Photosensitivity reaction, to antibiotics, *1970:* Jan., 60
to tetracyclines, *1970:* Sept., 1182
Physical examination, in amenorrhea, *1968:* March, 348
in hemiplegia, *1969:* May, 543–544
in rheumatoid arthritis, *1968:* May, 494
Physical handicaps, driver education and, *1969:* May, **685–696**
home planning for patients, *1969:* May, **703–711**
use of telephone and, *1969:* May, **697–702**
Physical therapy. See also *Exercise; Heat therapy.*
for rheumatoid arthritis, *1968:* May, 701, **707–716**
Physiology, clinical, tests, in community hospital laboratory, *1969:* Jan., 15
Pigmentation, anomalies, deafness and, *1969:* July, 767
Piperocaine (Metycaine), for epidural anesthesia, *1968:* Jan., 212
Pituitary gland, amenorrhea and, *1968:* March, 342
Crooke cell of, *1968:* March, 320
disorders, laboratory tests in, *1969:* Jan., 80–85
function, central nervous system disease and, *1968:* March, **357–369**
radiation suppression of, *1968:* Jan., 206
insufficiency, hypoglycemia and, *1970:* March, 534
removal, for malignant exophthalmos, *1969:* March, 472
tumors. See also *Chromophobe adenoma.*
pathophysiology, *1968:* March, 321
treatment, *1968:* March, 324
Pituitary hormones, thyroid disease and, *1970:* July, 1038
Placenta, abnormalities, abortion and, *1969:* July, 777
functions, *1969:* Sept., 1052
Placidyl. See *Ethchlorvynol.*
Plant alkaloids, bases of action of, *1969:* Nov., 1268
Plaquenil. See *Hydroxychloroquine.*
Plasma, appearance, in lipoprotein anomalies, *1970:* Nov., 1386
cholesterol, atherosclerotic cardiovascular disease and, *1970:* Nov., 1450
factors, assay of, *1970:* July, 896
deficiencies, evaluation of, *1969:* Nov., 1318
tests for, *1970:* July, 894–897
role in hemostasis, *1969:* Nov., 1310
lipids. See *Lipids; Lipoproteins.*
triglycerides, atherosclerotic cardiovascular disease and, *1970:* Nov., 1450
Plasma clot time test, *1970:* July, 894

Platelets, function, tests of, *1969:* Jan., 66; *1970:* July, 891
role in hemostasis, *1969:* Nov., 1310
Pleural effusion, in uremia, *1970:* March, 416
Pleuritis, in uremia, *1970:* March, 416
Pneumonia, aspiration, penicillins for, *1970:* Sept., 1088
mycoplasma, erythromycin for, *1970:* Sept., 1206
pneumococcal, erythromycin for, *1970:* Sept., 1205
penicillins for, *1970:* Sept., 1088, 1133
viral, vs. intractable heart failure, *1970:* March, 313
Point mutations, radiation-induced, *1969:* July, 970
Poisoning, arsenical, neuropathy and, *1968:* Jan., 112, July, 905
Poliodystrophy, progressive, inheritance and gastrointestinal manifestations, *1968:* Nov., 1278
Poliomyelitis, neurophysiology in, *1969:* May, 625–626
Polyarthritis, benign, *1968:* May, 488
peripheral, with ulcerative colitis, *1968:* May, 508
Polycythemia, erythropoietin and, *1970:* Jan., 177–178
Polymorphisms, human, *1969:* July, **887–901**
Polymyxin B sulfate, *1970:* Sept., 1259
Polymyxin E. See also *Colistin.*
Polymyxin E sulfomethyl derivative, *1970:* Sept., 1259, 1262
Polymyxins, *1970:* Sept., **1257–1265**
clinical indications, *1970:* Sept., 1263
for diarrheal disease, *1970:* March, 451
preparations and dosage, *1970:* Sept., 1260
reduction schedule to avoid renal injury, *1970:* Sept., 1261
spectrum of activity, *1970:* Sept., 1257
toxic reactions, *1970:* Sept., 1263
Polyneuritis, infectious, acute, *1968:* July, 901
neurophysiology in, *1969:* May, 625–626
Polyneuropathies, *1968:* Jan., 112
chronic, *1968:* July, 902
Polyploidy, *1969:* Sept., 1042
Polyps, of colon, familial, inheritance, *1968:* Nov., 1274
Polyradiculoneuropathy, infectious, *1968:* July, 901
Polyradiculopathy, *1968:* Jan., 115
Polystyrene sulfonate (Kayexalate), for hyperkalemia, *1969:* March, 411
Polyuria, causes of, *1968:* March, 383
diagnosis, *1968:* March, 386–388
renal failure with, *1969:* March, 399
Pompe's disease, fibroblast cultures in, *1970:* May, 706
Pontocaine. See *Tetracaine.*
Population genetics, future of, *1969:* July, 1004
Porphyria, intermittent, acute, abdominal pain and, *1968:* Nov., 1277
neuropathy and, *1968:* July, 902
Porphyria (*Continued*)
orthostatic hypotension and, *1968:* July, 812
vs. Guillain-Barré-Strohl syndrome, *1968:* July, 901
Porphyrin, disturbances, griseofulvin and, *1970:* Sept., 1341
metabolism, drug effects on, *1969:* Jan., 216
Porta hepatis, tumors of, radiation therapy for pain of, *1968:* Jan., 205
"Position of injury" of hand, *1969:* May, 646, 648
Post-heparin lipolytic activity (PHLA), *1970:* Nov., 1385
Posterior fossa, lesions, rehabilitation after, *1969:* May, **677–684**
Posture, examination, in low back pain, *1969:* May, 529
in neck and shoulder pain, *1969:* May, 513
Potassium, alkalosis and, *1968:* Sept., 1105
benzothiadiazine therapy and, *1968:* Sept., 1105
body content of, *1968:* Sept., 1103
measurement with whole-body counter, *1969:* Jan., 207
cardiac arrhythmias and, *1968:* Sept., 1105
cardiovascular disease and, *1968:* Sept., **1103–1113**
deficiency. See *Hypokalemia.*
excess. See *Hyperkalemia.*
exchangeable body, in acromegaly, *1970:* Nov., 1475
measurement of, *1970:* Nov., 1368, 1370
excretion, thiazide diuretics and, *1969:* Nov., 1325
in intravenous hyperalimentation, *1970:* May, 584
iodide, for thyrotoxicosis, *1970:* Jan., 127
metabolism, myopathy and, *1968:* March, 249
plasma concentration, *1968:* Sept., 1104
salts, for digitalis intoxication, *1969:* Nov., 1283
therapeutic administration, *1968:* Sept., 1108; *1969:* March, 410
Prebetalipoproteins, plasma transport, *1970:* Nov., 1385
Precordium, inspection of, *1969:* Jan., 102
Prednisone. See also *Corticosteroids.*
for rheumatoid arthritis, *1968:* May, 693, 743
neurologic side effects, *1968:* July, 850
Pregnancy, coagulation system in, *1969:* Sept., 1085
complicating coagulation disorders, *1969:* Sept., 1092
endocrine functions in, *1968:* March, **253–262**
injury during, *1969:* Sept., 1035–1038
intestinal obstruction during, *1969:* Sept., 1022–1025
pain relief in, *1968:* Jan., **137–146**
prosthetic heart valves and, *1968:* Sept., 1139
test for, in amenorrhea, *1968:* March, 349

Pregnancy (*Continued*)
toxemia of, hypertension and, *1968:* Sept., 1234
varicose veins in, *1968:* Sept., 1085
wastage, genetic factors in, *1969:* Sept., **1039–1050**
Pregnanediol, tests for, drug effects on, *1969:* Jan., 212
Prematurity, deafness and, *1969:* July, 754
Presbyopia, *1969:* Sept., 1141
Probenecid (Benemid), for hyperuricemia, basis of action of, *1969:* Nov., 1340–1341
Procainamide, for cardiac arrhythmia, basis of action of, *1969:* Nov., 1301
for ventricular premature beats, *1969:* March, 323
in acute pulmonary edema, *1969:* March, 329
Procaine (Novocaine), in office, *1968:* Jan., 175
Prochlorperazine (Compazine), for pain, *1968:* Jan., 51
Product replacement, in treatment of inherited metabolic disorders, *1969:* July, 947
Progesterone test, in amenorrhea, *1968:* March, 349
Progestogens, oral, for amenorrhea, *1968:* March, 355
Proinsulin, *1970:* Jan., **191–199**
Prolactin, secretion of, excess, *1968:* March, 360
Promazine (Sparine), for pain, *1968:* Jan., 51
Promethazine (Phenergan), for pain, *1968:* Jan., 51
Pronetalol (Alderlin; Nethalide), blocking action of, *1968:* Sept., 1011
Propitocaine (Citanest), for epidural anesthesia, *1968:* Jan., 212
Properdin, nutritional deficiency and, *1970:* Nov., 1499
Propranolol (Inderal), blocking action of, *1968:* Sept., 1011
dosage, administration, and side effects, *1968:* Sept., 1026–1027
for angina pectoris, *1968:* Sept., 1031
for cardiac arrhythmias, *1968:* Sept., 1020–1026
basis of action of, *1969:* Nov., 1304
for intractable angina, *1970:* March, 337, 338–342
for thyrotoxicosis, *1970:* Jan., 128
preoperative, for pheochromocytoma, *1969:* Nov., 1354
Propriomazine (Largon), for pain, *1968:* Jan., 52
Propylthiouracil, for exophthalmic goiter, *1970:* Jan., 124
Prostate, carcinoma of, radiation therapy for pain of, *1968:* Jan., 206
Prosthesis, for extremity, conditioning for, *1969:* May, 661–662
in malignant disease, *1969:* May, 612
prescribing, *1969:* May, 662–663
leg, immediate fitting after amputation, *1969:* May, **665–676**
Protein binding, in penicillins, *1970:* Sept., 1094, 1095, 1131
Protein-bound iodine. See *Iodine, protein-bound.*
Proteinosis, alveolar, bronchopulmonary lavage for, *1970:* May, 762
Proteins, absorption, normal, *1968:* Nov., 1342
studies, *1968:* Nov., 1350
deficiency, after gastrointestinal surgery, *1969:* Nov., 1396–1397
liver disease and, *1970:* March, 467–470
metabolism, in liver disease, *1970:* Nov., 1456
nutritional status during infectious disorders, *1970:* Nov., 1500
requirements, for diabetics, *1970:* Nov., 1579
restriction, in uremia, *1970:* March, 425–428
serum, electrophoresis of, *1969:* Jan., **147–157**
"M," *1969:* Jan., 151
test for, *1968:* Nov., 1411, 1433
drug effects on, *1969:* Jan., 212
variants, as examples of polymorphism, *1969:* July, 893
synthesis of, cardiac hypertrophy and, *1970:* Jan., 214–216
insulin and, *1970:* Jan., **201–207**
measurement, *1970:* Nov., 1481
regulation, thyroxine in, *1970:* Nov., 1481
total body, measurement, *1970:* Nov., 1368
urinary, tests for, *1969:* Jan., 27
drug effects on, *1969:* Jan., 212
Proteolytic agents, for status asthmaticus, *1970:* March, 500
Proteus infections, choice of therapy for, *1970:* Sept., 1162
Prothrombin complex, abnormalities, tests for, *1969:* Jan., 74
Prothrombin consumption test, *1970:* July, 896
Prothrombin time test, *1970:* July, 895
drug effects, *1969:* Jan., 213
Pruritus ani, candidal, nystatin for, *1970:* Sept., 1335
Pseudobulbar palsy, speech disturbances in, *1968:* July, 838–841
Pseudocyesis, amenorrhea and, *1968:* March, 340
Pseudomonas infections, choice of therapy for, *1970:* Sept., 1162
polymyxins for, *1970:* Sept., 1263
sodium colistimethate for, *1970:* Sept., 1270
efficacy, *1970:* Sept., 1273
Pseudoxanthoma elasticum, inheritance and gastrointestinal manifestations, *1968:* Nov., 1278
Psittacosis, tetracyclines for, *1970:* Sept., 1179
Psoriasis, immunosuppression for, *1969:* Nov., 1237
with arthritis, *1968:* May, 506–507
Psychiatric emergencies, *1969:* March, **281–284**
Psychiatric problems, in hemiplegic patient, *1969:* May, 558

Psychological evaluation, automated, *1970:* July, **835–849**
Psychosis, toxic, acute, *1969:* March, **275–279**
chronic renal failure and, *1968:* July, 846
Psychosomatic factors in abortion, *1969:* July, 776
Psychotherapy, for hypothalamic amenorrhea, *1968:* March, 341
PTC (phenylthiocarbamide) tasters and nontasters, as examples of polymorphism, *1969:* July, 891
Puberty, early or late, radioimmunoassay of gonadal hormones in, *1970:* July, 1054, 1055
Public health, rehabilitation medicine and, *1969:* May, **719–733**
Pulmonary. See also *Lungs.*
Pulmonary disease, obstructive, chronic, rehabilitation in, *1969:* May, **593–606**
Pulmonary edema, acute, management, *1969:* March, **327–330**
after myocardial infarction, *1968:* Sept., 1072
Pulmonary embolism. See *Embolism, pulmonary.*
Pulmonary emphysema, vs. intractable heart failure, *1970:* March, 314
Pulmonary function studies, during rehabilitation in chronic obstructive pulmonary disease, *1969:* May, 596
Pulmonary tuberculosis. See *Tuberculosis.*
Pulse, venous, jugular, in pulmonary embolism, *1969:* March, 368
PULSES profile, in evaluation of hemiplegia, *1969:* May, 542
Pupil, Adie's, *1968:* July, 880
Argyll Robertson, *1968:* July, 879
Horner's, *1968:* July, 879
neurologic diagnosis and, *1968:* July, **871–884**
reflexes, examination, *1968:* July, 872–876
neuroanatomic pathways, *1968:* July, 873
Pupillometer, *1968:* July, 872
Purine, metabolism, hyperuricemia and, *1969:* Nov., 1332, 1333
Purpura, fulminans, *1969:* March, 265
Henoch-Schönlein, vs. juvenile rheumatoid arthritis of acute onset, *1968:* May, 575
thrombocytopenic. See also *Thrombocytopenia.*
idiopathic, immunosuppression for, *1969:* Nov., 1234
vascular (nonthrombocytopenic), tests in, *1969:* Jan., 75
Pyelogram, intravenous, periodic, for urinary tract damage with myelomeningocele, *1969:* May, 497
Pyloric obstruction, diagnosis, *1968:* Nov., 1331
intravenous hyperalimentation for, *1970:* May, 584
management, *1968:* Nov., **1329–1337**
medical, *1968:* Nov., 1333–1336
surgical, *1968:* Nov., 1336
Pyoderma gangrenosum, intestinal disorders and, *1969:* Sept., 1202
Pyridostigmine bromide (Mestinon), for myasthenic crisis, *1969:* March, 288
Pyridoxine, as antagonist to levodopa effect, *1970:* May, 783
for vitamin B_6-dependent convulsive disorders, *1970:* Nov., 1444
for xanthurenic aciduria, *1970:* Nov., 1445
Pyroglobulins, *1970:* July, 924
Pyroscan, use of, *1970:* May, 605
Pyruvate kinase deficiency, *1969:* July, 822
red cell 2,3-diphosphoglycerate and, *1970:* May, 737

QUADRIPLEGIA, traumatic, driver training and, *1969:* May, 686, 688
vocational potential in, *1969:* May, **713–718**
Quick one-stage test, drug effects on, *1969:* Jan., 213
Quinidine, for atrial and nodal premature beats, *1969:* March, 321
for cardiac arrhythmia, basis of action of, *1969:* Nov., 1301

RADIATION. See also *Roentgen.*
genetic effects of, *1969:* July, **965–976**; Sept., 1047
monitoring, with whole-body counter, *1969:* Jan., 206
therapy, for pain, *1968:* Jan., **203–207**
Radiofrequency current coagulation, in percutaneous cordotomy, complications, *1968:* Jan., 199
results, *1968:* Jan., 195–198
technique, *1968:* Jan., 189–195
Radioimmunoassay, for follicle-stimulating and luteinizing hormones, *1970:* July, **1049–1059**
for growth hormone, *1969:* Jan., 80
principles, *1968:* March, 373
Radioiodine tests, in thyroid disorders, *1969:* Jan., 85
Radioisotope scanning. See *Scanning.*
RAIU (radioactive iodine uptake) test, *1968:* March, 464
Range of motion, after amputation, *1969:* May, 661
Raynaud's syndrome, thermography in, *1970:* May, 612
Reading difficulties, diagnosis and counseling in, *1969:* Sept., **1123–1129**
Reagin, *1969:* March, 249
Receptors, adrenergic. See *Adrenergic receptors.*
Recessivity, genetic, *1969:* July, 743
Rectum, anomalies, inheritance, *1968:* Nov., 1274
examination, in low back pain, *1969:* May, 530
hemorrhage, causes, *1969:* March, 418
Red cells. See *Erythrocytes.*
Reflexes, disturbed, chronic renal failure and, *1968:* July, 849

Reflexes (*Continued*)
muscle stretch, cervical root pain and, *1968:* July, 775
pupillary, examination of, *1968:* July, 872–876
neuroanatomic pathways of, *1968:* July, 873
Refsum's disease, *1968:* July, 904
dietary control, *1970:* Nov., *1442*
Regional enteritis *1968:* Nov., 1392–1395; *1969:* Sept., 1206
diet in, *1970:* Nov., 1361
disaccharidase deficiency and, *1968:* Nov., 1361
intravenous hyperalimentation for, *1970:* May, 585
malabsorption in, *1969:* Sept., 1187
prolonged fever and, *1970:* March, 391
with ankylosing spondylitis, *1968:* May, 508, 512
Regional Medical Programs, rural, *1970:* Jan., **19–28**
urban, *1970:* Jan., **29–33**
Regitine. See *Phentolamine.*
Rehabilitation, in rheumatoid arthritis, *1968:* May, 713–714
symposium on, *1969:* May, **485–733**
Reiter's syndrome, vs. rheumatoid arthritis, *1968:* May, 504–505
Renal. See also *Kidney.*
Renal failure, due to cephaloridine, *1970:* Sept., 1222
methicillin in patients with, *1970:* Sept., 1118
hypertension, treatment, *1968:* Sept., 1230
Renal insufficiency, sodium colistimethate dosage in patients with, *1970:* Sept., 1272
Renal toxicity. See *Nephrotoxic reactions.*
Renal tubular acidosis, dietary control, *1970:* Nov., 1442
Renin, formation of angiotensin and, *1968:* March, 264
release of, mechanism of, *1968:* March, 275
uterine, *1968:* March, 265
Renovascular disease, dietary control, *1970:* Nov., 1453
Reproduction and sexual adjustment, case studies in, *1969:* Sept., **1019–1038**
symposium on, *1969:* Sept., **1017–1096**
Reserpine (Sandril; Serpasil), for hypertensive encephalopathy, *1969:* March, 352, 354
Respiration. See also *Breathing; Ventilation.*
assisted, in cardiopulmonary resuscitation, *1969:* March, 390
in respiratory failure, *1969:* March, 246
insufficient, anesthesiologist and, *1969:* March, **385–396**
Respiratory failure, from pancreatitis, *1969:* March, 433
in asthma, *1969:* March, 245
Respiratory tract infection, lower, oxacillin and cloxacillin for, *1970:* Sept., 1133
Rest, bed, after myocardial infarction, *1968:* Sept., 1066
as factor in thromboembolism, *1969:* March, 341
for low back pain, *1969:* May, 532
in refractory heart failure, *1968:* Sept., 1164
chair, in refractory heart failure, *1968:* Sept., 1164
Resuscitation, cardiopulmonary, anesthesiologist and, *1969:* March, **385–396**
Reticulocytes, decreased, in anemia, *1969:* Jan., 56
Reticulum cell sarcoma, chemotherapy for, *1969:* Nov., 1271
lymphography in, *1970:* July, 940
Retina, detached, *1969:* Sept., **1161–1168**
lesions of, pupillary reflexes in, *1968:* July, 877
Retinal artery, occlusion of, fluorescein angiography of fundus in, *1968:* July, 866
Retinitis pigmentosa, deafness and, *1969:* July, 766
Retinopathy, chloroquine-induced, *1968:* May, 760
fluorescein angiography of fundus in, *1968:* July, 866
diabetic, fluorescein angiography of fundus in, *1968:* July, 858
Retinoscopy, in measurement of refractive error, *1969:* Sept., 1136
Revascularization of myocardium, coronary arteriography after, *1970:* July, 991–993
for intractable angina, *1970:* March, 343–346
RF. See *Rheumatoid factor.*
Rh antibodies, *1969:* Sept., 1071
Rh chromosomes, *1969:* Sept., 1068
Rh factor, past, present, and future, *1969:* Sept., **1063–1084**
Rh-Hr antigens, *1969:* Sept., 1067
Rh-negative couple, management of, *1969:* Sept., 1070
Rhegmae of eye, significance and treatment of, *1969:* Sept., 1165
Rheumatism, palindromic, vs. rheumatoid arthritis, *1968:* May, 509–510
Rheumatoid arthritis. See *Arthritis, rheumatoid.*
Rheumatoid factor, epidemiology of rheumatoid arthritis and, *1968:* May, 487–488
in rheumatoid arthritis, significance of, *1968:* May, **533–538**
tests for, *1968:* May, 545
RhoGAM, *1969:* Sept., 1080–1083
Rickets, vitamin D-dependent, dietary management, *1970:* Nov., 1445
Rickettsial infections, chloramphenicol for, *1970:* Sept., 1191
tetracyclines for, *1970:* Sept., 1179
Riley-Day syndrome, *1968:* July, 900
Ristocetin, allergic reactions to, incidence of, *1970:* Jan., 64
Ritalin. See *Methylphenidate.*
RMP. See *Regional Medical Programs.*

Roentgen examination, in bleeding esophageal varices, *1968:* Nov., 1463
in chronic pancreaticis, *1970:* March, 484
in colitis, *1968:* Nov., 1390
in hyperparathyroidism, *1970:* March, 521
in liver disease, *1968:* Nov., 1408
in pulmonary embolism, *1969:* March, **375–383**; *1970:* March, 364
in rheumatoid arthritis, *1968:* May, **655–665**
juvenile, *1968:* May, 577, 580
of bile ducts, percutaneous and transhepatic, *1970:* July, **875–879**
of cervical spine, for neck and shoulder pain, *1969:* May, 516
of chest, in pulmonary embolism, *1969:* March, 375
of fetus, *1969:* Sept., 1053
of skull, cerebellopontine angle lesions and, *1968:* July, 790
chromophobe adenoma and, *1968:* July, 829
in diagnosis of intracranial disorders, *1969:* March, 294
Roentgen treatment, enteritis due to, jejunal biopsy in, *1970:* July, 858
Rotor syndrome, *1968:* Nov., 1422
Rubella, maternal, deafness and, *1969:* July, 754
Rubella synovitis, vs. juvenile rheumatoid arthritis of polyarticular onset, *1968:* May, 578
Rubin tube, for jejunal biopsy, *1970:* July, 852
Rumpel-Leede test, *1969:* Jan., 64

SACROILIAC joints, in ankylosing spondylitis, *1968:* May, 518
in rheumatoid arthritis, *1968:* May, 518
Salicylates, for rheumatoid arthritis, *1968:* May, 699, **703–706**
Saline load test, in pyloric obstruction, *1968:* Nov., 1332
Salmonella infections, ampicillin for, *1970:* Sept., 1152
chloramphenicol for, *1970:* Sept., 1191
choice of therapy for, *1970:* Sept., 1162
Sanarelli-Shwartzman reaction, skin necrosis and, *1969:* March, 265
Sandril. See *Reserpine.*
Sarcoma, osteogenic, thermography in, *1970:* May, 612
reticulum cell, chemotherapy for, *1969:* Nov., 1271
lymphography in, *1970:* July, 940
Scalenus anticus syndrome, *1968:* July, 777
Scanning, dual channel, *1969:* Jan., **189–203**
in anemia, *1969:* Jan., 57
liver, *1968:* Nov., 1412
pancreas, *1970:* March, 486; July, **881–888**
pulmonary, in pulmonary embolism, *1969:* March, 378; *1970:* March, 365
Schilling test, in megaloblastic-macroovalocytic anemias, *1970:* May, 637
Schizophrenia, somatic effects, *1969:* March, 283
Sciatica, enigma of, *1968:* Jan., **183–188**
experimental findings in causes of, *1968:* Jan., 184
inflammation and, *1968:* Jan., 186
Scintiscanning, in classification of thyroid nodules, *1968:* March, 412
Scleroderma, esophageal involvement, motility studies in, *1970:* July, 868
thermography in, *1970:* May, 612
Sclerosis, amyotrophic lateral, speech disturbances in, *1968:* July, 838–842
systemic, progressive, vs. rheumatoid arthritis, *1968:* May, 560, 562
Secretin, structure, secretion, and action, *1968:* Nov., 1300
Secretin-pancreozymin test, in chronic pancreatitis, *1968:* Nov., 1488
Sedation, for status asthmaticus, *1970:* March, 502
Sedatives, for pain, *1968:* Jan., **47–53**
Seizures, absence, features of, *1968:* July, 961
medical treatment for, *1968:* July, 963
chronic renal failure and, *1968:* July, 846–847
convulsive, classification of, *1968:* July, 960
medical treatment for, *1968:* July, **959–975**. See also *Anticonvulsants.*
vitamin B_6-dependent, management, *1970:* Nov., 1444
electroencephalographic evaluation of, *1968:* July, 938, **949–957**
activation of abnormalities, *1968:* July, 952–953
localization of origin, *1968:* July, 953–957
focal at onset, medical treatment for, *1968:* July, 966
indications for surgery for, *1968:* July, 973
mixed, medical treatment for, *1968:* July, 966
nonconvulsive, features of, *1968:* July, 961
medical treatment for, *1968:* July, 963
recurrent, diazepam for, *1968:* July, **977–987**
tonic-clonic, isolated, medical treatment for, *1968:* July, 968
vs. orthostatic hypotension, *1968:* July, 811
withdrawal, medical treatment for, *1968:* July, 969
Selection, genetic, against deafness, *1969:* July, 764
in human populations, genetic consequences, *1969:* July, 981–984
Selenium, nutritional significance, *1970:* Nov., 1523–1525
Sella turcica, changes in, chromophobe adenoma and, *1968:* July, 829
Sengstaken-Blakemore tube, in therapy of bleeding esophageal varices, *1968:* Nov., 1466

Sepsis, neonatal, *1969:* Sept., 1058
Septal defects, cardiac catheterization in, *1970:* July, 975–976
Septic abortion, coagulation defects and, *1969:* Sept., 1089
Serial thrombin time, in disseminated intravascular coagulation, *1970:* May, 559
Serotonin, rheumatoid arthritis inflammation and, *1968:* May, 625
Serpasil. See *Reserpine.*
Serratia infections, choice of therapy for, *1970:* Sept., 1162
Serum, amylase, tests for, *1969:* Jan., 118–119
  antilymphocyte (ALS). See *Antilymphocyte serum.*
  enzymes, in pulmonary embolism, *1970:* March, 365
    tests for, in community hospital laboratory, *1969:* Jan., 13
      reliability and value of, *1969:* Jan., **115–135**
  globulin, immune, for prophylaxis of infectious hepatitis, *1970:* March, 463
  glutamic pyruvic transaminase, in Down's syndrome, *1970:* May, 811
  in rheumatoid arthritis, abnormalities, *1968:* May, 543–544, **559–565**
    tests, *1968:* May, 544–547
  proteins, electrophoresis of, *1969:* Jan., **147–157**
    increased, causes, *1969:* Jan., 151
    variants, as examples of polymorphism, *1969:* July, 893
  screening, automated, *1969:* Jan., **175–188**
Serum inhibitor, leukocyte chemotaxis disorder and, *1970:* May, 719
Serum sickness, vs. juvenile rheumatoid arthritis of polyarticular onset, *1968:* May, 578
Serum sickness-like reactions to drugs, *1970:* Sept., 1094
Sex glands. See *Ovary(ies)* and *Testes.*
Sex-linked inheritance, *1969:* July, 745
Sex ration, primary and secondary, *1969:* July, 787
Sexual adjustment, reproduction and, case studies in, *1969:* Sept., **1019–1038**
  symposium on, *1969:* Sept., **1017–1096**
SGPT. See *Serum glutamic pyruvic transaminase.*
Sheehan's syndrome, *1968:* March, 342
  nutritional changes in, *1970:* Nov., 1478
Shigellosis, ampicillin for, *1970:* Sept., 1153
  choice of therapy for, *1970:* Sept., 1163
Shock, adrenergic receptor blockers and, *1968:* Sept., **1049–1060**
  bacterial infection and, *1969:* March, 442
  cardiogenic, after myocardial infarction, *1968:* Sept., 1073
    treatment, *1969:* March, **309–313**
  hemodynamic defect in, *1968:* Sept., 1050–1051
  in adrenal crisis, *1969:* March, 459
  myocardial infarction and, *1970:* Jan., 237–238
  sympathoadrenal response to, *1968:* Sept., 1051–1056
  venous tone in, *1968:* Sept., 1082
Shoulder, examination, in hemiplegic patient, *1969:* May, 546
  girdle, range of motion test, *1969:* May, 515
  in rheumatoid arthritis, *1968:* May, 497
    surgery of, *1968:* May, 724
  pain, evaluation and conservative management, *1969:* May, **511–524**
Shoulder-hand syndrome, *1968:* Jan., 119
Shunts, right-to-left, blood gas measurements in, *1970:* May, 624–626
    hypoxia due to, *1970:* May, 620–624
  ventriculoatrial, for hydrocephalus, *1969:* May, 494
Shwartzman reaction, generalized, pathogenesis of, *1970:* May, 562
  human equivalent to, *1969:* March, 302
Sight. See *Vision.*
Sigmoidoscopy, in colitis, *1968:* Nov., 1389
  in gastrointestinal hemorrhage, *1969:* March, 421
Simmond's disease, nutritional changes in, *1970:* Nov., 1478
Single active X theory, *1969:* July, 801
Sintrom. See *Acenocoumarol.*
Sinusitis, acute bacterial, penicillins in, *1970:* Sept., 1087
Sitosterol (Cytellin), for hypercholesterolemia, *1968:* Sept., 1253
Skeletal system. See *Bone.*
Skin, carcinoma, inheritance of, *1969:* July, 928
  disease, autoimmune factors in, *1970:* Jan., **95–105**
  infarction, anemic or ischemic, *1969:* March, 262–266
  necrosis, clinical significance, *1969:* March, **259–274**
  osteoporosis and, *1970:* Jan., 143
  reactions, to antibiotics, *1970:* Jan., 60
  to penicillins, *1970:* Sept., 1094
  vancomycin, *1970:* Sept., 1281
  tests, for anaphylaxis, *1969:* March, 253
    for penicillin allergy, *1970:* July, **997–1007**
Skull, roentgen examination, cerebellopontine angle lesions and, *1968:* July, 790
  thermography of, *1970:* May, 613
SLE. See *Lupus erythematosus, systemic.*
Sleep, deprivation of, delirium and, *1969:* March, 277
Sleepiness, excessive and recurrent, *1968:* July, 781
"Small-for-dates" pregnant uterus, *1969:* Sept., 1028–1032
Snake venom, skin necrosis and, *1969:* March, 267
Sodium, absorption, normal, *1968:* Nov., 1343
  balance, in diabetic coma, *1970:* May, 689
  body, measurement with whole-body counter, *1969:* Jan., 208
  deficiency. See *Hyponatremia.*
  excess. See *Hypernatremia.*
  excretion, tissue hormones and, *1968:* March, 276–278
  restriction, for chronic heart failure, *1970:* March, 324
    for congestive heart failure, *1970:* Nov., 1452

Sodium (*Continued*)
restriction, for hypertension, *1968:* Sept., 1231
in liver disease, *1970:* Nov., 1466
in refractory heart failure, *1968:* Sept., 1165
urinary, in diagnosis of kidney failure, *1969:* March, 401
Sodium colistimethate, *1970:* Sept., **1267–1276**
Sodium nitroprusside, for hypertensive encephalopathy, *1969:* March, 352, 357
Sodium salicylate, site of action of, *1968:* Jan., 8
Solganol. See *Gold thioglucose.*
Somatic cell genetics, *1969:* July, **795–811**
clinical diagnosis and, *1969:* July, 806–808
future of, *1969:* July, 1003
Somatotropin, radioimmunoassay of, *1968:* March, 373
secretion of, decreased, *1968:* March, 367
excess, *1968:* March, 361
diagnosis of, *1968:* March, **371–380**
tests for, *1969:* Jan., 80
Sophisticated diagnostic procedures, symposium on, *1970:* July, **823–1070**
Sounds, cardiac. See under *Heart.*
Sparine. See *Promazine.*
Spasm, esophageal, diffuse, motility studies in, *1970:* July, 870
Spasticity, pain related to, neurolytic substances for, *1968:* Jan., 165
Spectacles. See *Eyeglasses.*
Speech, after laryngectomy, *1969:* May, 617–618
disturbed, cerebral vascular accident and, *1969:* May, 566
classification, *1969:* May, 563–566
clinical observation of, *1968:* July, 835–837
in hemiplegic patient, *1969:* May, 557
in parkinsonism, *1969:* May, 640
kinds of, *1968:* July, 837–841
neurologic disease and, *1968:* July, **835–844;** *1969:* May, 566–570
with brain damage in adults, diagnosis, *1969:* May, **561–573**
normal, *1969:* May, 562–563
Spherocytosis, hereditary, enzyme deficiencies and, *1969:* July, 821
Sphingolipidoses, genetics and, *1969:* July, **827–838**
Sphingolipids, structure, *1969:* July, 827–828
Spider venom, skin necrosis and, *1969:* March, 267
Spina bifida, and myelomeningocele, muscle imbalance deformities in, *1969:* May, 502, 504
static or malposition deformities in, *1969:* May, 502, 504
management, *1969:* May, **487–509**
Spinal cord, hypertrophy of, cervical root pain and, *1968:* July, 775
pain in, *1968:* Jan., 115
pain transmission in, *1968:* Jan., 16
Spinal fluid. See *Cerebrospinal fluid.*
Spine, cervical, examination, in neck and shoulder pain, *1969:* May, 513
"functional unit," *1969:* May, 526
in rheumatoid arthritis, *1968:* May, 501
mobility, examination, in low back pain, *1969:* May, 529
nerve blocks in, *1968:* Jan., 125
thermography of, *1970:* May, 613
Spirillum infections, choice of therapy for, *1970:* Sept., 1162
Spironolactone (Aldactone), for ascites in Laennec's cirrhosis, *1969:* Nov., 1362
for hypertension, *1969:* Sept., 1231
for primary aldosteronism, *1968:* Sept., 1228
for refractory heart failure, *1968:* Sept., 1174
Spleen, congenital hypoplasia of, susceptibility to infections in, *1970:* May, 720
Splenomegaly, with rheumatoid arthritis, *1968:* May, 529
juvenile, *1968:* May, 570
Splints and appliances, for rheumatoid arthritis, *1968:* May, 712–713
Spondylitis, ankylosing, epidemiology of, *1968:* May, 524
familial factors in, *1968:* May, 524
low back pain and, *1968:* Jan., 64
prognosis in, *1968:* May, 525–526
radiation therapy for pain of, *1968:* Jan., 203
sex and, *1968:* May, 524
systemic manifestations, *1968:* May, 523–524
vs. rheumatoid arthritis, *1968:* May, 503–504, 512, **517–526**
with regional enteritis or ulcerative colitis, *1968:* May, 508, 512
Marie-Strümpell. See *Spondylitis, ankylosing.*
rheumatoid. See *Spondylitis, ankylosing.*
tuberculous, low back pain and, *1968:* Jan., 63
Spondylolisthesis, low back pain and, *1968:* Jan., 59
Sprue, *1968:* Nov., 1360
nontropical, *1969:* Sept., 1179; *1970:* May, **647–656**
jejunal biopsy in, *1970:* July, 854
tropical, *1968:* Nov., **1367–1385;** *1969:* Sept., 1183
jejunal biopsy in, *1970:* July, 855, 858
treatment, *1968:* Nov., 1379
Squint, accommodative, correction of, *1969:* Sept., 1137
SRS-A (slow-reacting substance of anaphylaxis), *1969:* March, 251
anaphylaxis and, inhibitors of, *1969:* March, 256
Staphylococcal abscess, intravenous hyperalimentation for, *1970:* May, 585
Staphylococcal infections, erythromycin for, *1970:* Sept., 1202, 1206
methicillin for, *1970:* Sept., 1113–1125
methicillin-resistant, *1970:* Sept., 1121
novobiocin for, *1970:* Sept., 1284
of eyes, *1969:* Sept., 1149

Staphylococcal infections (*Continued*)
penicillin G vs. methicillin for, *1970:* Sept., 1114
semisynthetic penicillins for, evaluation, *1970:* Sept., 1118–1121
soft-tissue, isoxazolyl penicillins for, *1970:* Sept., 1132
vancomycin for, *1970:* Sept., 1277–1281
Starvation, metabolic response to, *1970:* Nov., 1367–1373
Status asthmaticus. See under *Asthma.*
Status epilepticus, diazepam for, *1968:* July, **977–987**
medical treatment, *1968:* July, 967
Steatorrhea, chronic pancreatitis and, *1968:* Nov., 1488
jejunal biopsy in, *1970:* July, 851
liver disease and, *1970:* Nov., 1458
Stein-Leventhal syndrome, *1968:* March, 345
Stenosis. See name of organ or part.
Sternoclavicular joint, in rheumatoid arthritis, *1968:* May, 497
Steroids, androgenic, in liver disease, *1970:* Nov., 1456
therapy. See *Corticosteroids.*
Stilbamidine, for trigeminal neuralgia, *1968:* July, 797
Stings, insect, anaphylactic reaction, immunotherapy for, *1969:* March, 255
Stokes-Adams syncope, office treatment for, *1969:* March, 333
Stomach, blood clots in, evacuation, *1969:* March, 420
carcinoma, environmental factors in, *1968:* Nov., 1279
genetic factors, *1968:* Nov., 1279
cytological examination of, *1968:* Nov., 1320
diseases, malnutrition caused by, *1968:* Nov., 1400
pain patterns in, *1968:* Jan., 107
emptying, clinical syndromes and, *1969:* Nov., **1403–1411**
functional anatomy and physiology, acid-peptic disease and, *1969:* Nov., 1380
hemorrhage, causes, *1969:* March, 418
retention of contents, *1969:* Nov., 1406
secretions, acid-peptic disease and, *1969:* Nov., 1381–1384
ulcer. See *Peptic ulcer.*
Stools, examination, in chronic pancreatitis, *1970:* March, 482
tests, in office laboratory, *1969:* Jan., 8
Straight leg raising, examination, in low back pain, *1969:* May, 529
Streptococcal infections, choice of therapy for, *1970:* Sept., 1162
erythromycin for, *1970:* Sept., 1204
lincomycin for, *1970:* Sept., 1298
oxacillin and cloxacillin for, *1970:* Sept., 1134
penicillin G vs. methicillin for, *1970:* Sept., 1114
tetracyclines for, *1970:* Sept., 1179
Streptokinase, for pulmonary embolism, *1970:* March, 369
Streptomycin, allergic reactions to, incidence of, *1970:* Jan., 63
avoiding, for emergency treatment of, infection, *1969:* March, 440
dosage, *1970:* Sept., 1164
pediatric, *1970:* Sept., 1166
for bacterial endocarditis, *1968:* Sept., 1098; *1970:* Sept., 1089
present status of, *1970:* Sept., **1161–1172**
recommended use against various organisms, *1970:* Sept., 1162
toxic reactions, *1970:* Sept., 1164, 1166
Stroke. See also *Cerebrovascular disease.*
hemorrhagic, *1968:* Sept., **1193–1212**
Strontium, body, measurement with whole-body counter, *1969:* Jan., 209
Stypven time test, *1970:* July, 895
Subacromial bursa, palpation, in neck and shoulder pain, *1969:* May, 515
Subaortic stenosis, muscular, drug effects and, *1969:* July, 853
Subclavian artery and vein, compression of, *1968:* July, 777
Subclavian vein catheterization, for intravenous hyperalimentation, *1970:* May, 578
Subdural hematoma, chronic, *1969:* March, 296
Subluxation of joints, in rheumatoid arthritis, *1968:* May, 660
Subphrenic abscess, and prolonged fever, *1970:* March, 385
Substrate restriction, in treatment of inherited metabolic disorders, *1969:* July, 946
Succinimides, for seizures, *1968:* July, 963
Succinylcholine, metabolism of, inherited variations in, *1969:* July, 844
Sucrase-isomaltase deficiency, *1968:* Nov., 1360
Suction, nasogastric, for pyloric obstruction, *1968:* Nov., 1333
Sulfinpyrazone, for hyperuricemia, basis of action, *1969:* Nov., 1340–1341
Sulfisoxazole (Gantrisin), for urinary tract infections, *1970:* Sept., 1079
Sulfonamides, for urinary tract infections, *1970:* Sept., **1077–1080**
dosage, *1970:* Sept., 1079
long-term therapy in children, *1970:* Sept., 1080
toxic reactions, *1970:* Sept., 1078
Sulfonylureas, hypoglycemia from, *1969:* March, **465–467;** *1970:* March, 536
Sulfose. See *Trisulfapyrimidines.*
Sulthiame (Ospolot), for seizures, *1968:* July, 972
Superinfection, during antibiotic therapy, *1969:* March, 441; *1970:* Sept., 1170
with lincomycin, *1970:* Sept., 1299
with tetracyclines, *1970:* Sept., 1183
Sural nerve, biopsy of, *1968:* July, 886–889
Surgery, for cardiac complications of myocardial infarction, *1968:* Sept., **1115–1131**
for chronic pancreatitis, *1970:* March, 488–490

Surgery (*Continued*)
for hyperparathyroidism, *1970:* March, 525
for pain relief, pain transmission and, *1968:* Jan., 19–20
general practice of, problems with pain in, *1968:* Jan., **103–109**
infection with, ampicillin for, *1970:* Sept., 1153
nutritional support in, *1970:* Nov., **1367–1381**
methods, *1970:* Nov., 1375–1381
orthopedic, for rheumatoid arthritis, *1968:* May, **717–731**
Susceptibility factors. See *Antigens, transplantation.*
Swiss-type agammaglobulinemia, *1970:* March, 288
Symbol confusion, therapy for, *1969:* Sept., 1128
Symmetrel. See *Amantidine.*
Sympathectomy, for relief of pain, *1968:* Jan., **147–159**
lumbar, *1968:* Jan., 158
thoracic, *1968:* Jan., 156
Sympathomimetic amines, adrenergic receptors and, *1968:* Sept., 1010
Synaptic transmission, in movement disorders, *1969:* May, 636–637
Syncope, Stokes-Adams, office treatment for, *1969:* March, 333
vasovagal, vs. orthostatic hypotension, *1968:* July, 811
Syndrome. See specific syndrome.
Synovial fluid, examination of, in rheumatoid arthritis, *1968:* May, 539–543
Synovitis, acute, in rheumatoid arthritis, *1968:* May, 608
rubella, vs. juvenile rheumatoid arthritis of polyarticular onset, *1968:* May, 578
Syphilis, penicillins for, *1970:* Sept., 1091
tetracyclines for, *1970:* Sept., 1180
Syringomyelia, lumbosacral, *1968:* July, 899
Systemic lupus erythematosus. See *Lupus erythematosus, systemic.*

T_3 RESIN uptake test, factors in interpretation, *1970:* Jan., 118
T_3 test, *1968:* March, 468
Tachycardia, atrial (supraventricular), after myocardial infarction, *1968:* Sept., 1067
conversion by pacing, *1969:* Nov., 1292–1293
paroxysmal, propranolol for, *1968:* Sept., 1020
with atrioventricular block, *1969:* March, 322
nodal, nonparoxysmal, *1969:* March, 322
pacemakers in prevention and treatment of, *1969:* Nov., **1287–1295**
sinus, *1969:* March, 322
ventricular, *1969:* March, 323
prevention by pacing, *1969:* Nov., 1287–1292
propranolol for, *1968:* Sept., 1025
Talking. See *Speech.*
Tamponade, cardiac, uremic pericarditis and, *1968:* Sept., 1237–1241
pericardial, in uremia, *1970:* March, 415
Tanned red cell agglutination test, for thyroid autoantibodies, *1970:* Jan., 120
Tay-Sachs disease, genetics and, *1969:* July, 836–837
Teeth, development, nutrition and, *1970:* Nov., 1556–1559
discolored, in children, due to tetracyclines, *1970:* Sept., 1183
Tegretol. See *Carbamazepine.*
Telangiectasia, hemorrhagic, inheritance and gastrointestinal manifestations, *1968:* Nov., 1277
Telephone services, for physically handicapped, *1969:* May, **697–702**
Tendons, thickening, in hyperlipoproteinemia, *1970:* Nov., 1388, 1389
Tension myoplasty, in leg amputation, *1969:* May, 669–670
Terminal ileitis. See *Regional enteritis.*
Test(s), acid-base balance, using arterialized capillary blood, *1969:* Jan., **137–145**
adrenal androgens, *1969:* Jan., 92
advances in, symposium on, *1969:* Jan., **1–231**
alkaline phosphatase, *1968:* Nov., 1410; *1969:* Jan., 115–118
anticoagulants, *1969:* Jan., 73
antinuclear factors in rheumatoid arthritis, *1968:* May, **559–565**
bacteriological, in community hospital laboratory, *1969:* Jan., 13
in office laboratory, *1969:* Jan., 8
Benedict's, drug effects on, *1969:* Jan., 212
bile pigment excretion, *1968:* Nov., 1412
bilirubin, *1968:* Nov., 1409
drug effects on, *1969:* Jan., 212
bleeding time, *1970:* July, 890
blood, in office laboratory, *1969:* Jan., 6
blood ammonia, *1968:* Nov., 1412
bromsulphalein excretion, *1968:* Nov., 1411
drug effects on, *1969:* Jan., 212
calcium, drug effects on, *1969:* Jan., 212
capillary fragility, *1970:* July, 890
chloride, drug effects on, *1969:* Jan., 212
cholesterol, *1968:* Nov., 1432
drug effects on, *1969:* Jan., 212
clinical chemistry, in community hospital laboratory, *1969:* Jan., 12
clinical physiology, in community hospital laboratory, *1969:* Jan., 15
clotting factor, deficiencies, *1969:* Jan., 72; *1970:* July, 896
coagulation, *1969:* Jan., 63; Nov., 1313–1316; *1970:* July, 893–897
in community hospital laboratory, *1969:* Jan., 15
Coombs antiglobulin, *1969:* Jan., 56
corticotropin, *1969:* Jan., 82
creatine phosphokinase, *1969:* Jan., 119–122
creatinine, urinary, drug effects on, *1969:* Jan., 212
drug effects on, *1969:* Jan., **211–222**

Test(s) (*Continued*)
expiratory velocity, *1969:* Jan., 43
fluorescein string, in gastrointestinal hemorrhage, *1969:* March, 420
functional, of lung. See under *Lungs.*
glucocorticoids, *1969:* Jan., 89
glucose, drug effects on, *1969:* Jan., 212
gonadotropins, *1969:* Jan., 84
growth hormone, *1969:* Jan., 80
hematuria, *1969:* Jan., 29
histamine, of gastric secretion, *1968:* Nov., 1307
17-hydroxycorticosteroids, *1969:* Jan., 89
drug effects on, *1969:* Jan., 212
immunohematology, in community hospital laboratory, *1969:* Jan., 14
immunoserology, in community hospital laboratory, *1969:* Jan., 16
in adrenocortical disorders, *1969:* Jan., 89–93
in amblyopia, *1969:* Sept., 1133
in amenorrhea, estrogen-progesterone, *1968:* March, 349
in ankylosing spondylitis, *1968:* May, 523–524
in ascorbic acid deficiency, *1969:* Jan., 74
in bleeding disorders, *1969:* Jan., **61–78**
in celiac disease, *1970:* May, 653
in Cushing's syndrome, *1970:* July, 1062
in disseminated intravascular clotting, *1969:* March, 304, 305
in endocrine disorders, *1969:* Jan., **79–95**
in evaluation of medical education, *1970:* May, 598
in fibrinolysis, *1970:* July, 896
in gastrointestinal hemorrhage, *1969:* March, 419
in hyperlipidemia, *1970:* July, **1029–1035**
in hyperosmolar hyperglycemic nonketotic diabetic coma, *1970:* May, 685
in hyperparathyroidism, *1970:* March, 519; *1970:* July, 1062
in jaundice, *1968:* Nov., 1427–1437
in kidney disease, office procedures, *1969:* Jan., **25–35**
in liver disease, *1968:* Nov., **1407–1416**
in malabsorption, *1968:* Nov., 1350
in megaloblastic-macroovalocytic anemias, *1970:* May, 632–640
in metabolic bone disease, *1970:* July, **1061–1070**
in orthostatic hypotension, *1968:* July, 814
in osteodystrophy, renal, *1970:* July, 1062
in osteomalacia, *1970:* July, 1062
in osteoporosis, primary, *1970:* July, 1062
in Paget's disease, *1970:* July, 1062
in pancreatic disease, *1968:* Nov., **1483–1492**
in pancreatitis, chronic, *1970:* March, 482–484
in pituitary gland disorders, *1969:* Jan., 80–85
in platelet function defects, *1969:* Jan., 66
in prothrombin complex abnormalities, *1969:* Jan., 74
in pulmonary embolism, *1970:* March, 365
in purpura, vascular (nonthrombocytopenic), *1969:* Jan., 75

Test(s) (*Continued*)
in rheumatoid arthritis, *1968:* May, **539–548**
juvenile, *1968:* May, 574, 577
in speech disorders in adults, *1969:* May, 571
in thrombocythemia hemorrhagica, *1969:* Jan., 68
in thyroid disorders, *1969:* Jan., 85–88; *1970:* July, 1043
in urogenital tuberculosis, *1969:* March, 450
in von Willebrand's disease, *1969:* Jan., 68
insulin, of gastric secretion, *1968:* Nov., 1309
iron, drug effects on, *1969:* Jan., 212
iron tolerance, oral, *1970:* July, 911
isoenzyme, in alcoholic muscle disease, *1970:* May, 726
lactic dehydrogenase, *1968:* Nov., 1410; *1969:* Jan., 122–128
Lee-White, *1969:* Jan., 64
liver function, drug effects on, *1969:* Jan., 214
Lundh, in chronic pancreatitis, *1968:* Nov., 1491
lung function, in office, *1969:* Jan., **37–45**
Maddox rod, *1969:* Sept., 1135
mannitol response, in diagnosis of kidney failure, *1969:* March, 401
maximal voluntary ventilation, *1969:* Jan., 43
mineralocorticoids, *1969:* Jan., 91
Murphy-Pattee, for thyroxine, *1970:* July, 1044
of vision, *1969:* Sept., 1132–1134
office, current place of, *1969:* Jan., **3–9**
facilities and equipment for, *1969:* Jan., 4
in kidney disease, *1969:* Jan., **25–35**
systems for, *1969:* Jan., 5
partial thromboplastin time, *1970:* July, 894
pathology, in community hospital laboratory, *1969:* Jan., 16
pentagastrin, of gastric secretion, *1968:* Nov., 1308
phenolsulphonphthalein, *1969:* Jan., 33
drug effects on, *1969:* Jan., 212
plasma clot time, *1970:* July, 894
platelet function, *1970:* July, 891
pregnanediol, drug effects on, *1969:* Jan., 212
proteinuria, *1969:* Jan., 27
drug effects on, *1969:* Jan., 212
prothrombin consumption, *1970:* July, 896
prothrombin time, *1970:* July, 895
drug effects on, *1969:* Jan., 213
Quick one-stage, drug effects on, *1969:* Jan., 213
radioisotope, in anemia, *1969:* Jan., 57
Rumpel-Leede, *1969:* Jan., 64
saline load, in pyloric obstruction, *1968:* Nov., 1332
screening, serum, automated, *1969:* Jan., **175–188**

Test(s) (*Continued*)
secretin-pancreozymin, in chronic pancreatitis, *1968:* Nov., 1488
serial thrombin time, in disseminated intravascular coagulation, *1970:* May, 559
serum, amylase, *1969:* Jan., 118–119
enzyme, in community hospital laboratory, *1969:* Jan., 13
reliability and value of, *1969:* Jan., **115–135**
iron and iron-binding capacity, *1970:* July, 909
naphthylamidase, *1969:* Jan., 128
5′-nucleotidase, *1969:* Jan., 128–129
ornithine carbamyl transferase, *1969:* Jan., 129–130
proteins, *1968:* Nov., 1411
by electrophoresis, *1969:* Jan., **147–157**
drug effects on, *1969:* Jan., 212
skin, for anaphylaxis, *1969:* March, 253
for penicillin allergy, *1970:* July, **997–1007**
Stypven time, *1970:* July, 895
tanned red cell agglutination, for thyroid autoantibodies, *1970:* Jan., 120
testosterone, *1969:* Jan., 93
thromboplastin generation, *1970:* July, 896
thymol turbidity, *1968:* Nov., 1411
thyroid function, *1970:* July, **1037–1047**
drug effects on, *1969:* Jan., 214
methods, advantages, and disadvantages, *1970:* July, 1044–1045
thyroid hormone binding, *1969:* Jan., 88
thyrotropin, *1969:* Jan., 83
transaminases, *1968:* Nov., 1410
transplantation antigens, *1970:* Jan., 46–52
uric acid, drug effects on, *1969:* Jan., 212
urine, amylase, *1969:* Jan., 118
catecholamines, drug effects on, *1969:* Jan., 212
in office laboratory, *1969:* Jan., 5, 26
pH, *1969:* Jan., 29
sediment, *1969:* Jan., 29
specific gravity, *1969:* Jan., 32
use and abuse of, *1969:* Jan., **223–231**
vanilmandelic acid, drug effects on, *1969:* Jan., 212
vital capacity, *1969:* Jan., 40
Testes, carcinoma of, chemotherapy for, *1969:* Nov., 1272
chromophobe adenoma and, *1968:* July, 830
failure of, radioimmunoassay of gonadal hormones in, *1970:* July, 1056
Testosterone, erythropoiesis and, *1968:* March, 232
leukopoiesis and, *1968:* March, 239
tests of, *1969:* Jan., 93
Tetracaine (Pontocaine), for epidural anesthesia, *1968:* Jan., 212
in office, *1968:* Jan., 175, 178
Tetracyclines, *1970:* Sept., **1173–1186**
allergic reactions to, incidence of, *1970:* Jan., 63
avoiding, for emergency treatment of infection, *1969:* March, 439
Tetracyclines (*Continued*)
fluorescence of, and tests for malignancy, *1970:* Sept., 1177
for bacterial endocarditis, *1968:* Sept., 1098
inactivation of, *1970:* Sept., 1175
major analogues, *1970:* Sept., 1174
preparations and routes of administration, *1970:* Sept., 1183
spectrum of activity, *1970:* Sept., 1177–1180
superinfections, *1970:* Sept., 1183
toxic reactions, *1970:* Sept., 1181–1183
Tetraploidy, *1969:* Sept., 1043
Thalamus, pain originating in, *1968:* Jan., 116
Thalassemia syndromes, genetic control of hemoglobin synthesis and, *1969:* July, **875–886**
Theophylline, for asthma, *1969:* March, 242, 243
Thermography, *1970:* May, **603–616**
Thiazides, effects and side-effects of, *1969:* Nov., **1321–1330**
for ascites in Laennec's cirrhosis, *1969:* Nov., 1362
for gout, *1970:* March, 432
for hypertension, *1968:* Sept., 1231
for refractory heart failure, *1968:* Sept., 1169
sites of antihypertensive action of, *1969:* Nov., 1324–1325
sites of diuretic action of, *1969:* Nov., 1322–1324
Thoracic outlet syndromes, *1968:* July, 777–778
Thoracotomy, for carcinoma of lung, rehabilitation after, *1969:* May, 618–619
Thorazine. See *Chlorpromazine.*
Thrombocythemia hemorrhagica, tests for, *1969:* Jan., 68
Thrombocytopenia, evaluation of, *1969:* Nov., 1317
Thromboembolism, oral contraception and, *1970:* Jan., 168
Thrombophlebitis, *1969:* March, **341–350**
complicating hemiplegia, *1969:* May, 549, 553
pelvic, and prolonged fever, *1970:* March, 391
Thromboplastin, infusion, skin necrosis and, *1969:* March, 265
Thromboplastin generation test, *1970:* July, 896
Thrombosis, arterial, sudden arterial occlusion and, *1969:* March, 335
intravascular, diffuse, *1969:* Nov., 1319
Thrombus, formation of, at prosthetic heart valve, *1968:* Sept., 1134
Thrush, nystatin for, *1970:* Sept., 1335
Thymol turbidity test, *1968:* Nov., 1411, 1435
Thymoma-agammaglobulinemia, *1970:* March, 297
Thymus gland, aplasia, *1969:* July, 910; *1970:* March, 286
functions of, *1970:* March, 281
Thyroid acropachy, *1968:* March, **393–398**

Thyroid active substances, side-effects, *1970:* Nov., 1612
Thyroid gland, autoantibodies. tanned red cell agglutination test for, *1970:* Jan., 120
carcinoma, radiation therapy for pain of, *1968:* Jan., 206
chromophobe adenoma and, *1968:* July, 831
destruction, for malignant exophthalmos, *1969:* March, 472
disorders, amenorrhea and, *1968:* March, 343
autoimmunity and, *1970:* Jan., 120
clubbing of fingers and toes in, *1968:* March, **393–398**
current concepts in management of, *1970:* Jan., **117–130**
deafness and, *1969:* July, 765
diagnosis, laboratory tests in, *1969:* Jan., 85–88; *1970:* July, 1037–1047
periosteal bone formation in, *1968:* March, **393–398**
function, erythropoiesis and, *1968:* March, 234
in amenorrhea, *1968:* March, 350
leukopoiesis and, *1968:* March, 239
oral contraception and, *1970:* Jan., 166
pregnancy and, *1968:* March, 257–259
tests of, *1968:* March, **463–472**
drug effects on, *1969:* Jan., 214
factors in interpretation, *1970:* Jan., 117–118
methods, advantages, and disadvantages, *1970:* July, 1044–1045
principles, *1970:* July, 1041–1042
subtotal resection, for exophthalmic goiter, *1970:* Jan., 126
Thyroid hormone, binding tests, in thyroid disorders, *1969:* Jan., 88
osteoporosis and, *1970:* Jan., 148–149
peripheral plasma concentration, in thyroid disorders, *1969:* Jan., 87
transport, *1970:* July, 1039–1041
Thyroid-stimulating hormone. See *thyrotropin.*
Thyroid suppression therapy, for goiter, *1968:* March, 413
Thyroiditis, and prolonged fever, *1970:* March, 391
Hashimoto's, parietal cell antibody and, *1968:* Nov., 1286
Thyrotoxicosis. See also *Hyperthyroidism.*
calcium balance in, *1970:* Nov., 1482
muscle wasting and, *1968:* March, 243
parietal cell antibody and, *1968:* Nov., 1286
radioactive iodine therapy for, *1968:* March, **417–429**
Thyrotropin, tests for, *1969:* Jan., 83; *1970:* July, 1044–1045
Thyroxine, abnormalities, metabolic changes in, *1970:* Nov., 1480
serum, measurement of, *1970:* Jan., 118–119; July, 1044
Tibial nerve, anterior, biopsy of, *1968:* July, 886
Tic douloureux, *1968:* Jan., 111
medical treatment, *1968:* July, **797–800**
Tinel's sign, *1968:* July, 778
Tissue. See also specific types.
integrity, nutrition and, *1970:* Nov., 1498
Tissue hormones, *1968:* March, **263–281**
Tissue typing, *1970:* Jan., 46–52
and tissue immunity, *1970:* Jan., **43–58**
Toes, clubbing of, hyperthyroidism and, *1968:* March, **393–398**
Tolbutamide (Orinase), for juvenile diabetes mellitus, *1969:* Nov., 1375
hypoglycemia from, *1969:* March, 465
tolerance test, in hypoglycemia, *1968:* March, 286–293
Tolerance, to drugs, *1968:* Jan., 33
Tolinase. See *Tolzamide.*
Tolseram. See *Mephenesin.*
Tolserol. See *Mephenesin.*
Tolzamide (Tolinase), hypoglycemia from, *1969:* March, 465
Tonsillitis, penicillins for, *1970:* Sept., 1086
Torsion dystonia, *1969:* May, 641–642
Toxemia of pregnancy, hypertension and, *1968:* Sept., 1234
Toxic psychosis or delirium, acute, *1969:* March, **275–279**
Toxins, bacterial, skin necrosis and, *1969:* March, 269
Trace elements, caries-inhibiting, *1970:* Nov., 1558
Trace minerals, current concepts, *1970:* Nov., **1509–1542**
Traction, cervical, for neck and shoulder pain, *1969:* May, 518
for low back pain, *1969:* May, 532
Tranquilizers, for pain, *1968:* Jan., **47–53**
uses of, *1968:* Jan., 50
Transaminases, serum, tests for, *1968:* Nov., 1410, 1428, 1430, 1431
Transfusions, in bleeding esophageal varices, *1968:* Nov., 1459
intrauterine, *1969:* Sept., 1077–1080
reactions, intragroup, *1969:* Sept., 1066
Transient global amnesia, cerebrovascular disease and, *1970:* March, 354
Transient ischemic attacks, cerebrovascular disease and, *1970:* March, 351
therapy for, *1970:* March, 356
"Transplant lung," *1970:* Jan., 89
Transplantation, donor selection in, *1970:* Jan., 79–81
early studies of, *1970:* Jan., 44
genetic locus in man, *1970:* Jan., 52
immunity and, *1970:* Jan., 44–45
of cornea, indications for, *1969:* Sept., **1099–1107**
of heart, hemodynamic observations after, *1970:* Jan., **107–113**
of kidneys, patient selection and management in, *1970:* Jan., **75–94**
Transplantation antigens. See under *Antigens.*
Trasylol, for pancreatitis, *1969:* March, 434
Trauma, arthritis from, *1968:* May, 580
cerebral, speech disorders and, *1969:* May, 569
rehabilitation after, *1969:* May, **677–684**
complicating hemiplegia, *1969:* May, 546
to back, *1968:* Jan., 60

Trauma (*Continued*)
to head, echoencephalography in diagnosis of, *1969:* Jan., 163
Treponemal infections, skin necrosis and, *1969:* March, 272
Triacetyloleandomycin, allergic reactions to, incidence of, *1970:* Jan., 63
Triamcinolone (Aristocort), for rheumatoid arthritis, *1968:* May, 743
Triamterene (Dyrenium), for hypertension, *1968:* Sept., 1231
for refractory heart failure, *1968:* Sept., 1174
Trichloroethylene (Trilene), for postoperative pain, *1968:* Jan., 88
for trigeminal neuralgia, *1968:* July, 797
in labor, *1968:* Jan., 142
Tricuspid valve, stenosis of, complicating heart failure, *1970:* March, 319
Trigeminal nerve, cerebellopontine angle lesions and, *1968:* July, 789
Trigeminal neuralgia, *1968:* Jan., 111
medical treatment of, *1968:* July, **797–800**
Triglycerides, atherosclerotic cardiovascular disease and, *1970:* Nov., 1450
medium chain, for tropical sprue, *1968:* Nov., 1380
in surgical nutrition, *1970:* Nov., 1375
metabolism, abnormal, obesity and, *1970:* Nov., 1535
clinical evaluation, *1970:* Nov., 1540
in adipose tissue, *1970:* Nov., 1539
plasma transport, physiology of, *1970:* Nov., 1384–1386
serum, tests for, *1970:* July, **1029–1035**
Trilene. See *Trichloroethylene.*
Trimetaphan camphorsulfonate (Arfonad), for hypertensive encephalopathy, *1969:* March, 352, 357
for pulmonary edema, *1970:* March, 322
Triosephosphate isomerase, deficiency, *1969:* July, 821
Triploidy, *1969:* Sept., 1042
Trisomy, *1969:* Sept., 1041
in abortuses, *1969:* July, 781
Trisomy 21, etiology of, *1969:* Sept., 1047
Trisulfapyrimidines (Sulfose), for urinary tract infections, advantages of, *1970:* Sept., 1078
Tropical sprue. See *Sprue, tropical.*
Tuberculosis, and prolonged fever, *1970:* March, 380–382
hepatic, *1970:* March, 381
miliary, without radiologic evidence, *1970:* March, 380
of adrenal glands, *1968:* March, 327
pulmonary, without radiologic evidence, *1970:* March, 381
treatment, ethambutol in, *1970:* Sept., 1320–1324
urogenital, *1969:* March, **449–453**
Tularemia, antimicrobials for, *1970:* Sept., 1192
Tumors, alpha-fetoprotein in, *1970:* May, **797–803**
carcinoid, chemotherapy for, *1969:* Nov., 1275
Tumors (*Continued*)
chemotherapy of, bases of, *1969:* Nov., **1265–1278**
chromosomal abnormalities in, *1970:* July, 1024–1025
intracranial, echoencephalography in diagnosis of, *1969:* Jan., 164
malignant, immunological deficiency diseases and, *1970:* March, 298–299
metastases to adrenal glands, *1969:* March, 461
vs. hyperparathyroidism, *1970:* Jan., 133
neurophysiology and, *1969:* May, 630
of organs. See under names of organs.
prolonged fever and, *1970:* March, 386–390
Turner's syndrome, chromosomal abnormality in, *1970:* July, 1018
Typhoid fever, chloramphenicol for, *1970:* Sept., 1191
Tyrosinosis, inheritance and gastrointestinal manifestations, *1968:* Nov., 1278
Tyrothricin, *1970:* Sept., 1291

ULCER, gastrointestinal, diet and, *1970:* Nov., 1357–1359
jejunal, after Billroth II reconstruction, gastrin and, *1968:* Nov., 1299
of foot, perforating, *1968:* July, 899
of leg, hypertension and, *1969:* March, 262
peptic. See *Peptic ulcer.*
Ulcerative colitis, *1969:* Sept., 1195–1206
autoimmunity and, *1968:* Nov., 1291
complications, *1968:* Nov., 1390
diagnosis, *1968:* Nov., 1389
diet in, *1970:* Nov., 1361
disaccharidase deficiency and, *1968:* Nov., 1361
immunosuppression for, *1969:* Nov., 1237
intravenous hyperalimentation for, *1970:* May, 585
pathology, *1968:* Nov., 1388
prognosis and treatment, *1968:* Nov., 1390
roentgen examination, *1968:* Nov., 1390
sigmoidoscopic examination, *1968:* Nov., 1389
vs. granulomatous colitis, *1968:* Nov., 1387–1392
with ankylosing spondylitis, *1968:* May, 508, 512
with arthritis, *1968:* May, 507–509
with erythema nodosum, *1968:* May, 508
with polyarthritis, *1968:* May, 508
Ultracentrifugation, in study of plasma lipoproteins, *1970:* Jan., 153
Ultrasound, in diagnosis of intracranial disorders, *1969:* Jan., 159–174; March, 294
in examination of fetus, *1969:* Sept., 1053
Unipette Systems, in office laboratory, *1969:* Jan., 7
Unitest System, in office laboratory, *1969:* Jan., 7

University of Chicago medical school system, *1970:* Jan., **35–40**
Urates, serum, elevated. See *Hyperuricemia.*
Uremia, chronic, dialysis vs. transplantation for, *1970:* Jan., 77
neuropathy and, *1968:* July, 906
pathogenesis and treatment, newer concepts in, *1970:* March, **411–430**
red cell 2,3-diphosphoglycerate and, *1970:* May, 736
Ureteroileostomy, for urinary tract damage with myelomeningocele, *1969:* May, 499, 500
Urethra, topical analgesia of, *1968:* Jan., 179
Urethritis, with arthritis, *1968:* May, 504
Uric acid, excess, in blood. See *Hyperuricemia.*
tests for, drug effects on, *1969:* Jan., 212
Uricosuric drugs, for hyperuricemia, basis of action of, *1969:* Nov., 1340–1341
Uridine phosphate, synthesis, defect in, *1970:* Nov., 1443
Urinary tract infections, *1970:* March, **397–410**
ampicillin for, *1970:* Sept., 1151
erythromycin for, *1970:* Sept., 1208
gentamicin for, *1970:* Sept., 1313
nalidixic acid for, *1970:* Sept., **1347–1350**
polymyxins for, *1970:* Sept., 1264
sodium colistimethate for, *1970:* Sept., 1271
sulfonamides for, *1970:* Sept., **1077–1080**
tetracyclines for, *1970:* Sept., 1180
obstruction, complicating heart failure, *1970:* March, 319
Urine, collection of, for analysis, *1969:* Jan., 26
examination, in urinary tract infection, *1970:* March, 399
output, normal, renal failure with, *1969:* March, 399
reduced, causes, *1969:* March, 398, 399
sodium concentration, in diagnosis of kidney failure, *1969:* March, 401
tests, for blood, *1969:* Jan., 29
for pH, *1969:* Jan., 29
for protein, *1969:* Jan., 27
for sediment, *1969:* Jan., 29
for specific gravity, *1969:* Jan., 32
in office laboratory, *1969:* Jan., 5, 26
Urokinase, for pulmonary embolism, *1970:* March, 371
Urticaria, anaphylaxis and, *1969:* March, 252
Uterus, failure of, amenorrhea and, *1968:* March, 347
perforation of, in pregnancy, *1969:* Sept., 1025–1028
pregnant, "small-for-dates," *1969:* Sept., 1028–1032

VAGINA, smear test, in amenorrhea, *1968:* March, 348
Vagotomy, insulin test after, *1968:* Nov., 1309
medical, *1968:* Nov., 1310
Valium. See *Diazepam.*
Valmid. See *Ethinamate.*
Valves, heart. See under *Heart* and names of valves.
Vancomycin, *1970:* Sept., **1277–1281**
allergic reactions to, incidence, *1970:* Jan., 64
for bacterial endocarditis, *1968:* Sept., 1098
for emergency treatment of infection, *1969:* March, 440
Vanilmandelic acid, tests for, drug effects on, *1969:* Jan., 212
Vascular collapse, peripheral, adrenal insufficiency and, *1969:* March, 460
Vascular disease, complicating juvenile diabetes mellitus, *1969:* Nov., 1372
hyperlipidemia and, *1970:* May, 660
peripheral, neuropathy and, *1968:* July, 905
thermography in, *1970:* May, 612
Vascular fragility, hemorrhage and, *1969:* Nov., 1316
Vascular purpura, tests in, *1969:* Jan., 75
Vasculitis, nerve biopsy in diagnosis, *1968:* July, 892
Vasodilation, in rheumatoid arthritis, factors in, *1968:* May, 629
Vasopressin therapy, for bleeding esophageal varices, *1968:* Nov., 1465
Vasoxyl. See *Methoxamine.*
Veins, adrenergic receptors in, *1968:* Sept., 1079
baroreceptor and chemoreceptor reflexes in, *1968:* Sept., 1080
insufficiency, chronic, vs. intractable heart disease, *1970:* March, 314
jugular, central venous pressure and, *1969:* Jan., 100
physical and emotional stimuli and, *1968:* Sept., 1080
reflex stimuli and, *1968:* Sept., 1079
resistance and capacitance functions of, *1968:* Sept., 1077, 1078
studies of functioning of, *1968:* Sept., 1078
tone of, central venous pressure and, *1968:* Sept., **1077–1090**
in congestive heart failure, *1968:* Sept., 1081
in hypotension, *1968:* Sept., 1082
in shock, *1968:* Sept., 1082
pregnancy and, *1968:* Sept., 1085
varicose, oral contraceptives and, *1968:* Sept., 1085
pregnancy and, *1968:* Sept., 1085
Vena cava, interruption, pulmonary embolism and, *1970:* March, 367
obstruction vs. intractable heart disease, *1970:* March, 315
Venereal disease, penicillins for, *1970:* Sept., 1090
Ventilation, assisted, for status asthmaticus, *1970:* March, 502
disturbances of, hypoxia due to, *1970:* May, 618
intermittent positive pressure, in cardiopulmonary resuscitation, *1969:* March, 390
tests of, *1969:* Jan., 43

Ventricle, aneurysm of, causes of and surgery for, *1968:* Sept., 1122–1124
left, dilatation of, surgery for, *1968:* Sept., 1120
Ventricular fibrillation, primary, after myocardial infarction, *1968:* Sept., 1064
treatment, *1969:* March, 324
Ventricular premature beats, propranolol for, *1968:* Sept., 1025
Ventricular septum, defects, cardiac catheterization in, *1970:* July, 975–976
rupture of, causes of and surgery for, *1968:* Sept., 1124–1126
Vertebrae, cervical, palpation, in neck and shoulder pain, *1969:* May, 514
defects. See *Spina bifida.*
Vertebral-basilar insufficiency, cerebrovascular disease and, *1970:* March, 354
Vibrio infections, choice of therapy for, *1970:* Sept., 1163
Vinblastine, bases of action of, *1969:* Nov., 1268
Vincristine, bases of action of, *1969:* Nov., 1268
Viomycin, *1970:* Sept., **1325–1326**
Viral hepatitis, *1970:* March, **455–466**
Australian antigen and, *1970:* May, **805–817**
Viral infections, diarrhea and, *1970:* March, 446–447
of eyes, *1969:* Sept., 1150–1155
rheumatoid arthritis and, *1968:* May, 598, 675
Vision. See also *Eyes.*
color, as example of polymorphism, *1969:* July, 891
corneal transplants and, *1969:* Sept., 1099
correction of. See *Eyeglasses.*
disturbed, chromophobe adenoma and, *1968:* July, 827
chronic renal failure and, *1968:* July, 847
due to ethambutol, *1970:* Sept., 1319
in hemiplegic patient, *1969:* May, 557
drugs and, *1969:* Sept., 1115, 1116
tests of, *1969:* Sept., 1132–1134
Vital capacity, tests of, *1969:* Jan., 40
Vitamin B, deficiency, neuropathy and, *1968:* July, 904
Vitamin-B_6-dependent convulsive disorder, management, *1970:* Nov., 1444
Vitamin B_{12}, absorption, studies of, *1968:* Nov., 1351
tests, in megaloblastic-macroovalocytic anemias, *1970:* May, 637
assay, in megaloblastic-macroovalocytic anemias, *1970:* May, 633
deficiency, etiology and pathogenesis of, *1970:* May, 640
for methylmalonic acidemia, *1970:* Nov., 1444
for trigeminal neuralgia, *1968:* July, 797
for tropical sprue, *1968:* Nov., 1379
measurement with whole-body counter, *1969:* Jan., 207
Vitamin C. See *Ascorbic acid.*
Vitamin D-dependent rickets, dietary management, *1970:* Nov., 1445
Vitamin K, in viral hepatitis, *1970:* Nov., 1462
Vitamins, deficiency, in liver disease, *1970:* Nov., 1459–1461
tooth development and, *1970:* Nov., 1557
enzymatic disorders and, *1970:* Nov., 1432
water-soluble, absorption, normal, *1968:* Nov., 1344
Vitreous, development of, *1969:* Sept., 1163–1165
VLDL. See *Lipoproteins, very low density.*
Vocational therapy. See also *Occupational therapy.*
in quadriplegia, *1969:* May, **713–718**
Vomiting, obstructive, in pyloric obstruction, *1968:* Nov., 1330
Von Bechterew's disease. See *Spondylitis, ankylosing.*
Von Willebrand's disease, diagnosis of, *1970:* July, 898
tests for, *1969:* Jan., 68
Vulvovaginitis, candidal, nystatin for, *1970:* Sept., 1336

WAARDENBURG's syndrome, *1969:* July, 768
Waldenström's macroglobulinemia, electrophoresis in diagnosis, *1970:* July, 923
Water, absorption, normal, *1968:* Nov., 1343
balance, in hyperglycemia, *1970:* May, 690
body. See *Fluids and electrolytes.*
intoxication, inappropriate secretion of antidiuretic hormone and, *1968:* July, 817
Weakness, neurophysiology in evaluation of, *1969:* May, **625–632**
Weanling diarrhea, *1970:* Nov., 1501–1503
Weight, body fat and, *1970:* Nov., 1369
Werlhof's disease. See *Purpura, thrombocytopenic, idiopathic.*
Wermer's syndrome. See *Multiple endocrine adenomatosis.*
WHDA syndrome, *1970:* May, 567
Wheezing, anaphylaxis and, *1969:* March, 252
causes, *1969:* March, 239–240
Whiplash injuries, *1968:* July, 775
Whipple's disease, *1969:* Sept., 1186
jejunal biopsy in, *1970:* July, 855, 856
with arthritis, *1968:* May, 508
White House Conference on Food, Nutrition and Health, recommendations, *1970:* Nov., 1592–1597
Whole-body counter, medical uses, *1969:* Jan., **205–210**
Wilkinson drainage, for gastrointestinal obstruction from ulcer, *1969:* March, 426
Wilms' tumor, and congenital abnormalities, *1969:* July, 931
Wilson's disease, copper metabolism and, *1968:* July, **989–1001**
inheritance and gastrointestinal manifestations, *1968:* Nov., 1278
Wiskott-Aldrich syndrome, *1969:* July, 909; *1970:* March, 292
Wound healing, nutrition and, *1970:* Nov., 1498
zinc and, *1970:* Nov., 1518, 1519

Wrist, in rheumatoid arthritis, surgery of, *1968:* May, 722
Wyamine. See *Mephentermine.*

XANTHELASMA, in hyperlipoproteinemia, *1970:* Nov., 1388
Xanthine oxidase inhibitors, for hyperuricemia, basis of action of, *1969:* Nov., 1341
Xanthoma, eruptive, in hyperlipoproteinemia, *1970:* Nov., 1387
in broad-beta lipoprotein disease, *1970:* Nov., 1389, 1390
Xanthurenic aciduria, management, *1970:* Nov., 1445
Xeroderma pigmentosum, inheritance of, *1969:* July, 927
X-linked inheritance, *1969:* July, 745, 747
genetic counseling and, *1969:* July, 996
X-ray. See *Radiation: Roentgen.*
Xylocaine. See *Lidocaine.*
d-Xylose excretion, in celiac disease, *1970:* May, 653

ZINC, deficiency, *1970:* Nov., 1517
nutritional significance, *1970:* Nov., 1514–1520
toxicity, *1970:* Nov., 1520
Zollinger-Ellison syndrome, *1968:* March, 301
diarrhea in, *1970:* May, 573
gastrin and, *1968:* Nov., 1300
Zoster. See *Herpes zoster.*
Zyloprim. See *Allopurinol.*